



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 175267

TO: Sarvamangala Devi
Location: REM-3B07/3C18
Art Unit: 1645 5
Friday, January 05 2006
Case Serial Number: 09/445517

From: Kristine
Location: Biotech-Chem Library
REM-1B69
Phone: (571)272-4161

Kristine.Hensle@uspto.gov

Search Notes

Examiner Devi,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Kristine Hensle
Librarian
STIC Biotech/Chem Library
(571)272-4161

THIS PAGE LEFT BLANK

STIC-Biotech/ChemLib

175267

From: Devi, Sarvamangala
Sent: Thursday, December 29, 2005 9:19 AM
To: STIC-Biotech/ChemLib
Subject: 09/445,517

In application 09/445,517, please perform a sequence search for SEQ ID NO: 14 in pending and commercial databses. Please provide me with a paper copy of first 50 hits.

Thanx.

S. DEVI, Ph.D.
Primary Examiner
AU 1645
Rems - 3C18

RECEIVED
DEC 29 2005
STIC/CHEN, D.
(STIC)

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA# _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____

THIS PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:46:27 ; Search time 13 Seconds
(without alignments)
24.155 Million cell updates/sec

Title: US-09-445-517-14
Perfect score: 139
Sequence: 1 XXNTATATQRLXNLFXXXXXNGXPXPXTXVGSNTY 37

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 61072 seqs, 8486849 residues

Total number of hits satisfying chosen parameters: 61072

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database : Published Applications AA-New:*

- 1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
- 2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 5: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
- 7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	ID	Description
1	102	73.4	37	6	US-10-516-768-26	Sequence 26, Appl
2	57	41.0	30	7	US-11-098-674-13	Sequence 13, Appl
3	43	30.9	37	6	US-10-516-768-23	Sequence 23, Appl
4	43	30.9	37	6	US-10-516-768-25	Sequence 25, Appl
5	41.5	29.9	668	7	US-11-052-554A-103	Sequence 103, Appl
6	37	28.6	40	6	US-10-516-768-6	Sequence 6, Appl
7	37	28.6	125	6	US-10-516-768-8	Sequence 8, Appl
8	36	25.9	37	6	US-10-516-768-24	Sequence 24, Appl
9	36	25.9	37	6	US-10-516-768-30	Sequence 30, Appl
10	36	25.9	38	6	US-10-516-768-1	Sequence 1, Appl
11	36	25.9	39	6	US-10-516-768-2	Sequence 2, Appl
12	36	25.9	126	6	US-10-516-768-4	Sequence 4, Appl
13	36	25.9	600	7	US-11-055-822-228	Sequence 228, Appl
14	36	25.9	600	7	US-11-055-822-716	Sequence 716, Appl
15	36	25.9	600	7	US-11-055-822-758	Sequence 758, Appl
16	36	25.9	745	6	US-10-858-730-224	Sequence 224, Appl
17	36	25.9	745	7	US-11-055-822-226	Sequence 226, Appl
18	36	25.9	745	7	US-11-055-822-714	Sequence 714, Appl
19	36	25.9	745	7	US-11-055-822-756	Sequence 756, Appl
20	36	25.9	745	7	US-11-168-476-2	Sequence 2, Appl
21	35	25.2	23	6	US-10-516-768-33	Sequence 33, Appl
22	35	25.2	497	6	US-10-793-626-2812	Sequence 2812, Ap
23	34	24.5	418	6	US-10-878-556A-78	Sequence 78, Appl
24	34	24.5	507	6	US-10-454-437-38	Sequence 38, Appl
25	34	24.5	759	6	US-10-858-730-75	Sequence 75, Appl

26	34	24.5	760	6	US-10-858-730-76	Sequence 76, Appl
27	34	24.5	771	6	US-10-467-657-5562	Sequence 5562, Ap
28	34	24.5	772	6	US-10-858-730-77	Sequence 77, Appl
29	34	24.5	805	6	US-10-518-599-24	Sequence 24, Appl
30	33	24.5	247	6	US-10-510-386-242	Sequence 242, App
31	33	23.7	271	6	US-10-995-561-533	Sequence 533, App
32	33	23.7	325	7	US-11-129-143-88	Sequence 88, Appl
33	33	23.7	382	7	US-11-055-822-302	Sequence 302, App
34	33	23.7	382	7	US-11-055-822-344	Sequence 344, App
35	33	23.7	408	6	US-10-467-657-7592	Sequence 7592, Ap
36	33	23.7	408	6	US-10-467-657-8366	Sequence 8366, Ap
37	33	23.7	409	7	US-11-055-822-290	Sequence 290, App
38	33	23.7	468	7	US-11-054-385-12	Sequence 12, Appl
39	33	23.7	555	7	US-11-124-368A-300	Sequence 300, App
40	33	23.7	578	6	US-10-858-730-103	Sequence 103, App
41	33	23.7	749	7	US-11-124-368A-299	Sequence 299, App
42	33	23.7	859	7	US-11-124-368A-298	Sequence 298, App
43	33	23.7	877	7	US-11-124-368A-302	Sequence 302, App
44	33	23.7	943	6	US-10-475-204-34	Sequence 34, Appl
45	32.5	23.4	362	7	US-11-052-554A-77	Sequence 77, Appl
46	32.5	23.4	362	7	US-11-052-554A-204	Sequence 204, App
47	32	23.0	126	6	US-10-793-626-670	Sequence 670, App
48	32	23.0	126	6	US-10-793-626-1604	Sequence 1604, Ap
49	32	23.0	232	6	US-10-793-626-1606	Sequence 1606, Ap
50	32	23.0	239	7	US-11-194-246-304	Sequence 304, App
51	32	23.0	306	6	US-10-793-626-574	Sequence 574, App
52	32	23.0	306	6	US-10-793-626-2490	Sequence 2490, Ap
53	32	23.0	306	6	US-10-793-626-2640	Sequence 2640, Ap
54	32	23.0	867	6	US-10-131-826A-20	Sequence 20, Appl
55	32	23.0	870	6	US-10-933-025-6	Sequence 6, Appl
56	32	23.0	870	6	US-10-933-025-15	Sequence 15, Appl
57	32	23.0	875	6	US-10-933-025-12	Sequence 12, Appl
58	32	23.0	875	6	US-10-933-025-18	Sequence 18, Appl
59	31.5	22.7	687	7	US-11-074-176-360	Sequence 260, App
60	31	22.3	66	6	US-10-986-501-160	Sequence 160, App
61	31	22.3	127	6	US-10-667-295-57	Sequence 57, Appl
62	31	22.3	128	6	US-10-667-295-21	Sequence 21, Appl
63	31	22.3	128	6	US-10-667-295-56	Sequence 56, Appl
64	31	22.3	128	6	US-10-667-295-182	Sequence 182, App
65	31	22.3	152	6	US-10-667-295-213	Sequence 213, App
66	31	22.3	153	6	US-10-667-295-213	Sequence 213, App
67	31	22.3	162	6	US-10-667-295-156	Sequence 156, App
68	31	22.3	162	6	US-10-667-295-181	Sequence 181, App
69	31	22.3	199	6	US-10-667-295-231	Sequence 231, App
70	31	22.3	199	6	US-10-667-295-232	Sequence 232, App
71	31	22.3	200	6	US-10-667-295-155	Sequence 155, App
72	31	22.3	200	6	US-10-667-295-180	Sequence 180, App
73	31	22.3	207	6	US-10-667-295-20	Sequence 20, Appl
74	31	22.3	207	6	US-10-667-295-55	Sequence 55, Appl
75	31	22.3	229	6	US-10-667-295-19	Sequence 19, Appl
76	31	22.3	232	6	US-10-667-295-212	Sequence 212, App
77	31	22.3	430	6	US-10-467-657-5700	Sequence 5700, Ap
78	31	22.3	430	6	US-10-467-657-7448	Sequence 7448, Ap
79	31	22.3	777	6	US-10-645-441-3	Sequence 3, Appl
80	31	22.3	841	7	US-11-050-804-2	Sequence 2, Appl
81	31	22.3	910	6	US-10-131-826A-112	Sequence 112, App
82	31	22.3	932	6	US-10-523-477-14	Sequence 14, Appl
83	31	22.3	1032	7	US-11-014-367-3	Sequence 3, Appl
84	31	22.3	1189	6	US-10-821-234-1209	Sequence 1209, Ap
85	31	22.3	1433	7	US-11-094-519A-40	Sequence 40, Appl
86	31	22.3	1538	6	US-10-995-561-772	Sequence 772, App
87	31	22.3	2339	7	US-11-096-281-11	Sequence 11, Appl
88	31	22.3	3157	7	US-11-052-554A-142	Sequence 142, App
89	31	22.3	5335	6	US-10-995-561-777	Sequence 777, App
90	31	22.3	5406	6	US-10-995-561-774	Sequence 774, App
91	31	22.3	5415	6	US-10-995-561-779	Sequence 779, App
92	31	22.3	5464	6	US-10-995-561-775	Sequence 775, App
93	31	22.3	5935	6	US-10-995-561-776	Sequence 776, App
94	30.5	21.9	81	7	US-11-020-772-2	Sequence 2, Appl
95	30	21.6	28	6	US-10-374-954-27	Sequence 27, Appl
96	30	21.6	136	6	US-10-793-626-1852	Sequence 1852, Ap
97	30	21.6	244	6	US-10-515-868-3	Sequence 3, Appl
98	30	21.6	255	7	US-11-115-086-11	Sequence 11, Appl

```

99 30 21.6 256 7 US-11-113-424-183
100 30 21.6 436 6 US-10-467-657-4550
101 30 21.6 438 6 US-10-641-678-49
102 30 21.6 525 6 US-10-641-678-52
103 30 21.6 525 6 US-10-641-678-53
104 30 21.6 720 6 US-10-793-626-2058
105 30 21.6 753 6 US-10-858-730-225
106 30 21.6 798 6 US-10-821-234-1034
107 30 21.6 834 6 US-11-052-554A-212
108 30 21.6 922 7 US-11-115-086-9
109 30 21.6 974 7 US-11-115-086-7
110 30 21.6 1562 6 US-11-052-554A-211
111 30 21.6 1998 6 US-10-374-954-21
112 30 21.6 2009 6 US-10-374-954-2
113 30 21.6 2710 6 US-10-051-453-41
114 29.5 21.2 132 6 US-10-986-501-138
115 29.5 21.2 208 6 US-10-467-657-8494
116 29.5 21.2 308 7 US-11-082-389-140
117 29.5 21.2 308 7 US-11-082-389-142
118 29.5 21.2 465 6 US-10-967-648A-6
119 29.5 21.2 736 7 US-11-145-035-22
120 29.5 21.2 1237 7 US-11-052-554A-95
121 29 20.9 54 7 US-11-150-054A-18
122 29 20.9 98 7 US-11-025-712-1
123 29 20.9 98 7 US-11-025-712-3
124 29 20.9 103 7 US-11-025-712-4
125 29 20.9 103 7 US-11-075-351-48
126 29 20.9 103 7 US-11-075-351-50
127 29 20.9 103 7 US-11-075-351-51
128 29 20.9 103 7 US-11-075-351-57
129 29 20.9 176 7 US-11-052-554A-326
130 29 20.9 220 7 US-11-094-625-10
131 29 20.9 229 6 US-10-923-327-13
132 29 20.9 229 6 US-10-923-327-14
133 29 20.9 232 7 US-11-025-712-10
134 29 20.9 232 7 US-11-173-564-2
135 29 20.9 232 7 US-11-052-554A-189
136 29 20.9 233 6 US-10-923-327-18
137 29 20.9 233 6 US-10-923-327-19
138 29 20.9 236 7 US-11-000-463-394
139 29 20.9 250 7 US-11-054-669-110
140 29 20.9 287 7 US-11-198-819-6
141 29 20.9 287 7 US-11-198-819-8
142 29 20.9 327 6 US-10-999-866-38
143 29 20.9 327 7 US-11-061-821-38
144 29 20.9 327 7 US-11-102-621-114
145 29 20.9 327 7 US-11-102-621-116
146 29 20.9 327 7 US-11-102-621-117
147 29 20.9 330 7 US-11-022-289-1
148 29 20.9 330 7 US-11-022-289-11
149 29 20.9 330 7 US-11-075-351-1
150 29 20.9 330 7 US-11-165-141-15

```

ALIGNMENTS

```

RESULT 1
US-10-516-768-26
; Sequence 26, Application US/10516768
; Publication No. US20050256302A1
; GENERAL INFORMATION:
; APPLICANT: MINAMINO, NAOTO
; APPLICANT: KATAFUCHI, TAKESHI
; TITLE OF INVENTION: NOVEL PEPTIDES HAVING CAMP PRODUCING ACTIVITY
; FILE REFERENCE: 62273(71526)
; CURRENT APPLICATION NUMBER: US/10/516,768
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: PCT/JP03/06641
; PRIOR FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: JP 2002-162797
; PRIOR FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 52

```

```

; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 26
; LENGTH: 37
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: C-term amidated
US-10-516-768-26

Query Match 73.4%; Score 102; DB 6; Length 37;
Best Local Similarity 62.9%; Pred. No. 1.2e-13;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFLXXXXXXXXXGXPLPTXVGSNTY 37
||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNFGAILSTNVGSNTY 37

RESULT 2
US-11-098-674-13
; Sequence 13, Application US/11098674
; Publication No. US20050267029A1
; GENERAL INFORMATION:
; APPLICANT: Ancsin, John B.
; APPLICANT: Kisilevsky, Robert
; APPLICANT: Elimova, Elena
; TITLE OF INVENTION: Compounds which Modulate Amyloidogenesis and Methods for Their
; FILE REFERENCE: PTQ-0066
; CURRENT APPLICATION NUMBER: US/11/098,674
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: US 60/559,122
; PRIOR FILING DATE: 2004-04-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-098-674-13

Query Match 41.0%; Score 57; DB 7; Length 30;
Best Local Similarity 85.7%; Pred. No. 5.3e-05;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFL 16
||||| ||||| |||||
Db 14 NTATCATQRLANFL 27

RESULT 3
US-10-516-768-23
; Sequence 23, Application US/10516768
; Publication No. US20050256302A1
; GENERAL INFORMATION:
; APPLICANT: MINAMINO, NAOTO
; APPLICANT: KATAFUCHI, TAKESHI
; TITLE OF INVENTION: NOVEL PEPTIDES HAVING CAMP PRODUCING ACTIVITY
; FILE REFERENCE: 62273(71526)
; CURRENT APPLICATION NUMBER: US/10/516,768
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: PCT/JP03/06641
; PRIOR FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: JP 2002-162797
; PRIOR FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 23
; LENGTH: 37
; TYPE: PRT
; ORGANISM: Sus sp.
; FEATURE:
; OTHER INFORMATION: C-term amidated

```



```
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 758
; LENGTH: 600
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-758

Query Match          25.9%; Score 36; DB 7; Length 600;
Best Local Similarity 60.0%; Pred. No. 16;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy      25 PXLPTXVGS 34
      |||||:
Db      411 PALPTTIGS 420

RESULT 16
US-10-858-730-224
; Sequence 224, Application US/10858730
; Publication No. US20050255568A1
; GENERAL INFORMATION:
; APPLICANT: Bailey, Richard B.
; APPLICANT: Blomquist, Paul
; APPLICANT: Doten, Reed
; APPLICANT: Driggers, Edward M.
; APPLICANT: Madden, Kevin T.
; APPLICANT: O'Leary, Jessica
; APPLICANT: O'Toole, George
; APPLICANT: Trueheart, Joshua
; APPLICANT: Walbridge, Michael J.
; APPLICANT: Yorgey, Peter S.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR AMINO ACID
; FILE REFERENCE: 14184-030001
; CURRENT APPLICATION NUMBER: US/10/858,730
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 60/475,000
; PRIOR FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: US 60/551,860
; PRIOR FILING DATE: 2004-03-10
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Coryne-bacterium glutamicum
US-10-858-730-224

Query Match          25.9%; Score 36; DB 6; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy      25 PXLPTXVGS 34
      |||||:
Db      411 PALPTTIGS 420

RESULT 17
US-11-055-822-226
; Sequence 226, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
; APPLICANT: Pompejus, Markus
; APPLICANT: Kroger, Burkhard
```

```
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberhauer, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; TITLE OF INVENTION: METABOLIC PATHWAY PROTEINS
; FILE REFERENCE: BGI-121CPCN
; CURRENT APPLICATION NUMBER: US/11/055,822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 226
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-226

Query Match          25.9%; Score 36; DB 7; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy      25 PXLPTXVGS 34
      |||||:
Db      411 PALPTTIGS 420

RESULT 18
US-11-055-822-714
; Sequence 714, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
; APPLICANT: Pompejus, Markus
; APPLICANT: Kroger, Burkhard
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberhauer, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; TITLE OF INVENTION: METABOLIC PATHWAY PROTEINS
; FILE REFERENCE: BGI-121CPCN
; CURRENT APPLICATION NUMBER: US/11/055,822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
```

```
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 714
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-714

Query Match      25.9%; Score 36; DB 7; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Db      25 PXLPTXVGS 34
      |||||:
      411 PALPTTTIGS 420

RESULT 19
US-11-055-822-756
; Sequence 756, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
; APPLICANT: Pompejus, Markus
; APPLICANT: Kroger, Burkhard
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberhauer, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; TITLE OF INVENTION: METABOLIC PATHWAY PROTEINS
; FILE REFERENCE: BGI-121PCN
; CURRENT APPLICATION NUMBER: US/11/055.822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 756
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-756

Query Match      25.9%; Score 36; DB 7; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Db      25 PXLPTXVGS 34
      |||||:
      411 PALPTTTIGS 420

Query Match      25.9%; Score 36; DB 7; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Db      25 PXLPTXVGS 34
      |||||:
      411 PALPTTTIGS 420
```

```
Db      411 PALPTTTIGS 420

RESULT 20
US-11-168-476-2
; Sequence 2, Application US/11168476
; Publication No. US20050266535A1
; GENERAL INFORMATION:
; APPLICANT: BATHE, BRIGITTE
; APPLICANT: MOECKEL, BETTINA
; APPLICANT: PFEFFERLE, WALTER
; APPLICANT: HUTHMACHER, KLAUS
; APPLICANT: RUECKERT, CHRISTIAN
; APPLICANT: KALINOWSKI, JOERN
; APPLICANT: PUEHLER, ALFRED
; APPLICANT: BINDER, MICHAEL
; APPLICANT: GRISSINGER, DIETER
; APPLICANT: THIERRACH, GEORG
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCES WHICH CODE FOR THE METE GENE
; FILE REFERENCE: 211710USOX
; CURRENT APPLICATION NUMBER: US/11/168.476
; CURRENT FILING DATE: 2005-06-29
; PRIOR APPLICATION NUMBER: US/09/919,835
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: DE 10038023.9
; PRIOR FILING DATE: 2000-08-02
; PRIOR APPLICATION NUMBER: DE 10109689.5
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: US 60/294,250
; PRIOR FILING DATE: 2001-05-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 745
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-168-476-2

Query Match      25.9%; Score 36; DB 7; Length 745;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy      25 PXLPTXVGS 34
      |||||:
      411 PALPTTTIGS 420

Db      411 PALPTTTIGS 420

RESULT 21
US-10-516-768-33
; Sequence 33, Application US/10516768
; Publication No. US20050256302A1
; GENERAL INFORMATION:
; APPLICANT: MINAMINO, NAOTO
; APPLICANT: KATAFUCHI, TAKESHI
; TITLE OF INVENTION: NOVEL PEPTIDES HAVING CAMP PRODUCING ACTIVITY
; FILE REFERENCE: 62273(71526)
; CURRENT APPLICATION NUMBER: US/10/516.768
; CURRENT FILING DATE: 2004-12-03
; PRIOR APPLICATION NUMBER: PCT/JP03/06641
; PRIOR FILING DATE: 2003-05-28
; PRIOR APPLICATION NUMBER: JP 2002-162797
; PRIOR FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 33
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Sus sp.
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: (2)
; OTHER INFORMATION: Variable amino acid
; FEATURE:
```


; CURRENT APPLICATION NUMBER: US/10/858,730
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 60/475,000
; PRIOR FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: US 60/551,860
; PRIOR FILING DATE: 2004-03-10
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 75
; LENGTH: 759
; TYPE: PRT
; ORGANISM: Mycobacterium tuberculosis
US-10-858-730-75

Query Match 24.5%; Score 34; DB 6; Length 759;
Best Local Similarity 60.0%; Pred. No. 51;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 25 PXLPTXVGS 34
| | | | : | |
Db 430 PPLPTTIGS 439

RESULT 26

US-10-858-730-76
; Sequence 76, Application US/10858730
; Publication No. US2005025568A1
; GENERAL INFORMATION:
; APPLICANT: Bailey, Richard B.
; APPLICANT: Blomquist, Paul
; APPLICANT: Doten, Reed
; APPLICANT: Driggers, Edward M.
; APPLICANT: Madden, Kevin T.
; APPLICANT: O'Leary, Jessica
; APPLICANT: O'Toole, George
; APPLICANT: Trueheart, Joshua
; APPLICANT: Walbridge, Michael J.
; APPLICANT: Yorgey, Peter S.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR AMINO ACID
; FILE REFERENCE: 14184-030001
; CURRENT APPLICATION NUMBER: US/10/858,730
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 60/475,000
; PRIOR FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: US 60/551,860
; PRIOR FILING DATE: 2004-03-10
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 760
; TYPE: PRT
; ORGANISM: Mycobacterium leprae
US-10-858-730-76

Query Match 24.5%; Score 34; DB 6; Length 760;
Best Local Similarity 60.0%; Pred. No. 51;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 25 PXLPTXVGS 34
| | | | : | |
Db 430 PPLPTTIGS 439

RESULT 27

US-10-467-657-5562
; Sequence 5562, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SPA
; APPLICANT: FONTANA Maria Rita
; APPLICANT: PIZZA Mariagrazia
; APPLICANT: MASIGNANI Vega

; APPLICANT: MONACI Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWin99, version 1.04
; SEQ ID NO 5562
; LENGTH: 771
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-5562

Query Match 24.5%; Score 34; DB 6; Length 771;
Best Local Similarity 60.0%; Pred. No. 52;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 25 PXLPTXVGS 34
| | | | : | |
Db 439 PPLPTTIGS 448

RESULT 28

US-10-858-730-77
; Sequence 77, Application US/10858730
; Publication No. US2005025568A1
; GENERAL INFORMATION:
; APPLICANT: Bailey, Richard B.
; APPLICANT: Blomquist, Paul
; APPLICANT: Doten, Reed
; APPLICANT: Driggers, Edward M.
; APPLICANT: Madden, Kevin T.
; APPLICANT: O'Leary, Jessica
; APPLICANT: O'Toole, George
; APPLICANT: Trueheart, Joshua
; APPLICANT: Walbridge, Michael J.
; APPLICANT: Yorgey, Peter S.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR AMINO ACID
; FILE REFERENCE: 14184-030001
; CURRENT APPLICATION NUMBER: US/10/858,730
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 60/475,000
; PRIOR FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: US 60/551,860
; PRIOR FILING DATE: 2004-03-10
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 77
; LENGTH: 772
; TYPE: PRT
; ORGANISM: Streptomyces coelicolor
US-10-858-730-77

Query Match 24.5%; Score 34; DB 6; Length 772;
Best Local Similarity 60.0%; Pred. No. 52;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 25 PXLPTXVGS 34
| | | | : | |
Db 439 PPLPTTIGS 448

RESULT 29

US-10-518-599-24
; Sequence 24, Application US/10518599
; Publication No. US20050251873A1
; GENERAL INFORMATION:
; APPLICANT: PENNINGER, JOSEPH M.
; APPLICANT: CRACKOWER, MICHAEL A.
; TITLE OF INVENTION: ACE2 ACTIVATION FOR TREATMENT OF HEART, LUNG AND

```
; TITLE OF INVENTION: KIDNEY DISEASE AND HYPERTENSION
; FILE REFERENCE: SONN:064US
; CURRENT APPLICATION NUMBER: US/10/518,599
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: PCT/CA03/00882
; PRIOR FILING DATE: 2003-06-19
; PRIOR APPLICATION NUMBER: US 60/389,709
; PRIOR FILING DATE: 2002-06-19
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 805
; TYPE: PRT
; ORGANISM: Rattus rattus
US-10-518-599-24

Query Match      24.5%; Score 34; DB 6; Length 805;
Best Local Similarity 39.1%; Pred. No. 55;
Matches 9; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

Qy 3 NTATYATQRLXNLFXXXXXNKG 25
Db 545 SNTEAGQKLLNML--SLGNSGP 565

RESULT 30
US-10-510-386-242
; Sequence 242, Application US/10510386
; Publication No. US20050244922A1
; GENERAL INFORMATION:
; APPLICANT: Andersen, Jens Tonne
; APPLICANT: Clausen, Ib Groth
; APPLICANT: Jorgensen, Steen Troels
; APPLICANT: Olsen, Peter Bjarke
; TITLE OF INVENTION: Improved Bacillus Host Cell
; FILE REFERENCE: 10294.204-US
; CURRENT APPLICATION NUMBER: US/10/510,386
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 242
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Bacillus licheniformis
US-10-510-386-242

Query Match      23.7%; Score 33; DB 6; Length 247;
Best Local Similarity 33.3%; Pred. No. 24;
Matches 7; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

Qy 5 ATXATQRLXNLFXXXXXNKG 25
Db 113 STHKQRLVSYLLVEQKAGP 133

RESULT 31
US-10-995-561-533
; Sequence 533, Application US/10995561
; Publication No. US20050272054A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
; TITLE OF INVENTION: DETECTION AND USES THEREOF
; FILE REFERENCE: CL001559
; CURRENT APPLICATION NUMBER: US/10/995,561
; CURRENT FILING DATE: 2004-11-24
; NUMBER OF SEQ ID NOS: 85702
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 533
; LENGTH: 271
; TYPE: PRT

; TITLE OF INVENTION: KIDNEY DISEASE AND HYPERTENSION
; FILE REFERENCE: SONN:064US
; CURRENT APPLICATION NUMBER: US/10/518,599
; CURRENT FILING DATE: 2004-12-17
; PRIOR APPLICATION NUMBER: PCT/CA03/00882
; PRIOR FILING DATE: 2003-06-19
; PRIOR APPLICATION NUMBER: US 60/389,709
; PRIOR FILING DATE: 2002-06-19
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 805
; TYPE: PRT
; ORGANISM: Rattus rattus
US-10-518-599-24

Query Match      24.5%; Score 34; DB 6; Length 805;
Best Local Similarity 39.1%; Pred. No. 55;
Matches 9; Conservative 3; Mismatches 9; Indels 2; Gaps 1;

Qy 3 NTATYATQRLXNLFXXXXXNKG 25
Db 545 SNTEAGQKLLNML--SLGNSGP 565

RESULT 30
US-10-510-386-242
; Sequence 242, Application US/10510386
; Publication No. US20050244922A1
; GENERAL INFORMATION:
; APPLICANT: Andersen, Jens Tonne
; APPLICANT: Clausen, Ib Groth
; APPLICANT: Jorgensen, Steen Troels
; APPLICANT: Olsen, Peter Bjarke
; TITLE OF INVENTION: Improved Bacillus Host Cell
; FILE REFERENCE: 10294.204-US
; CURRENT APPLICATION NUMBER: US/10/510,386
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 242
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Bacillus licheniformis
US-10-510-386-242

Query Match      23.7%; Score 33; DB 6; Length 247;
Best Local Similarity 33.3%; Pred. No. 24;
Matches 7; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

Qy 5 ATXATQRLXNLFXXXXXNKG 25
Db 113 STHKQRLVSYLLVEQKAGP 133

RESULT 31
US-10-995-561-533
; Sequence 533, Application US/10995561
; Publication No. US20050272054A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
; TITLE OF INVENTION: DETECTION AND USES THEREOF
; FILE REFERENCE: CL001559
; CURRENT APPLICATION NUMBER: US/10/995,561
; CURRENT FILING DATE: 2004-11-24
; NUMBER OF SEQ ID NOS: 85702
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 533
; LENGTH: 271
; TYPE: PRT

; ORGANISM: Homo sapiens
US-10-995-561-533

Query Match      23.7%; Score 33; DB 6; Length 271;
Best Local Similarity 50.0%; Pred. No. 26;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 25 PXLPTXVXGNT 36
Db 208 PEIPKTIITGSET 219

RESULT 32
US-11-129-143-88
; Sequence 88, Application US/11129143
; Publication No. US20050266518A1
; GENERAL INFORMATION:
; APPLICANT: BERRY, Alan
; APPLICANT: BRETZEL, Werner
; APPLICANT: HUMBEIN, Markus
; APPLICANT: LOPEZ-ULIBARRI, Rual
; APPLICANT: MAYER, Anne F.
; APPLICANT: YELISEEV, Alexei A.
; TITLE OF INVENTION: IMPROVED ISOPRENOID PRODUCTION
; FILE REFERENCE: C38435/121966
; CURRENT APPLICATION NUMBER: US/11/129,143
; CURRENT FILING DATE: 2005-05-13
; NUMBER OF SEQ ID NOS: 197
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 88
; LENGTH: 325
; TYPE: PRT
; ORGANISM: Enterococcus faecium
US-11-129-143-88

Query Match      23.7%; Score 33; DB 7; Length 325;
Best Local Similarity 25.0%; Pred. No. 32;
Matches 7; Conservative 5; Mismatches 16; Indels 0; Gaps 0;

Qy 8 ATQRLXNLFXXXXXNKGXPLXPTXVGSN 35
Db 68 ATKVSOQFLDLFRKEAGLSLKASVISQN 95

RESULT 33
US-11-055-822-302
; Sequence 302, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
; APPLICANT: Pompejus, Markus
; APPLICANT: Kroger, Burkhard
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberhauser, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; FILE REFERENCE: BGI-121CPCN
; CURRENT APPLICATION NUMBER: US/11/055,822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
```

```
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 302
; LENGTH: 382
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-302

Query Match      23.7%; Score 33; DB 7; Length 382;
Best Local Similarity 53.8%; Pred. No. 38;
Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 4 TATXATQRLXNPL 16
   |||||: |||
Db 2 TATYTTETAINPL 14

RESULT 34
US-11-055-822-344
; Sequence 344, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
; APPLICANT: Pompejus, Markus
; APPLICANT: Kroger, Burkhard
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberer, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; FILE REFERENCE: BGI-121CPN
; CURRENT APPLICATION NUMBER: US/11/055,822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 344
; LENGTH: 382
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-344

Query Match      23.7%; Score 33; DB 7; Length 382;
Best Local Similarity 53.8%; Pred. No. 38;
Matches 7; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 4 TATXATQRLXNPL 16
   |||||: |||
Db 2 TATYTTETAINPL 14
```

```
RESULT 35
US-10-467-657-7592
; Sequence 7592, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SpA
; APPLICANT: FONTANA Maria Rita
; APPLICANT: PIZZA Mariagrazia
; APPLICANT: MASIGNANI Vega
; APPLICANT: MONACI Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWin99, version 1.04
; SEQ ID NO 7592
; LENGTH: 408
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-7592

Query Match      23.7%; Score 33; DB 6; Length 408;
Best Local Similarity 46.2%; Pred. No. 41;
Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNF 15
   ||||: |||
Db 267 NTAPQSLERILNF 279

RESULT 36
US-10-467-657-8366
; Sequence 8366, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SpA
; APPLICANT: FONTANA Maria Rita
; APPLICANT: PIZZA Mariagrazia
; APPLICANT: MASIGNANI Vega
; APPLICANT: MONACI Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWin99, version 1.04
; SEQ ID NO 8366
; LENGTH: 408
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-8366

Query Match      23.7%; Score 33; DB 6; Length 408;
Best Local Similarity 46.2%; Pred. No. 41;
Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNF 15
   ||||: |||
Db 267 NTAPQSLERILNF 279

RESULT 37
US-11-055-822-290
; Sequence 290, Application US/11055822
; Publication No. US20050260707A1
; GENERAL INFORMATION:
```

; APPLICANT: Pompejus, Markus
; APPLICANT: Krogex, Burkhard
; APPLICANT: Schroder, Hartwig
; APPLICANT: Zelder, Oskar
; APPLICANT: Haberhauer, Gregor
; TITLE OF INVENTION: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING
; TITLE OF INVENTION: METABOLIC PATHWAY PROTEINS
; FILE REFERENCE: BGI-121CPN
; CURRENT APPLICATION NUMBER: US/11/055,822
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: 09/606,740
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/141,031
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 60/142,101
; PRIOR FILING DATE: 1999-07-02
; PRIOR APPLICATION NUMBER: 60/148,613
; PRIOR FILING DATE: 1999-08-12
; PRIOR APPLICATION NUMBER: 60/187,970
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: DE 19930476.9
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: DE 19931415.2
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931418.7
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931419.5
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: DE 19931420.9
; PRIOR FILING DATE: 1999-07-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1158
; SEQ ID NO 290
; LENGTH: 409
; TYPE: PRT
; ORGANISM: Corynebacterium glutamicum
US-11-055-822-290

Query Match 23.7%; Score 33; DB 7; Length 409;
Best Local Similarity 36.8%; Pred. No. 41;
Matches 7; Conservative 1; Mismatches 11; Indels 0; Gaps 0;

Qy 16 LXXXXXXGXPXPTXVGS 34
Db 276 LLSAANIGPALEDAQVGT 294

RESULT 38
US-11-054-385-12
; Sequence 12, Application US/11054385
; Publication No. US20050257291A1
; GENERAL INFORMATION:
; APPLICANT: MIZUTANI, Masako
; APPLICANT: TANAKA, Yoshikazu
; APPLICANT: KUSUMI, Takaaki
; APPLICANT: SAITO, Kazuki
; APPLICANT: YAMAZAKI, Mami
; APPLICANT: ZHIZHONG, GONG
; TITLE OF INVENTION: GENES ENCODING PROTEINS HAVING TRANSGLYCOSYLATION
; TITLE OF INVENTION: ACTIVITY
; FILE REFERENCE: 001560-350
; CURRENT APPLICATION NUMBER: US/11/054,385
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: US/09/147,955
; PRIOR FILING DATE: 1999-03-24
; PRIOR APPLICATION NUMBER: PCT/JP98/03199
; PRIOR FILING DATE: 1998-07-16
; PRIOR APPLICATION NUMBER: JP 9-200571
; PRIOR FILING DATE: 1997-07-25
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 12
; LENGTH: 468

; TYPE: PRT
; ORGANISM: Petunia hybrida
US-11-054-385-12

Query Match 23.7%; Score 33; DB 7; Length 468;
Best Local Similarity 41.7%; Pred. No. 48;
Matches 5; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 24 GPXLPXTXVGSN 35
Db 238 GPLPSAFLGCGN 249

RESULT 39

US-11-124-368A-300
; Sequence 300, Application US/11124368A
; Publication No. US20050287559A1
; GENERAL INFORMATION:
; APPLICANT: Michele Cargill
; APPLICANT: James J. Devlin
; APPLICANT: May Luke
; TITLE OF INVENTION: Genetic Polymorphisms Associated with
; TITLE OF INVENTION: Vascular Diseases, Methods of Detection and Uses Thereof
; FILE REFERENCE: CLO01524
; CURRENT APPLICATION NUMBER: US/11/124,368A
; CURRENT FILING DATE: 2005-05-09
; PRIOR APPLICATION NUMBER: US 60/568,845
; PRIOR FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: US 60/625,936
; PRIOR FILING DATE: 2004-11-09
; NUMBER OF SEQ ID NOS: 21112
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 300
; LENGTH: 555
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-124-368A-300

Query Match 23.7%; Score 33; DB 7; Length 555;
Best Local Similarity 46.2%; Pred. No. 57;
Matches 6; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNF 15
Db 437 NTVKCKTKLANF 449

RESULT 40

US-10-858-730-103
; Sequence 103, Application US/10858730
; Publication No. US20050255568A1
; GENERAL INFORMATION:
; APPLICANT: Bailey, Richard B.
; APPLICANT: Blomquist, Paul
; APPLICANT: Doten, Reed
; APPLICANT: Driggers, Edward M.
; APPLICANT: Madden, Kevin T.
; APPLICANT: O'Leary, Jessica
; APPLICANT: O'Toole, George
; APPLICANT: Trueheart, Joshua
; APPLICANT: Walbridge, Michael J.
; APPLICANT: Yorgey, Peter S.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR AMINO ACID
; TITLE OF INVENTION: PRODUCTION
; FILE REFERENCE: 14184-030001
; CURRENT APPLICATION NUMBER: US/10/858,730
; CURRENT FILING DATE: 2004-06-01
; PRIOR APPLICATION NUMBER: US 60/475,000
; PRIOR FILING DATE: 2003-05-30
; PRIOR APPLICATION NUMBER: US 60/551,860
; PRIOR FILING DATE: 2004-03-10
; NUMBER OF SEQ ID NOS: 364
; SOFTWARE: FastSeq for Windows Version 4.0

```
; SEQ ID NO 103
; LENGTH: 578
; TYPE: PRT
; ORGANISM: Streptomyces coelicolor
US-10-858-730-103

Query Match      23.7%; Score 33; DB 6; Length 578;
Best Local Similarity 37.0%; Pred. No. 60;
Matches 10; Conservative 1; Mismatches 12; Indels 4; Gaps 1;

Oy 11 RLXNFXLXXXXXNXPXLPXTXVGSNTY 37
Db 493 RFASALPYTTAAIGLPLP----GSATY 515

RESULT 41
US-11-124-368A-299
; Sequence 299, Application US/11124368A
; Publication No. US20050287559A1
; GENERAL INFORMATION:
; APPLICANT: Michele Cargill
; APPLICANT: James J. Devlin
; APPLICANT: May Luke
; TITLE OF INVENTION: Genetic Polymorphisms Associated with
; TITLE OF INVENTION: Vascular Diseases, Methods of Detection and Uses Thereof
; FILE REFERENCE: CL001524
; CURRENT APPLICATION NUMBER: US/11/124,368A
; CURRENT FILING DATE: 2005-05-09
; PRIOR APPLICATION NUMBER: US 60/568,845
; PRIOR FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: US 60/625,936
; PRIOR FILING DATE: 2004-11-09
; NUMBER OF SEQ ID NOS: 21112
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 299
; LENGTH: 749
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-124-368A-299

Query Match      23.7%; Score 33; DB 7; Length 749;
Best Local Similarity 46.2%; Pred. No. 79;
Matches 6; Conservative 2; Mismatches 5; Indels 5; Gaps 0;

Oy 3 NTATXATQRLXNF 15
Db 327 NTVKCTKGLANF 339

RESULT 42
US-11-124-368A-298
; Sequence 298, Application US/11124368A
; Publication No. US20050287559A1
; GENERAL INFORMATION:
; APPLICANT: Michele Cargill
; APPLICANT: James J. Devlin
; APPLICANT: May Luke
; TITLE OF INVENTION: Genetic Polymorphisms Associated with
; TITLE OF INVENTION: Vascular Diseases, Methods of Detection and Uses Thereof
; FILE REFERENCE: CL001524
; CURRENT APPLICATION NUMBER: US/11/124,368A
; CURRENT FILING DATE: 2005-05-09
; PRIOR APPLICATION NUMBER: US 60/568,845
; PRIOR FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: US 60/625,936
; PRIOR FILING DATE: 2004-11-09
; NUMBER OF SEQ ID NOS: 21112
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 298
; LENGTH: 859
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-124-368A-298

Query Match      23.7%; Score 33; DB 6; Length 859;
Best Local Similarity 53.8%; Pred. No. 1e+02;
Matches 7; Conservative 1; Mismatches 5; Indels 5; Gaps 0;

Oy 4 TATXATQRLXNF 16
Db 455 NTVKCTKGLANF 467

RESULT 43
US-11-124-368A-302
; Sequence 302, Application US/11124368A
; Publication No. US20050287559A1
; GENERAL INFORMATION:
; APPLICANT: Michele Cargill
; APPLICANT: James J. Devlin
; APPLICANT: May Luke
; TITLE OF INVENTION: Genetic Polymorphisms Associated with
; TITLE OF INVENTION: Vascular Diseases, Methods of Detection and Uses Thereof
; FILE REFERENCE: CL001524
; CURRENT APPLICATION NUMBER: US/11/124,368A
; CURRENT FILING DATE: 2005-05-09
; PRIOR APPLICATION NUMBER: US 60/568,845
; PRIOR FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: US 60/625,936
; PRIOR FILING DATE: 2004-11-09
; NUMBER OF SEQ ID NOS: 21112
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 302
; LENGTH: 877
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-124-368A-302

Query Match      23.7%; Score 33; DB 7; Length 877;
Best Local Similarity 46.2%; Pred. No. 94;
Matches 6; Conservative 2; Mismatches 5; Indels 5; Gaps 0;

Oy 3 NTATXATQRLXNF 15
Db 455 NTVKCTKGLANF 467

RESULT 44
US-10-475-204-34
; Sequence 34, Application US/10475204
; Publication No. US20050277116A1
; GENERAL INFORMATION:
; APPLICANT: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF
; TITLE OF INVENTION: PROTEIN INTERACTIONS IN VERTEBRATE CELLS
; FILE REFERENCE: HMV-056.25
; CURRENT APPLICATION NUMBER: US/10/475,204
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: PCT/US02/13008
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: 60/285,509
; PRIOR FILING DATE: 2001-04-20
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 943
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-475-204-34

Query Match      23.7%; Score 33; DB 6; Length 943;
Best Local Similarity 53.8%; Pred. No. 1e+02;
Matches 7; Conservative 1; Mismatches 5; Indels 5; Gaps 0;

Oy 4 TATXATQRLXNF 16
Db 455 NTVKCTKGLANF 467
```

Db 583 TATKGNQVQKFL 595

RESULT 45

US-11-052-554A-77

Sequence 77, Application US/11052554A

Publication No. US2005028866A1

GENERAL INFORMATION:

APPLICANT: Sachdeva, et al.

TITLE OF INVENTION: COMPUTATIONAL METHOD FOR IDENTIFYING ADHESIN AND ADHESIN-LIKE

FILE REFERENCE: 30853/40359A

CURRENT APPLICATION NUMBER: US/11/052,554A

CURRENT FILING DATE: 2005-02-07

PRIOR APPLICATION NUMBER: US 60/589,227

PRIOR FILING DATE: 2004-07-20

PRIOR APPLICATION NUMBER: IN 173/DEL/2004

PRIOR FILING DATE: 2004-02-06

NUMBER OF SEQ ID NOS: 763

SOFTWARE: PatentIn version 3.3

SEQ ID NO 77

LENGTH: 362

TYPE: PRT

ORGANISM: Escherichia coli 0157:H7

US-11-052-554A-77

Query Match 23.4%; Score 32.5; DB 7; Length 362;

Best Local Similarity 25.0%; Pred. No. 45;

Matches 9; Conservative 5; Mismatches 21; Indels 1; Gaps 1;

Qy 3 NTATXATQRLXNFXLXXXXXN-XGPKLPXTXVGSNTY 37

Db 157 NTSNNTKVRIDPIIQAQDGLSGFGMACTTVAKQTY 192

RESULT 46

US-11-052-554A-204

Sequence 204, Application US/11052554A

Publication No. US2005028866A1

GENERAL INFORMATION:

APPLICANT: Sachdeva, et al.

TITLE OF INVENTION: COMPUTATIONAL METHOD FOR IDENTIFYING ADHESIN AND ADHESIN-LIKE

FILE REFERENCE: 30853/40359A

CURRENT APPLICATION NUMBER: US/11/052,554A

CURRENT FILING DATE: 2005-02-07

PRIOR APPLICATION NUMBER: US 60/589,227

PRIOR FILING DATE: 2004-07-20

PRIOR APPLICATION NUMBER: IN 173/DEL/2004

PRIOR FILING DATE: 2004-02-06

NUMBER OF SEQ ID NOS: 763

SOFTWARE: PatentIn version 3.3

SEQ ID NO 204

LENGTH: 362

TYPE: PRT

ORGANISM: Shigella flexneri 2a str. 2457T

US-11-052-554A-204

Query Match 23.4%; Score 32.5; DB 7; Length 362;

Best Local Similarity 25.0%; Pred. No. 45;

Matches 9; Conservative 5; Mismatches 21; Indels 1; Gaps 1;

Qy 3 NTATXATQRLXNFXLXXXXXN-XGPKLPXTXVGSNTY 37

Db 157 NTSNNTKVRIDPIIQAQDGLSGFGMACTTVAKQTY 192

RESULT 47

US-10-793-626-670

Sequence 670, Application US/10793626

Publication No. US20050255478A1

GENERAL INFORMATION:

APPLICANT: KIMMERLY, WILLIAM JOHN

TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 670

LENGTH: 126

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: synthetic

OTHER INFORMATION: amino acid sequence

US-10-793-626-670

Query Match 23.0%; Score 32; DB 6; Length 126;

Best Local Similarity 26.5%; Pred. No. 18;

Matches 9; Conservative 3; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNT 36

Db 82 STGGVTTSPVSGFLTPGLPGTSSWLPGFAGFGNS 115

RESULT 48

US-10-793-626-1604

Sequence 1604, Application US/10793626

Publication No. US20050255478A1

GENERAL INFORMATION:

APPLICANT: KIMMERLY, WILLIAM JOHN

TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1604

LENGTH: 126

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: synthetic

OTHER INFORMATION: amino acid sequence

US-10-793-626-1604

Query Match 23.0%; Score 32; DB 6; Length 126;

Best Local Similarity 26.5%; Pred. No. 18;

Matches 9; Conservative 3; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNT 36

Db 82 STGGVTTSPVSGFLTPGLPGTSSWLPGFAGFGNS 115

RESULT 49

US-10-793-626-1606

Sequence 1606, Application US/10793626

Publication No. US20050255478A1

GENERAL INFORMATION:

APPLICANT: KIMMERLY, WILLIAM JOHN

TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1606

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 670

LENGTH: 126

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: synthetic

OTHER INFORMATION: amino acid sequence

US-10-793-626-670

Query Match 23.0%; Score 32; DB 6; Length 126;

Best Local Similarity 26.5%; Pred. No. 18;

Matches 9; Conservative 3; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNT 36

Db 82 STGGVTTSPVSGFLTPGLPGTSSWLPGFAGFGNS 115

RESULT 48

US-10-793-626-1604

Sequence 1604, Application US/10793626

Publication No. US20050255478A1

GENERAL INFORMATION:

APPLICANT: KIMMERLY, WILLIAM JOHN

TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1604

LENGTH: 126

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: synthetic

OTHER INFORMATION: amino acid sequence

US-10-793-626-1604

Query Match 23.0%; Score 32; DB 6; Length 126;

Best Local Similarity 26.5%; Pred. No. 18;

Matches 9; Conservative 3; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNT 36

Db 82 STGGVTTSPVSGFLTPGLPGTSSWLPGFAGFGNS 115

RESULT 49

US-10-793-626-1606

Sequence 1606, Application US/10793626

Publication No. US20050255478A1

GENERAL INFORMATION:

APPLICANT: KIMMERLY, WILLIAM JOHN

TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS

FILE REFERENCE: P03480US

CURRENT APPLICATION NUMBER: US/10/793,626

CURRENT FILING DATE: 2004-03-04

PRIOR APPLICATION NUMBER: 60/164,258

PRIOR FILING DATE: 1999-11-09

NUMBER OF SEQ ID NOS: 4472

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1606

; LENGTH: 232
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
US-10-793-626-1606

Query Match 23.0%; Score 32; DB 6; Length 232;
Best Local Similarity 26.5%; Pred. No. 35;
Matches 9; Conservative 3; Mismatches 22; Indels 0; Gaps 0;
Qy 3 NTATYATQRLXNFLXXXXXNGPXLPTXYVGSNT 36
Db 82 STGGVTTSPVSGFLTPGLPGTSSWLPFGAFGSNS 115

RESULT 50
US-11-194-246-304
; Sequence 304, Application US/11194246
; Publication No. US20050272089A1
; GENERAL INFORMATION:
; APPLICANT: Mott, John
; APPLICANT: Trepod, Catherine
; APPLICANT: Arvidson, Staffan
; TITLE OF INVENTION: CRITICAL GENES AND POLYPEPTIDES OF HAEMOPHILUS INFLUENZAE AND MET
; FILE REFERENCE: 00592.US1 (M&R 268.05920101)
; CURRENT APPLICATION NUMBER: US/11/194,246
; CURRENT FILING DATE: 2005-08-01
; PRIOR APPLICATION NUMBER: US/10/274,586
; PRIOR FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: US 60/345,438
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 621
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 304
; LENGTH: 239
; TYPE: PRT
; ORGANISM: HAEMOPHILUS INFLUENZAE
US-11-194-246-304

Query Match 23.0%; Score 32; DB 7; Length 239;
Best Local Similarity 54.5%; Pred. No. 36;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
Qy ~ 6 TXATQRLXNFL 16
Db 187 TSGEQRISNFL 197

Search completed: January 4, 2006, 12:00:12
Job time : 14 secs

"C" PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:45:42 ; Search time 164 Seconds
(without alignments)
94.266 Million cell updates/sec

Title: US-09-445-517-14

Perfect score: 139

Sequence: 1 XXNTATXATQRLXNLFXXXXXNCGPXLPTXVGSNTY 37

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database :

Published Applications AA Main:
1: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	118	84.9	36	2	US-08-851-965-5
2	118	84.9	36	2	US-08-851-965-12
3	118	84.9	36	2	US-08-851-965-35
4	118	84.9	36	2	US-08-870-762A-12
5	118	84.9	36	2	US-08-870-762A-13
6	118	84.9	36	3	US-09-454-533-18
7	118	84.9	36	3	US-09-454-533-39
8	118	84.9	36	4	US-10-649-138-18
9	118	84.9	36	4	US-10-649-138-39
10	118	84.9	36	4	US-10-643-681-6
11	118	84.9	36	4	US-10-643-681-13
12	118	84.9	36	5	US-10-991-597-23
13	118	84.9	36	5	US-10-991-597-44
14	118	84.9	37	2	US-08-851-965-4
15	118	84.9	37	2	US-08-851-965-11
16	118	84.9	37	2	US-08-851-965-13
17	118	84.9	37	2	US-08-851-965-15
18	118	84.9	37	2	US-08-851-965-34
19	118	84.9	37	2	US-08-870-762A-3
20	118	84.9	37	2	US-08-870-762A-11
21	118	84.9	37	3	US-09-454-533-10
22	118	84.9	37	3	US-09-454-533-17
23	118	84.9	37	3	US-09-454-533-19
24	118	84.9	37	3	US-09-454-533-21
25	118	84.9	37	3	US-09-454-533-38
26	118	84.9	37	4	US-10-649-138-10
27	118	84.9	37	4	US-10-649-138-17
Sequence 5, Appli					
Sequence 12, Appli					
Sequence 13, Appli					
Sequence 18, Appli					
Sequence 39, Appli					
Sequence 18, Appli					
Sequence 36, Appli					
Sequence 13, Appli					
Sequence 23, Appli					
Sequence 44, Appli					
Sequence 11, Appli					
Sequence 15, Appli					
Sequence 34, Appli					
Sequence 3, Appli					
Sequence 11, Appli					
Sequence 10, Appli					
Sequence 17, Appli					
Sequence 21, Appli					
Sequence 38, Appli					
Sequence 10, Appli					
Sequence 17, Appli					

28	118	84.9	37	4	US-10-649-138-19	Sequence 19, Appli
29	118	84.9	37	4	US-10-649-138-21	Sequence 21, Appli
30	118	84.9	37	4	US-10-649-138-38	Sequence 38, Appli
31	118	84.9	37	4	US-10-643-681-3	Sequence 3, Appli
32	118	84.9	37	4	US-10-643-681-12	Sequence 12, Appli
33	118	84.9	37	4	US-10-643-681-14	Sequence 14, Appli
34	118	84.9	37	4	US-10-643-681-16	Sequence 16, Appli
35	118	84.9	37	5	US-10-991-597-15	Sequence 15, Appli
36	118	84.9	37	5	US-10-991-597-22	Sequence 22, Appli
37	118	84.9	37	5	US-10-991-597-24	Sequence 24, Appli
38	118	84.9	37	5	US-10-991-597-26	Sequence 26, Appli
39	118	84.9	37	5	US-10-991-597-43	Sequence 43, Appli
40	117	84.2	36	3	US-08-454-533-11	Sequence 11, Appli
41	117	84.2	36	4	US-10-649-138-11	Sequence 11, Appli
42	117	84.2	36	5	US-10-991-597-16	Sequence 16, Appli
43	117	84.2	37	2	US-08-851-965-27	Sequence 27, Appli
44	117	84.2	37	3	US-09-454-533-33	Sequence 33, Appli
45	117	84.2	37	4	US-10-649-138-33	Sequence 33, Appli
46	117	84.2	37	4	US-10-643-681-28	Sequence 28, Appli
47	117	84.2	37	5	US-10-991-597-38	Sequence 38, Appli
48	116	83.5	36	2	US-08-851-965-8	Sequence 8, Appli
49	116	83.5	36	2	US-08-851-965-9	Sequence 9, Appli
50	116	83.5	36	2	US-08-851-965-18	Sequence 18, Appli
51	116	83.5	36	2	US-08-870-762A-14	Sequence 14, Appli
52	116	83.5	36	2	US-08-870-762A-15	Sequence 15, Appli
53	116	83.5	36	3	US-09-454-533-24	Sequence 24, Appli
54	116	83.5	36	4	US-10-649-138-24	Sequence 24, Appli
55	116	83.5	36	4	US-10-643-681-9	Sequence 9, Appli
56	116	83.5	36	4	US-10-643-681-10	Sequence 10, Appli
57	116	83.5	36	4	US-10-643-681-19	Sequence 19, Appli
58	116	83.5	36	5	US-10-991-597-29	Sequence 29, Appli
59	116	83.5	37	2	US-08-851-965-1	Sequence 1, Appli
60	116	83.5	37	2	US-08-851-965-6	Sequence 6, Appli
61	116	83.5	37	2	US-08-851-965-7	Sequence 7, Appli
62	116	83.5	37	2	US-08-851-965-10	Sequence 10, Appli
63	116	83.5	37	2	US-08-851-965-14	Sequence 14, Appli
64	116	83.5	37	2	US-08-851-965-16	Sequence 16, Appli
65	116	83.5	37	2	US-08-851-965-17	Sequence 17, Appli
66	116	83.5	37	2	US-08-851-965-21	Sequence 21, Appli
67	116	83.5	37	2	US-08-870-762A-1	Sequence 1, Appli
68	116	83.5	37	2	US-08-870-762A-2	Sequence 2, Appli
69	116	83.5	37	2	US-08-870-762A-5	Sequence 5, Appli
70	116	83.5	37	3	US-09-454-533-4	Sequence 4, Appli
71	116	83.5	37	3	US-09-454-533-9	Sequence 9, Appli
72	116	83.5	37	3	US-09-454-533-12	Sequence 12, Appli
73	116	83.5	37	3	US-09-454-533-13	Sequence 13, Appli
74	116	83.5	37	3	US-09-454-533-16	Sequence 16, Appli
75	116	83.5	37	3	US-09-454-533-20	Sequence 20, Appli
76	116	83.5	37	3	US-09-454-533-22	Sequence 22, Appli
77	116	83.5	37	3	US-09-454-533-23	Sequence 23, Appli
78	116	83.5	37	3	US-09-454-533-27	Sequence 27, Appli
79	116	83.5	37	4	US-10-306-645A-1	Sequence 1, Appli
80	116	83.5	37	4	US-10-649-138-4	Sequence 4, Appli
81	116	83.5	37	4	US-10-649-138-9	Sequence 9, Appli
82	116	83.5	37	4	US-10-649-138-9	Sequence 9, Appli
83	116	83.5	37	4	US-10-649-138-12	Sequence 12, Appli
84	116	83.5	37	4	US-10-649-138-13	Sequence 13, Appli
85	116	83.5	37	4	US-10-649-138-16	Sequence 16, Appli
86	116	83.5	37	4	US-10-649-138-20	Sequence 20, Appli
87	116	83.5	37	4	US-10-649-138-22	Sequence 22, Appli
88	116	83.5	37	4	US-10-649-138-23	Sequence 23, Appli
89	116	83.5	37	4	US-10-649-138-27	Sequence 27, Appli
90	116	83.5	37	4	US-10-643-681-1	Sequence 1, Appli
91	116	83.5	37	4	US-10-643-681-7	Sequence 7, Appli
92	116	83.5	37	4	US-10-643-681-8	Sequence 8, Appli
93	116	83.5	37	4	US-10-643-681-11	Sequence 11, Appli
94	116	83.5	37	4	US-10-643-681-15	Sequence 15, Appli
95	116	83.5	37	4	US-10-643-681-17	Sequence 17, Appli
96	116	83.5	37	4	US-10-643-681-18	Sequence 18, Appli
97	116	83.5	37	4	US-10-643-681-22	Sequence 22, Appli
98	116	83.5	37	5	US-10-991-597-9	Sequence 9, Appli
99	116	83.5	37	5	US-10-991-597-14	Sequence 14, Appli
100	116	83.5	37	5	US-10-991-597-17	Sequence 17, Appli


```
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 1,6
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 36
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; US-08-851-965-12
Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXXXXXNGPXLPTXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNLPGVLPSTNVGSNTY 36

RESULT 3
US-08-851-965-35
; Sequence 35, Application US/08851965
; Publication No. US20020010133A1
; GENERAL INFORMATION:
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: GEDULIN, Bronislava
; APPLICANT: BEYNON, Gareth Wyn
; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
; TITLE OF INVENTION: AGONISTS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851.965
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:

; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 1,6
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 36
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; US-08-870-762A-12
Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXXXXXNGPXLPTXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNLPGVLPSTNVGSNTY 36

RESULT 4
US-08-870-762A-12
; Sequence 12, Application US/08870762A
; Publication No. US20030026812A1
; GENERAL INFORMATION:
; APPLICANT: Duft, Bradford
; APPLICANT: Kolterman, Orville
; TITLE OF INVENTION: METHODS FOR TREATING OBESITY
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/870,762A
; FILING DATE: 06-JUN-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 226/104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-2200
; TELEFAX: 619-552-0159
; TELEX:
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 1,6
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 36
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; US-08-870-762A-12
Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXXXXXNGPXLPTXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNLPGVLPSTNVGSNTY 36
```

Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36

RESULT 5

US-08-870-762A-13

Sequence 13, Application US/08870762A

Publication No. US20030026812A1

GENERAL INFORMATION:

APPLICANT: Duft, Bradford

APPLICANT: Kolterman, Orville

TITLE OF INVENTION: METHODS FOR TREATING OBESITY

NUMBER OF SEQUENCES: 15

CORRESPONDENCE ADDRESS:

ADDRESSEE: LYON & LYON

STREET: 633 WEST FIFTH STREET, SUITE 4700

CITY: LOS ANGELES

STATE: CA

COUNTRY: USA

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/870,762A

FILING DATE: 06-JUN-1997

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: DUFT, BRADFORD J

REGISTRATION NUMBER: 32,219

REFERENCE/DOCKET NUMBER: 226/104

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619-552-2200

TELEFAX: 619-552-0159

TELEX:

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 36 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

LOCATION: 1,6

OTHER INFORMATION: disulfide bridge between the Cys residues

OTHER INFORMATION: 36

LOCATION: 36

OTHER INFORMATION: amidated Tyr (Tyrosinamide)

US-08-870-762A-13

Query Match 84.9%; Score 118; DB 2; Length 36;

Best Local Similarity 68.6%; Pred. No. 6.9e-15;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37

Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36

RESULT 6

US-09-454-533-18

Sequence 18, Application US/09454533

Publication No. US20020187923A1

GENERAL INFORMATION:

APPLICANT: GAETA, Laura S.L. Et Al.

TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND USES THEREFOR

NUMBER OF SEQUENCES: 41

CORRESPONDENCE ADDRESS:

ADDRESSEE: LYON & LYON

STREET: 633 WEST FIFTH STREET

CITY: LOS ANGELES

STATE: CALIFORNIA

COUNTRY: USA

ZIP: 90017

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

ADDRESSEE: LYON & LYON

STREET: 633 WEST FIFTH STREET

CITY: LOS ANGELES

STATE: CALIFORNIA

COUNTRY: USA

ZIP: 90017

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

Qy 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37

Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36

RESULT 7

US-09-454-533-39

Sequence 39, Application US/09454533

Publication No. US20020187923A1

GENERAL INFORMATION:

APPLICANT: GAETA, Laura S.L. Et Al.

TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND USES THEREFOR

NUMBER OF SEQUENCES: 41

CORRESPONDENCE ADDRESS:

ADDRESSEE: LYON & LYON

STREET: 633 WEST FIFTH STREET

CITY: LOS ANGELES

STATE: CALIFORNIA

COUNTRY: USA

ZIP: 90017

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

Qy 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37

Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36

Query Match 84.9%; Score 118; DB 3; Length 36;

Best Local Similarity 68.6%; Pred. No. 6.9e-15;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37

Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 39
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 36
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 39:
US-09-454-533-39

Query Match      84.9%; Score 118; DB 3; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPKLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNFGPILPSTNVGSNTY 36

RESULT 8
US-10-649-138-18
; Sequence 18, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S. L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
```

```
;
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 18
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 36
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-649-138-18

Query Match      84.9%; Score 118; DB 4; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPKLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNGLPVPSTNVGSNTY 36

RESULT 9
US-10-649-138-39
; Sequence 39, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S. L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
```


Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 12

US-10-991-597-23
; Sequence 23, Application US/10991597
; Publication No. US20050143303A1
; GENERAL INFORMATION:
; APPLICANT: Quay, Steven C.
; APPLICANT: Costantino, Henry R.
; TITLE OF INVENTION: INTRANASAL ADMINISTRATION OF
; FILE REFERENCE: 03-14US
; CURRENT APPLICATION NUMBER: US/10/991,597
; CURRENT FILING DATE: 2004-11-18
; PRIOR APPLICATION NUMBER: 60/532,337
; PRIOR FILING DATE: 2003-12-26
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 36
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-991-597-23

Query Match 84.9%; Score 118; DB 5; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 13

US-10-991-597-44
; Sequence 44, Application US/10991597
; Publication No. US20050143303A1
; GENERAL INFORMATION:
; APPLICANT: Quay, Steven C.
; APPLICANT: Costantino, Henry R.
; TITLE OF INVENTION: INTRANASAL ADMINISTRATION OF
; FILE REFERENCE: 03-14US
; CURRENT APPLICATION NUMBER: US/10/991,597
; CURRENT FILING DATE: 2004-11-18
; PRIOR APPLICATION NUMBER: 60/532,337
; PRIOR FILING DATE: 2003-12-26
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 36
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-991-597-44

Query Match 84.9%; Score 118; DB 5; Length 36;
Best Local Similarity 68.6%; Pred. No. 6.9e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 14

US-08-851-965-4
; Sequence 4, Application US/08851965
; Publication No. US20020010133A1
; GENERAL INFORMATION:
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: GEDULIN, Bronislava
; APPLICANT: BEYNON, Gareth Wyn

; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851,965
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-4

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXLPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 15

US-08-851-965-11
; Sequence 11, Application US/08851965
; Publication No. US20020010133A1
; GENERAL INFORMATION:
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: GEDULIN, Bronislava
; APPLICANT: BEYNON, Gareth Wyn
; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851.965
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-11

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLNFXLXXXXXNGPXPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 16
US-08-851-965-13
; Sequence 13, Application US/08851965
; Publication No. US20020010133A1
; GENERAL INFORMATION:
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: GEDULIN, Bronislava
; APPLICANT: BEYNON, Gareth Wyn
; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
; TITLE OF INVENTION: AGONISTS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851.965
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200

; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-13

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLNFXLXXXXXNGPXPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 17
US-08-851-965-15
; Sequence 15, Application US/08851965
; Publication No. US20020010133A1
; GENERAL INFORMATION:
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: GEDULIN, Bronislava
; APPLICANT: BEYNON, Gareth Wyn
; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
; TITLE OF INVENTION: AGONISTS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/851.965
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 224/042
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; the Cys residues
; OTHER INFORMATION: the Cys residues


```
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/870,762A
; FILING DATE: 06-JUN-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 226/104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-2200
; TELEFAX: 619-552-0159
; TELEX:
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; US-08-870-762A-11

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.le-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFLXXXXXNGPXLPTXVGSNTY 37
||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNFGPILPSTNVGSNTY 37

RESULT 21
US-09-454-533-10
; Sequence 10, Application US/09454533
; Publication No. US20020187923A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-454-533-10

Query Match 84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.le-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFLXXXXXNGPXLPTXVGSNTY 37
||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNFGPILPSTNVGSNTY 37

RESULT 22
US-09-454-533-17
; Sequence 17, Application US/09454533
; Publication No. US20020187923A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
```

TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-454-533-17
Query Match 84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 3 NTATXATQRLNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
|||||
RESULT 23
US-09-454-533-19
; Sequence 19, Application US/09454533
; Publication No. US20020187923A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-454-533-21
Query Match 84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 3 NTATXATQRLNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
|||||

LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-454-533-19
Query Match 84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 3 NTATXATQRLNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
|||||
RESULT 24
US-09-454-533-21
; Sequence 21, Application US/09454533
; Publication No. US20020187923A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-454-533-21
Query Match 84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 3 NTATXATQRLNFXLXXXXXNGPXLPTXVGSNTY 37
|||||

```
Db      3  NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 25
US-09-454-533-38
; Sequence 38, Application US/09454533
; Publication No. US20020187923A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
;
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 38
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-454-533-38

Query Match      84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy      3  NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      3  NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 26
US-10-649-138-10
; Sequence 10, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
;
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 38
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-454-533-38

Query Match      84.9%; Score 118; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy      3  NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      3  NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 27
US-10-649-138-17
; Sequence 17, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
;
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-649-138-10

Query Match      84.9%; Score 118; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy      3  NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      3  NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 28
US-10-649-138-18
; Sequence 18, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
;
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-649-138-18
```

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/10/649,138
;; FILING DATE: 26-Aug-2003
;; CLASSIFICATION: <Unknown>
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/09/454,533
;; FILING DATE: 06-Dec-1999
;; APPLICATION NUMBER: 08/892,549
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 07/794,266
;; FILING DATE: 19-NOV-1991
;; APPLICATION NUMBER: US 07/667,040
;; FILING DATE: 08-MAR-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 227/006
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 213/955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 37 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
;; FEATURE:
;; LOCATION: 37
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-649-138-17

Query Match 84.9%; Score 118; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFKLXXXXXNGPXLPTXXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
|||||

RESULT 28
US-10-649-138-19
; Sequence 19, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US/09/454,533
;; FILING DATE: 06-Dec-1999
;; APPLICATION NUMBER: 08/892,549
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 07/794,266
;; FILING DATE: 19-NOV-1991
;; APPLICATION NUMBER: US 07/667,040
;; FILING DATE: 08-MAR-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 227/006
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 213/955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 19:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 37 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
;; FEATURE:
;; LOCATION: 37
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-10-649-138-19

Query Match 84.9%; Score 118; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. No. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFKLXXXXXNGPXLPTXXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
|||||

RESULT 29
US-10-649-138-21
; Sequence 21, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:

```
;
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-649-138-21

Query Match      84.9%; Score 118; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. NO. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXXXXXGPKLPXTXVGSNTY 37
Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 30
US-10-649-138-38
; Sequence 38, Application US/10649138
; Publication No. US20040038900A1
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/649,138
; FILING DATE: 26-Aug-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 38
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 38
US-10-643-681-3

NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 227/006
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-649-138-38

Query Match      84.9%; Score 118; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. NO. 7.1e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXXXXXGPKLPXTXVGSNTY 37
Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 31
US-10-643-681-3
; Sequence 3, Application US/10643681
; Publication No. US20040097415A1
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; YOUNG, Andrew A.
; RINK, Timothy J.
; BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/643,681
; FILING DATE: 18-Aug-2003
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/302,069A
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-10-643-681-3
```


DOS
#1.0, version #1.25

COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS
SOFTWARE: PatentIn Release

NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:

;; APPLICATION NUMBER: US/10/649,138
;; FILING DATE: 26-Aug-2003
;; CLASSIFICATION: <Unknown>
;; PRIORITY INFORMATION DATA:
;; APPLICATION NUMBER: US/09/454,533
;; FILING DATE: 06-Dec-1999
;; APPLICATION NUMBER: 08/892,549
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 07/794,266
;; FILING DATE: 19-NOV-1991
;; APPLICATION NUMBER: US 07/667,040
;; FILING DATE: 08-MAR-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 227/006
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 213/955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 11:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 36 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; FEATURE:
;; LOCATION: 36
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-649-138-11

Query Match 84.2%; Score 117; DB 4; Length 36;
Best Local Similarity 68.6%; Pred. No. 1.1e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNLFXXXXXXXXXGXPXLPXTXVGSNTY 37
DB 2 NTATCATQRLANFLVHRSNNFGPILPSTNVGSNTY 36

RESULT 42
US-10-991-597-16
;; Sequence 16, Application US/10991597
;; Publication No. US20050143303A1
;; GENERAL INFORMATION:
;; APPLICANT: Quay, Steven C.
;; TITLE OF INVENTION: INTRANASAL ADMINISTRATION OF
;; FILE REFERENCE: 03-14US
;; CURRENT APPLICATION NUMBER: US/10/991,597
;; CURRENT FILING DATE: 2004-11-18
;; PRIOR APPLICATION NUMBER: 60/532,337
;; PRIOR FILING DATE: 2003-12-26
;; NUMBER OF SEQ ID NOS: 47
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 16
;; LENGTH: 36
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-991-597-16

Query Match 84.2%; Score 117; DB 5; Length 36;
Best Local Similarity 68.6%; Pred. No. 1.1e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNLFXXXXXXXXXGXPXLPXTXVGSNTY 37
DB 2 NTATCATQRLANFLVHRSNNFGPILPSTNVGSNTY 36

RESULT 43
US-08-851-965-27
;; Sequence 27, Application US/08851965
;; Publication No. US20020010133A1
;; GENERAL INFORMATION:
;; APPLICANT: YOUNG, Andrew A.
;; APPLICANT: GEDULIN, Bronislava
;; APPLICANT: REYNON, Gareth WYN
;; TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
;; TITLE OF INVENTION: USING AMYLIN OR AMYLIN
;; NUMBER OF SEQUENCES: 35
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: LYON & LYON
;; STREET: 633 WEST FIFTH STREET
;; CITY: LOS ANGELES
;; STATE: CALIFORNIA
;; COUNTRY: USA
;; ZIP: 90017
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/851,965
;; FILING DATE: 06-MAY-1997
;; CLASSIFICATION: 514
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 224/042
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 213/955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 27:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 37 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
;; FEATURE:
;; LOCATION: 2,7
;; OTHER INFORMATION: disulfide bridge between
;; OTHER INFORMATION: the Cys residues
;; LOCATION: 37
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-27

Query Match 84.2%; Score 117; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.1e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNLFXXXXXXXXXGXPXLPXTXVGSNTY 37
DB 3 NTATCATQRLTNFLVRRSHNIGPALPPTDVGSNTY 37

RESULT 44
US-09-454-533-33
;; Sequence 33, Application US/09454533
;; Publication No. US20020187923A1
;; GENERAL INFORMATION:
;; APPLICANT: GAETA, Laura S.L. Et Al.
;; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
;; NUMBER OF SEQUENCES: 41
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: LYON & LYON
;; STREET: 633 WEST FIFTH STREET
;; CITY: LOS ANGELES

STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/454,533
FILING DATE: 06-Dec-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/892,549
FILING DATE: <Unknown>
APPLICATION NUMBER: 07/794,266
FILING DATE: 19-NOV-1991
APPLICATION NUMBER: US 07/667,040
FILING DATE: 08-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 227/006
TELEPHONE: 619/552-2200
TELEFAX: 619/552-2200
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-454-533-33
Query Match 84.2%; Score 117; DB 3; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.le-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLXPTXVGSNTY 37
Db 3 NTATCATQRLTNFLVRSSHNGLPALPPTDVGSTY 37
RESULT 45
US-10-649-138-33
Sequence 33, Application US/10649138
Publication No. US20040038900A1
GENERAL INFORMATION:
APPLICANT: GAETA, Laura S.L. Et Al.
TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
USES THEREFOR
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/649,138
FILING DATE: 26-Aug-2003

CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/454,533
FILING DATE: 06-Dec-1999
APPLICATION NUMBER: 08/892,549
FILING DATE: <Unknown>
APPLICATION NUMBER: 07/794,266
FILING DATE: 19-NOV-1991
APPLICATION NUMBER: US 07/667,040
FILING DATE: 08-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 227/006
TELEPHONE: 619/552-2200
TELEFAX: 619/552-2200
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-649-138-33
Query Match 84.2%; Score 117; DB 4; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.le-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLXPTXVGSNTY 37
Db 3 NTATCATQRLTNFLVRSSHNGLPALPPTDVGSTY 37
RESULT 46
US-10-643-681-28
Sequence 28, Application US/10643681
Publication No. US20040097415A1
GENERAL INFORMATION:
APPLICANT: KOLTERMAN, Orville G.
YOUNG, Andrew A.
RINK, Timothy J.
BROWN, Kathleen Ann Keiting
TITLE OF INVENTION: METHODS FOR REGULATING
GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/643,681
FILING DATE: 18-Aug-2003
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/302,069A
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993

APPLICATION NUMBER: US/08/851,965
FILING DATE: 06-MAY-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 224/042
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
MOLECULE TYPE: protein
FEATURE:
LOCATION: 1,6
OTHER INFORMATION: disulfide bridge between
the Cys residues
LOCATION: 36
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-9

Query Match 83.5%; Score 116; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 1.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNNLGPILPPTNVGSNTY 36

RESULT 50

US-08-851-965-18
Sequence 18, Application US/08851965
Publication No. US2002010133A1
GENERAL INFORMATION:
APPLICANT: YOUNG, Andrew A.
APPLICANT: GEDULIN, Bronislava
APPLICANT: BEYNON, Gareth Wyn
TITLE OF INVENTION: METHOD FOR PREVENTING GASTRITIS
TITLE OF INVENTION: USING AMYLIN OR AMYLIN
TITLE OF INVENTION: AGONISTS
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/851,965
FILING DATE: 06-MAY-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 224/042
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:

LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 1,6
OTHER INFORMATION: disulfide bridge between
the Cys residues
LOCATION: 36
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-851-965-18
Query Match 83.5%; Score 116; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 1.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNNLGPILPPTNVGSNTY 36

Search completed: January 4, 2006, 11:59:53
Job time : 165 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:30:41 ; Search time 227 Seconds

(without alignments)
114.998 Million cell updates/sec

Title: US-09-445-517-14

Perfect score: 139

Sequence: 1 XXNTATXATQRLXNLFXXXXXXGXGXPXTXVGSNTY 37

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database : UniProt_05.80.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	116	83.5	93	1	IAPP_MOUSE
2	116	83.5	93	1	IAPP_MOUSE
3	109	78.4	91	1	IAPP_MOUSE
4	107	77.0	37	1	IAPP_MOUSE
5	107	77.0	92	1	IAPP_MOUSE
6	102	73.4	89	1	IAPP_MOUSE
7	100	71.9	89	1	IAPP_MOUSE
8	100	71.9	89	1	IAPP_MOUSE
9	99	71.2	92	1	IAPP_MOUSE
10	87	62.6	135	2	Q90743_CHICK
11	78	56.1	66	2	Q9BEF0_ERIEU
12	72	51.8	51	2	Q4TB97_TETNG
13	69	49.6	67	1	IAPP_MOUSE
14	66	47.5	32	1	IAPP_MOUSE
15	63	45.3	32	1	IAPP_MOUSE
16	58	41.7	32	1	IAPP_MOUSE
17	58	41.7	115	1	CALCR_PHYBI
18	51	36.7	126	2	Q9DGJ9_BRARE
19	50	36.0	32	1	IAPP_MOUSE
20	50	36.0	37	1	CALCR_MOUSE
21	49	35.3	52	2	P79814_ONCGO
22	49	35.3	126	2	Q90FT9_FUGRU
23	49	35.3	184	2	Q4S167_TETNG
24	48	34.5	56	2	Q92164_ONCSP
25	48	34.5	125	1	CALCA_CHICK
26	46	33.1	25	2	Q9BEE1_MACRU
27	45.5	32.7	560	2	Q59PM5_CANAL
28	45	32.4	51	2	Q4S173_TETNG
29	43.5	31.3	667	2	Q9X748_HELPY
30	43	30.9	23	1	IAPP_MOUSE
31	43	30.9	37	1	CALCA_MOUSE

32	43	30.9	44	2	Q4THN9_TETNG
33	43	30.9	53	2	Q8WNX2_CALJA
34	43	30.9	127	1	CALCB_HUMAN
35	43	30.9	127	1	Q56910_HUMAN
36	43	30.9	130	1	CALCB_MOUSE
37	43	30.9	469	1	Q0B1_CABEL
38	43	30.9	482	2	Q4WLC6_ASPFU
39	43	30.9	1502	2	Q55HY4_CRYNE
40	43	30.9	1502	2	Q5K7G8_CRYNE
41	42	30.2	37	1	CALCA_SHEEP
42	42	30.2	50	2	Q66VCI_RAT
43	42	30.2	128	1	CALCA_MOUSE
44	42	30.2	128	1	CALCA_MOUSE
45	42	30.2	129	1	CALCB_MOUSE
46	42	30.2	171	2	Q51QAI_MAGGR
47	42	30.2	378	2	Q411A8_GIBZE
48	42	30.2	465	2	Q9Y029_DROME
49	42	30.2	534	2	P92031_DROME
50	42	30.2	534	2	Q9VJ37_DROME
51	42	30.2	853	2	Q7RYF3_NEUGR
52	42	30.2	916	2	Q7UZ06_RHOBA
53	42	30.2	1121	2	Q615K0_CABER
54	42	30.2	1974	2	Q688L3_ORYSA
55	42	30.2	3902	2	Q4SC60_TETNG
56	41.5	29.9	668	2	Q9ZNS1_HELPY
57	41.5	29.9	669	2	Q9X747_HELPY
58	41	29.5	104	2	Q6DGM9_BRARE
59	41	29.5	128	1	CALCA_CANFA
60	41	29.5	134	1	CALCB_RAT
61	41	29.5	363	2	Q8TTZ1_METAC
62	41	29.5	413	2	Q6CLA9_KIULA
63	41	29.5	850	2	Q5KGH4_CRYNE
64	41	29.5	905	2	Q55S22_CRYNE
65	40	28.8	89	2	Q9UZB5_PYRAB
66	40	28.8	201	2	Q811B4_MOUSE
67	40	28.8	232	2	Q8KAW5_CHLTE
68	40	28.8	461	2	Q4H7N0_9DEIO
69	40	28.8	486	2	Q66JTA_MOUSE
70	40	28.8	512	2	Q5TGN7_HUMAN
71	40	28.8	597	2	Q88JQ3_PSEPK
72	40	28.8	772	2	Q54J94_DICDI
73	40	28.8	789	2	Q7RMW7_PLAVO
74	40	28.8	1075	2	Q5CGP3_CRYHO
75	40	28.8	1115	2	Q9BL72_CABHL
76	40	28.8	1165	2	Q6F3F9_MOUSE
77	40	28.8	1193	2	Q6F3F7_HUMAN
78	40	28.8	1221	1	GP126_HUMAN
79	40	28.8	1221	2	Q6F3F8_HUMAN
80	40	28.8	1222	2	Q6F3F5_HUMAN
81	40	28.8	1222	2	Q81XA4_HUMAN
82	40	28.8	1222	2	Q6DHZ4_HUMAN
83	40	28.8	1250	2	Q6F3F6_HUMAN
84	40	28.8	1636	1	PTN23_HUMAN
85	39.5	28.4	192	1	Y525_BUCAP
86	39.5	28.4	2153	2	Q9YQR5_VIRIU
87	39	28.1	316	2	Q6CTY0_KIULA
88	39	28.1	384	2	Q9A4K3_CAUCR
89	39	28.1	405	1	RMDH_METJA
90	39	28.1	436	2	Q755Z5_ASHGO
91	39	28.1	454	2	Q5V6X5_HALGO
92	39	28.1	461	2	Q4NKC8_9MICC
93	39	28.1	581	2	Q5E070_VIBFI
94	39	28.1	587	2	Q5Y87_CRYNE
95	39	28.1	587	2	Q5KLQ1_CRYNE
96	39	28.1	665	2	Q6CH71_YARLI
97	39	28.1	774	2	Q17124_BRACL
98	39	28.1	774	2	Q8D1P8_TERPE
99	39	28.1	776	2	Q74PN4_YERPE
100	39	28.1	830	2	Q6QDZ2_YERPS
101	39	28.1	833	2	Q8ZAV3_YERPE
102	39	28.1	877	2	Q6XD55_XENLA
103	39	28.1	877	2	Q6PCK5_XENLA
104	39	28.1	1002	2	Q55W56_CRYNE

Q4thn9	tetraodon n
Q8wnx2	callithrix
P10092	homo sapien
Q56910	homo sapien
Q99mp3	mus musculus
Q92555	caenorhabdi
Q4wlc6	aspergillus
Q5shy4	cryptococcu
Q5K7G8	cryptococcu
P30881	ovis aries
Q66vci	rattus norv
Q99ja0	mus musculus
P01256	rattus norv
Q9n0t3	equus cabal
Q51qai	magnaporthe
Q411a8	gibberella
Q9Y029	drosophila
P92031	drosophila
Q9VJ37	drosophila
Q7ryp3	neurospora
Q7uz06	rhodospirill
Q615k0	caenorhabdi
Q688l3	oryza sativ
Q4sc60	tetraodon n
Q9zn51	helicobacte
Q9x747	helicobacte
Q6dgm9	brachydanio
Q9myv1	canis famli
P10093	rattus norv
Q8ttz1	methanosarc
Q6cla9	kluyveromyc
Q5kgH4	cryptococcu
Q55s22	cryptococcu
Q9uzB5	pyrococcus
Q811e4	mus musculus
Q8kaw5	chlorobium
Q4h7n0	deinococcus
Q66jta	mus musculus
Q5tgn7	homo sapien
Q88jq3	pseudomonas
Q54j94	dictyosteli
Q7rmw7	plasmodium
Q5cgp3	cryptospori
Q9bl72	caenorhabdi
Q6f3f9	mus musculus
Q6f3f7	homo sapien
Q86sq4	homo sapien
Q6f3f8	homo sapien
Q6f3f5	homo sapien
Q81xa4	homo sapien
Q6dhz4	homo sapien
Q6f3f6	homo sapien
Q9h3e7	homo sapien
Q8k934	buchnera ap
Q9yqr5	tula virus.
Q6cty0	kluyveromyc
Q9a4k3	caulobacter
Q58116	methanococc
Q5v6x5	haloarcula
Q4nkc8	arthrobacte
Q5e070	vibrio fisc
Q5y87	cryptococcu
Q5klq1	cryptococcu
Q6ch71	yarrowia li
Q17124	branchiost
Q8d1p8	yersinia pe
Q74pn4	yersinia pe
Q6qdZ2	yersinia ps
Q8ZAV3	yersinia ps
Q6XD55	xenopus lae
Q6PCK5	xenopus lae
Q55W56	cryptococcu

105 39 28.1 1002 2 Q5KK38 CRYNE
 106 39 28.1 1376 1 VGL2_CVM4
 107 39 28.1 1376 1 VGL2_CVM4
 108 39 28.1 1662 2 P71431 LEPDI
 109 39 28.1 1900 2 Q7XPC9 ORYSA
 110 38.5 27.7 115 2 Q8V180 HEPC
 111 38.5 27.7 115 2 Q8V181 HEPC
 112 38.5 27.7 115 2 Q8V182 HEPC
 113 38.5 27.7 115 2 Q8V183 HEPC
 114 38.5 27.7 115 2 Q8V184 HEPC
 115 38.5 27.7 115 2 Q8V185 HEPC
 116 38.5 27.7 115 2 Q8V186 HEPC
 117 38.5 27.7 115 2 Q8V187 HEPC
 118 38.5 27.7 209 2 Q7VFJ9 HELHP
 119 38.5 27.7 280 2 Q415A0 GIBZE
 120 38.5 27.7 377 2 Q6XQ71 SACKL
 121 38.5 27.7 545 2 Q64935 9CORO
 122 38 27.3 70 2 Q88TK1 LACPL
 123 38 27.3 326 2 Q5V824 HALMA
 124 38 27.3 332 2 Q5WV07 LEGPL
 125 38 27.3 332 2 Q5X5G7 LEGPA
 126 38 27.3 332 2 Q5ZVP2 LEGPH
 127 38 27.3 362 2 Q8PWN3 METMA
 128 38 27.3 368 2 Q6VZ92 CNPV
 129 38 27.3 385 2 Q575V5 SULTO
 130 38 27.3 392 1 PRD PROMM
 131 38 27.3 420 2 Q6BF12 YEAST
 132 38 27.3 427 2 Q6FNQ3 CANGA
 133 38 27.3 431 2 Q8E2N6 STRA3
 134 38 27.3 431 2 Q8DWT6 STRA5
 135 38 27.3 499 2 Q8QUT8 9VIRU
 136 38 27.3 504 2 Q6N445 RHOPA
 137 38 27.3 509 2 Q5SN48 CRYNE
 138 38 27.3 562 1 OXAA_PSESM
 139 38 27.3 581 2 Q5Z645 ORYSA
 140 38 27.3 606 2 Q6GPR2 XENLA
 141 38 27.3 646 2 Q7GS13 GLALA
 142 38 27.3 678 2 Q6BU31 DEBHA
 143 38 27.3 693 2 Q4FY44 LEIMA
 144 38 27.3 720 2 Q5ASJ9 EMENI
 145 38 27.3 777 2 Q6DEW2 XENTR
 146 38 27.3 785 2 Q6NU42 XENLA
 147 38 27.3 797 2 Q5U9G5 ASPFU
 148 38 27.3 797 2 Q4WJ78 ASPFU
 149 38 27.3 815 2 Q6CH35 YARLI
 150 38 27.3 861 1 POLG_EC16H

ALIGNMENTS

RESULT 1
 IAPP MOUSE
 ID IAPP MOUSE STANDARD; PRT; 93 AA.
 AC P12958;
 DT 01-OCT-1989 (Rel. 12, Created)
 DT 01-OCT-1989 (Rel. 12, Last sequence update)
 DT 13-SEP-2005 (Rel. 48, Last annotation update)
 DE Islet amyloid polypeptide precursor (Diabetes-associated peptide)
 DE (DAP) (Amylin).
 GN Name=Iapp;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=89345542; PubMed=2668946;
 RT Nishi M., Chan S.J., Nagamatsu S., Bell G.I., Steiner D.F.;
 RT "Conservation of the sequence of islet amyloid polypeptide in five
 RT mammals is consistent with its putative role as an islet hormone.";
 RT Proc. Natl. Acad. Sci. U.S.A. 86:5738-5742(1989).
 RL

[2]
 NUCLEOTIDE SEQUENCE
 RP STRAIN=DBA/2J; TISSUE=Liver;
 RC MEDLINE=97424750; PubMed=9278863; DOI=10.1677/jme.0.0190079;
 RX Kawa K., Nishi M., Ohagi S., Sanke T., Nanjo K.;
 RA "Cloning of mouse islet amyloid polypeptide gene and characterization
 RT of its promoter.";
 RL J. Mol. Endocrinol. 19:79-86(1997).
 [3]
 NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
 RP STRAIN=C57BL/6J; TISSUE=Thymus;
 RC MEDLINE=92388257; PubMed=12477932; DOI=10.1073/pnas.2426038899;
 RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L.H., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haeh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Tohiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Ioquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Whiting M., Madan A., Kettman M., Madan A., Rodriguez S., Sanchez A.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [4]
 PROTEIN SEQUENCE OF 38-74.
 RP MEDLINE=89325677; PubMed=2666169; DOI=10.1016/0014-5793(89)81467-X;
 RX Besholtz C., Christmann L., Engstrom U., Rorsman F., Svensson V.,
 RA Johnson K.H., Westermarck P.;
 RA "Sequence divergence in a specific region of islet amyloid polypeptide
 RT (IAPP) explains differences in islet amyloid formation between
 RT species.";
 RL FEBS Lett. 251:261-264(1989).
 CC -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
 CC utilization and glycogen deposition in muscle, while not affecting
 CC adipocyte glucose metabolism.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the calcitonin family.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 CC EMBL; M25389; AAA37874.1; -; mRNA.
 CC EMBL; D31820; BAA22051.1; -; Genomic DNA.
 CC EMBL; BC027527; AAH27527.1; -; mRNA.
 CC PIR; C33542; C33542.
 CC Ensembl; ENSMUSG000000041681; Mus musculus.
 CC MG1; MG1:96382; Iapp.
 CC GO; GO:0005615; C:extracellular space; TAS.
 CC InterPro; IPR000443; Amylin.
 CC InterPro; IPR001693; Calcitonin-like.
 CC InterPro; IPR002163; Calcitonin.B.
 CC Pfam; PF00214; Calc_CGRP_IAPP; I.
 CC PRINTS; PR00817; CALCITONINB.
 CC PRINTS; PR00818; ISLETAMYLOID.
 CC SMART; SM00113; CALCITONIN; 1.
 CC PROSITE; PS00258; CALCITONIN; 1.
 CC Amidation; Amyloid; Cleavage on pair of basic residues;
 KW Direct protein sequencing; Hormone; Signal.
 FT SIGNAL 1 23 Potential.
 FT PROPEP 24 35
 FT PEPTIDE 38 74 Islet amyloid polypeptide.


```
FT PROPEP 78 93 Tyrosine amide (G-75 provides amide
FT MOD_RES 74 74 group).
FT DISULFID 39 44 By similarity.
SQ SEQUENCE 93 AA; 10022 MW; B135DBBC81475B15 CRC64;
Query Match 83.5%; Score 116; DB 1; Length 93;
Best Local Similarity 68.6%; Pred. No. 1.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATYATQRLXNLFXXXXXNGXPLPXTXVGSNTY 37
||||| ||||| ||||| ||||| ||||| |||||
Db 40 NTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY 74
-----
RESULT 2
IAPP RAT
ID IAPP RAT STANDARD; PRT; 93 AA.
AC P12969;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Islet amyloid polypeptide precursor (Diabetes-associated peptide)
DE (DAP) (Amylin).
GN Name=iapp;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
[1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=893145542; PubMed=2668946;
RA Nishi M., Chan S.J., Nagamatsu S., Bell G.I., Steiner D.F.;
RT "Conservation of the sequence of islet amyloid polypeptide in five
RL mammals is consistent with its putative role as an islet hormone."
[2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89240689; PubMed=2654937;
RA Leffert J.D., Newgard C.B., Okamoto H., Milburn J.L., Luskey K.L.;
RT "Rat amylin: cloning and tissue-specific expression in pancreatic
RL islets."
[3]
RP NUCLEOTIDE SEQUENCE.
RX STRAIN-WAP; TISSUE=Liver;
RA MEDLINE=91027936; PubMed=2223885; DOI=10.1016/0167-4781(90)90210-S;
RA van Mansfeld A.D.M., Mosseman S., Hoepfner J.W.M., Zandberg J.,
RA van Teeffelen H.A.M., Baas P.D., Lips C.J.M., Jansz H.S.;
RT "Islet amyloid polypeptide: structure and upstream sequences of the
RL IAPP gene in rat and man."
RL Biochim. Biophys. Acta 1087:235-240 (1990).
[4]
RP PROTEIN SEQUENCE OF 38-74.
RX MEDLINE=90026410; PubMed=2679555;
RA Asai J., Nakazato M., Kangawa K., Matsukura S., Matsuo H.;
RT "Isolation and sequence determination of rat islet amyloid
RL polypeptide."
[5]
RX Biochem. Biophys. Res. Commun. 164:400-405 (1989).
RP PROTEIN SEQUENCE OF 38-74.
RX MEDLINE=90290528; PubMed=2357234;
RA Asai J., Nakazato M., Miyazato M., Kangawa K., Matsuo H.,
RA Matsukura S.;
RT "Regional distribution and molecular forms of rat islet amyloid
RL polypeptide."
[6]
RX Biochem. Biophys. Res. Commun. 169:788-795 (1990).
RP NUCLEOTIDE SEQUENCE OF 38-74.
RX MEDLINE=89325677; PubMed=2666169; DOI=10.1016/0014-5793(89)81467-X;
RA Besholtz C., Christmansson L., Engstroem U., Koreman F., Svensson V.,
RA Johnson K.H., Westermark P.;
```

```
RT "Sequence divergence in a specific region of islet amyloid polypeptide
RT (IAPP) explains differences in islet amyloid formation between
RT species."
CC FEBS Lett. 251:261-264 (1989).
CC -1- FUNCTION: Selectively inhibits insulin-stimulated glucose
CC utilization and glycogen deposition in muscle, while not affecting
CC adipocyte glucose metabolism.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Abundant in the islets of Langerhans but is
CC not present in the brain or seven other tissues examined.
CC -1- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; M25390; AAA41359.1; -; mRNA.
CC EMBL; J04544; AAA40730.1; -; mRNA.
CC EMBL; X52820; CAA37003.1; -; Genomic DNA.
CC EMBL; X52821; CAA37003.1; JOINED; Genomic DNA.
CC PIR; S13566; TCHTIA.
CC Ensembl; ENSRNOC0000012417; Rattus norvegicus.
CC RGD; 2854; iapp.
CC InterPro; IPR000443; Amylin.
CC InterPro; IPR001693; Calcitonin-like.
CC InterPro; IPR002163; Calcitonin B.
CC Pfam; PF00214; Calc_CGRP_IAPP; I.
CC PRINTS; PR00817; CALCITONINB.
CC PRINTS; PR00818; ISLETAMYLOID.
CC SMART; SM00113; CALCITONIN; 1.
CC PROSITE; PS00258; Calcitonin; 1.
CC Amidation; Amyloid; Cleavage on pair of basic residues;
KW Direct protein sequencing; Hormone; Signal.
FT SIGNAL 1 23 Potential.
FT PROPEP 24 35 Islet amyloid polypeptide.
FT PEPTIDE 38 74
FT PROPEP 78 93 Tyrosine amide (G-75 provides amide
FT MOD_RES 74 74 group).
FT DISULFID 39 44 By similarity.
SQ SEQUENCE 93 AA; 10015 MW; 5A76C92E624DA962 CRC64;
Query Match 83.5%; Score 116; DB 1; Length 93;
Best Local Similarity 68.6%; Pred. No. 1.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATYATQRLXNLFXXXXXNGXPLPXTXVGSNTY 37
||||| ||||| ||||| ||||| ||||| |||||
Db 40 NTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY 74
-----
RESULT 3
IAPP OCTDE
ID IAPP OCTDE STANDARD; PRT; 91 AA.
AC P22889;
DT 01-AUG-1991 (Rel. 19, Created)
DT 01-AUG-1991 (Rel. 19, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Islet amyloid polypeptide precursor (Amylin).
GN Name=iapp;
OS Octodon degus (Degu).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
OC Hystricognathi; Octodontidae; Octodon.
OX NCBI_TaxID=10160;
[1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=91155952; PubMed=2293024;
RA Nishi M., Steiner D.F.;
RT "Cloning of complementary DNAs encoding islet amyloid polypeptide,
RT insulin, and glucagon precursors from a New World rodent, the degu,
```

RT Octodon degus."; 4:1192-1198(1990).
RL Mol. Endocrinol.
CC -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
CC utilization and glycogen deposition in muscle, while not affecting
CC adipocyte glucose metabolism.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; M57669; AAA0589.1; -, mRNA.
DR PIR; A36118; A36118.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc_CGRP_IAPP; 1.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
DR Amidation; Amyloid; Cleavage on pair of basic residues; Hormone;
KW Signal.
KW SIGNAL 1 22 Potential.
FT PROPEP 23 34
FT PEPTIDE 37 73 Islet amyloid polypeptide.
FT PROPEP 77 91
FT MOD_RES 73 73 Tyrosine amide (G-74 provides amide
FT group).
FT DISULFID 38 43 By similarity.
FT SEQUENCE 91 AA; 9925 MW; 42AB31AE1CE9EA99 CRC64;
Query Match 78.4%; Score 109; DB 1; Length 91;
Best Local Similarity 65.7%; Pred. No. 3.9e-13;
Matches 23; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Qy 3 NTATXATQRLNFKLXXXXXNKGXPLPTXVGSNTY 37
Db 39 NTATCATQRLTNFLVRSHNLGAALPPTKVGSTY 73
RESULT 4
ID IAPP CRIGR STANDARD; PRT; 37 AA.
AC P19890;
DT 01-FEB-1991 (Rel. 17, Created)
DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Islet amyloid polypeptide (Amylin).
GN Name=IAPP;
OS Cricetus griseus (Chinese hamster).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Cricetidae; Cricetinae; Cricetulus.
OX NCBI_TaxID=10029;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=89325677; PubMed=2666169; DOI=10.1016/0014-5793(89)81467-X;
RA Betsholtz C., Christmansson L., Engstrom U., Rorsman F., Svensson V.,
RA Johnson K.H., Westermark P.;
RT "Sequence divergence in a specific region of islet amyloid polypeptide
RT (IAPP) explains differences in islet amyloid formation between
RT species";
RL FEMS Lett. 251:261-264 (1989).
CC -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
CC utilization and glycogen deposition in muscle, while not affecting
CC adipocyte glucose metabolism.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the calcitonin family.
CC

CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; S05037; S05037.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc_CGRP_IAPP; 1.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
DR Amidation; Amyloid; Hormone.
KW Tyrosine amide.
FT MOD_RES 37 37 By similarity.
FT DISULFID 2 7
FT SEQUENCE 37 AA; 3921 MW; FE433D9905EBP82E CRC64;
Query Match 77.0%; Score 107; DB 1; Length 37;
Best Local Similarity 65.7%; Pred. No. 3.5e-13;
Matches 23; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Qy 3 NTATXATQRLNFKLXXXXXNKGXPLPTXVGSNTY 37
Db 3 NTATCATQRLANFLVHSNNLGPVLSPTNVGSNTY 37
RESULT 5
ID IAPP MESAU STANDARD; PRT; 92 AA.
AC P23442;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Islet amyloid polypeptide precursor (Amylin).
GN Name=IAPP;
OS Mesocricetus auratus (Golden hamster).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridea; Cricetidae; Cricetinae; Mesocricetus.
OX NCBI_TaxID=10036;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=91067493; PubMed=2251153;
RA Nishi M., Bell G.I., Steiner D.F.;
RT "Sequence of a cDNA encoding Syrian hamster islet amyloid polypeptide
RT precursor";
RL Nucleic Acids Res. 18:6726-6726(1990).
CC -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
CC utilization and glycogen deposition in muscle, while not affecting
CC adipocyte glucose metabolism.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; X56067; CAA39545.1; -, mRNA.
DR PIR; S13116; S13116.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc_CGRP_IAPP; 1.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
DR Amidation; Amyloid; Cleavage on pair of basic residues; Hormone;
KW

KW Signal. 1 22 Potential.
 FT PROPEP 23 34 Islet amyloid polypeptide.
 FT PEPTIDE 37 73
 FT PROPEP 77 92 Tyrosine amide (G-74 provides amide
 FT MOD_RES 73 73 group).
 FT DISULFID 38 43 By similarity.
 FT SEQUENCE 92 AA; 9899 MW; 6D2F7359C4A1D029 CRC64;
 Query Match 77.0%; Score 107; DB 13; Length 92;
 Best Local Similarity 65.7%; Pred. No. 9.9e-13;
 Matches 23; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
 QY 3 NTATXATQRLNFXLXXXXXNGPLPXTXVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 DB 39 NTATCATQRLANFLVHNSNNLGPVLSPTNVGSNTY 73
 RESULT 6
 ID_IAPP_HUMAN STANDARD; PRT; 89 AA.
 AC P10997; Q14598;
 DT 01-JUL-1989 (Rel. 11, Created)
 DT 01-JUL-1989 (Rel. 11, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Islet amyloid polypeptide precursor (Diabetes-associated peptide)
 DE (DAP) (Amylin) (Insulinoma amyloid peptide).
 GN Name=IAPP;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP MEDLINE=89211434; PubMed=2651160; DOI=10.1016/0014-5793(89)81260-8;
 RX Mosselman S., Hoepfner J.W.M., Lips C.J.M., Jansz H.S.;
 RA "The complete islet amyloid polypeptide precursor is encoded by two
 RT exons";
 RL FEBS Lett. 247:154-158 (1989).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=90114181; PubMed=2608057;
 RA Nishi M., Sanke T., Seino S., Eddy R.L., Fan Y.-S., Byers M.G.,
 RA Shows T.B., Bell G.I., Steiner D.F.;
 RT "Human islet amyloid polypeptide gene: complete nucleotide sequence,
 RT chromosomal localization, and evolutionary history.";
 RL Mol. Endocrinol. 3:1775-1781 (1989).
 RN [3]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=89034238; PubMed=3053705;
 RA Sanke T., Bell G.I., Sample C., Rubenstein A.H., Steiner D.F.;
 RA "An islet amyloid peptide is derived from an 89-amino acid precursor
 RT by proteolytic processing.";
 RL J. Biol. Chem. 263:17243-17246 (1988).
 RN [4]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=90306394; PubMed=2365085; DOI=10.1016/0014-5793(90)80314-9;
 RA Christmanon L., Korsman F., Stenman G., Westermark P., Betsholtz C.;
 RA "The human islet amyloid polypeptide (IAPP) gene. Organization,
 RT chromosomal localization and functional identification of a promoter
 RT region.";
 RL FEBS Lett. 267:160-166 (1990).
 RN [5]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=91027936; PubMed=2223885; DOI=10.1016/0167-4781(90)90210-S;
 RA van Mansfeld A.D.M., Mosselman S., Hoepfner J.W.M., Zandberg J.,
 RA van Teffelen H.A.A.M., Baas P.D., Lips C.J.M., Jansz H.S.;
 RT "Islet amyloid polypeptide: structure and upstream sequences of the
 RT IAPP gene in rat and man.";
 RL Biochim. Biophys. Acta 1087:235-240 (1990).
 RN [6]

RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=93129228; PubMed=1282806;
 RA Hoepfner J.W.M., Oosterwijk C., Visser-Vernooij H.J., Lips C.J.M.,
 RA Jansz H.S.;
 RT "Characterization of the human islet amyloid polypeptide/amylin gene
 RT transcripts: identification of a new polyadenylation site.";
 RL Biochem. Biophys. Res. Commun. 189:1569-1577 (1992).
 RN [7]
 RP NUCLEOTIDE SEQUENCE OF 28-89.
 RX MEDLINE=9031237; PubMed=3181427; DOI=10.1016/0014-5793(88)80922-0;
 RA Mosselman S., Hoepfner J.W.M., Zandberg J., van Mansfeld A.D.M.,
 RA Geurts van Kessel A.H.M., Lips C.J.M., Jansz H.S.;
 RT "Islet amyloid polypeptide: identification and chromosomal
 RT localization of the human gene.";
 RL FEBS Lett. 239:227-232 (1988).
 RN [8]
 RP PROTEIN SEQUENCE OF 34-52.
 RX MEDLINE=87048863; PubMed=3535798;
 RA Westermark P., Wernstedt C., Wilander E., Sletten K.;
 RA "A novel peptide in the calcitonin gene related peptide family as an
 RT amyloid fibril protein in the endocrine pancreas.";
 RL Biochem. Biophys. Res. Commun. 140:827-831 (1986).
 RN [9]
 RP PROTEIN SEQUENCE OF 34-70.
 RX MEDLINE=87231921; PubMed=3035556;
 RA Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D.,
 RA Johnson K.H.;
 RT "Amyloid fibrils in human insulinoma and islets of Langerhans of the
 RT diabetic cat are derived from a neuro-peptide-like protein also present
 RT in normal islet cells.";
 RL Proc. Natl. Acad. Sci. U.S.A. 84:3881-3885 (1987).
 RN [10]
 RP PROTEIN SEQUENCE OF 30-89.
 RX MEDLINE=9009324; PubMed=2690069;
 RA Roberts A.N., Leighton B., Todd J.A., Cockburn D., Schofield P.N.,
 RA Surtan R., Holt S., Boyd Y., Day A.J., Foot E.A., Willis A.C.,
 RA Reid K.B.M., Cooper G.J.S.;
 RT "Molecular and functional characterization of amylin, a peptide
 RT associated with type 2 diabetes mellitus.";
 RL Proc. Natl. Acad. Sci. U.S.A. 86:9662-9666 (1989).
 RN [11]
 RP STRUCTURE BY NMR OF IAPP.
 RX MEDLINE=91248117; PubMed=2039456;
 RA Hubbard J.A.M., Martin S.R., Chaplin L.C., Bose C., Kelly S.M.,
 RA Price N.C.;
 RT "Solution structures of calcitonin-gene-related-peptide analogues of
 RT calcitonin-gene-related peptide and amylin.";
 RL Biochem. J. 275:785-788 (1991).
 RN [12]
 RP VARIANT GLY-53.
 RX MEDLINE=96368727; PubMed=8772735;
 RA Sakagashira S., Sanke T., Hanabusa T., Shimomura H., Ohagi S.,
 RA Kumagaye K.Y., Nakajima K., Nanjo K.;
 RT "Missense mutation of amylin gene (S20G) in Japanese NIDDM patients.";
 RL Diabetes 45:1279-1281 (1996).
 RN [13]
 RP VARIANT GLY-53.
 RX MEDLINE=9010531; PubMed=9794116; DOI=10.1007/s001250051060;
 RA Chuang L.M., Lee K.C., Huang C.N., Wu H.P., Tai T.Y., Lin B.J.;
 RT "Role of S20G mutation of amylin gene in insulin secretion, insulin
 RT sensitivity, and type II diabetes mellitus in Taiwanese patients.";
 RL Diabetologia 41:1250-1251 (1998).
 CC -1- FUNCTION: Selectively inhibits insulin-stimulated glucose
 CC utilization and glycogen deposition in muscle, while not affecting
 CC adipocyte glucose metabolism.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- DISEASE: IAPP is the peptide subunit of amyloid found in
 CC pancreatic islets of type 2 diabetic patients and in insulinomas.
 CC -1- SIMILARITY: Belongs to the calcitonin family.
 CC
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its

Oryctolagus.
 NCBI_TaxID=9986;
 (1)
 NUCLEOTIDE SEQUENCE OF 1-66.
 van Dijk M.A.M., de Jong W.W.;
 "Indels indicate that rodents are monophyletic and lagomorphs are
 their sister group.";
 Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 (2)
 NUCLEOTIDE SEQUENCE OF 36-67.
 Albrandt K., Sierzege M.E., Mull E., Brady E.M.G.;
 "PCR amplification of amylin 3-34 from genomic DNA."
 Submitted (AUG-1996) to the EMBL/GenBank/DBJ databases.
 (3)
 NUCLEOTIDE SEQUENCE OF 42-64.
 STRAIN=New Zealand white;
 MEDLINE=93215963; PubMed=8462765; DOI=10.1007/BF00399947;
 Christmann L., Betscholtz C., Leckstroem A., Engstroem U., Cortie C.,
 Johnson K.H., Adrian T.E., Westermarck P.;
 "Islet amyloid polypeptide in the rabbit and European hare: studies on
 its relationship to amyloidogenesis";
 Diabetologia 36:183-188(1993).
 -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
 utilization and glycogen deposition in muscle, while not affecting
 adipocyte glucose metabolism.
 -!- SUBCELLULAR LOCATION: Secreted.
 -!- SIMILARITY: Belongs to the calcitonin family.

 This Swiss-Prot entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use as long as its content is in no way modified and this statement is not
 removed.

 EMBL; AJ286814; CAC28529.1; -; mRNA.
 EMBL; U62630; AAB05917.1; -; Genomic_DNA.
 EMBL; S57804; AAB26084.1; -; mRNA.
 PIR; I46934; I46934.
 InterPro; IPR000443; Amylin.
 InterPro; IPR001693; Calcitonin-like.
 Pfam; PF00214; Calc_CGRP_IAPP; 1.
 PRINTS; PR00818; ISETAMYL0ID.
 SMART; SM00113; CALCITONIN; 1.
 PROSITE; PS00258; CALCITONIN; PARTIAL.
 Amyloid; Cleavage on pair of basic residues; Hormone; Signal.
 SIGNAL 1 22 Potential.
 PROPEP 23 31 Islet amyloid polypeptide.
 PEPTIDE 35 >67
 DISULFID 35 40 By similarity.
 NON TER 67 67
 SEQUENCE 67 AA; 7230 MW; BF5FEC2064F69646 CRC64;
 Query Match 49.6%; Score 69; DB 1; Length 67;
 Best Local Similarity 50.0%; Pred. No. 2e-05; Indels 0; Gaps 0;
 Matches 16; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXGXPXPTXVGS 34
 DB 36 NTVTCATQRLANFLHSSNNGAFSPSPVGS 67
 RESULT 14
 IAPP_PIG
 ID IAPP_PIG STANDARD; PRT; 32 AA.
 AC Q29119;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Islet amyloid polypeptide (Amylin) (Fragment).
 GN Name=IAPP;
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;

Sus.
 NCBI_TaxID=9823;
 (1)
 NUCLEOTIDE SEQUENCE.
 Albrandt K., Sierzege M.E., Mull E., Brady E.M.G.;
 "PCR amplification of amylin 3-34 from genomic DNA."
 Submitted (AUG-1996) to the EMBL/GenBank/DBJ databases.
 -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
 utilization and glycogen deposition in muscle, while not affecting
 adipocyte glucose metabolism.
 -!- SUBCELLULAR LOCATION: Secreted.
 -!- SIMILARITY: Belongs to the calcitonin family.

 This Swiss-Prot entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use as long as its content is in no way modified and this statement is not
 removed.

 EMBL; U62628; AAB05919.1; -; Genomic_DNA.
 InterPro; IPR000443; Amylin.
 InterPro; IPR001693; Calcitonin-like.
 Pfam; PF00214; Calc_CGRP_IAPP; 1.
 PRINTS; PR00818; ISETAMYL0ID.
 SMART; SM00113; CALCITONIN; 1.
 PROSITE; PS00258; CALCITONIN; PARTIAL.
 Amyloid; Hormone.
 PEPTIDE <1 >32 Islet amyloid polypeptide.
 NON TER 1 1
 NON TER 32 32
 NON TER 32 32
 SEQUENCE 32 AA; 3466 MW; 7EB37E990BE555C8 CRC64;
 Query Match 47.5%; Score 66; DB 1; Length 32;
 Best Local Similarity 50.0%; Pred. No. 3.4e-05;
 Matches 16; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXGXPXPTXVGS 34
 DB 1 NMTATCATQRLANFLDRSRNLTGTFSPTKVGS 32
 RESULT 15
 IAPP_SAGOE
 ID IAPP_SAGOE STANDARD; PRT; 32 AA.
 AC Q28934;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Islet amyloid polypeptide (Amylin) (Fragment).
 GN Name=IAPP;
 OS Saguinus oedipus (Cotton-top tamarin).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Platyrrhini;
 OC Callitrichidae; Saguinus.
 NCBI_TaxID=9490;
 (1)
 NUCLEOTIDE SEQUENCE.
 Albrandt K., Sierzege M.E., Mull E., Brady E.M.G.;
 "PCR amplification of amylin 3-34 from genomic DNA."
 Submitted (AUG-1996) to the EMBL/GenBank/DBJ databases.
 -!- FUNCTION: Selectively inhibits insulin-stimulated glucose
 utilization and glycogen deposition in muscle, while not affecting
 adipocyte glucose metabolism.
 -!- SUBCELLULAR LOCATION: Secreted.
 -!- SIMILARITY: Belongs to the calcitonin family.

 This Swiss-Prot entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use as long as its content is in no way modified and this statement is not
 removed.

 EMBL; U62627; AAB05918.1; -; Genomic_DNA.


```
RESULT 18
Q6DGJ9 BRARE
ID Q6DGJ9 BRARE PRELIMINARY; PRT; 126 AA.
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE ZGC:92886.
GN ORFNames=zgc:92886;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN NUCLEOTIDE SEQUENCE.
[1]
RP TISSUE=Brain;
RC MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klapper S.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Sapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Vallalao D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A.C., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A.C., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC076343; AAH76343.1; -, mRNA.
DR ZFIN; ZDB-GENE-040718-173; zgc:92886.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc CGRP IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
SQ SEQUENCE 126 AA; 13957 MW; 9A9399E3683D7B16 CRC64;

Query Match 36.78; Score 51; DB 2; Length 126;
Best Local Similarity 37.14; Pred. No. 0.14; Mismatches 20; Indels 0; Gaps 0;
Matches 13; Conservative 2;

QY 3 NTATATQRLXNLFXXXXXXXXXNGPXPXVGSNTY 37
|||||
DB 83 NTATCTVTRLADFLSRSGGIGSSKFVFTNVGSQAF 117
|||||

RESULT 19
IAPP_BOVIN
ID IAPP_BOVIN PRELIMINARY; PRT; 32 AA.
AC Q28207;
DT 15-JUN-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)

10-MAY-2005 (Rel. 47, Last annotation update)
Name=IAPP;
GN Bos taurus (Bovine).
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC Pecora; Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN NUCLEOTIDE SEQUENCE.
[1]
RP Albrandt K., Sierzega M.E., Mull E., Brady E.M.G.;
RT "PCR amplification of amylin 3-34 from genomic DNA.";
RL Submitted (AUG-1996) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: Selectively inhibits insulin-stimulated glucose
CC utilization and glycogen deposition in muscle, while not affecting
CC adipocyte glucose metabolism.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; U62626; AAB05915.1; -, Genomic DNA.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR Pfam; PF00214; Calc CGRP IAPP; 1.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; PARTIAL.
KW Amyloid; Hormone.
FT PEPTIDE <1> >32 Islet amyloid polypeptide.
FT NON_TER 1 1
FT NON_TER 32 32
SQ SEQUENCE 32 AA; 3247 MW; 9A5709394EB44C19 CRC64;

Query Match 36.0%; Score 50; DB 1; Length 32;
Best Local Similarity 41.9%; Pred. No. 0.048;
Matches 13; Conservative 1; Mismatches 17; Indels 0; Gaps 0;

QY 4 TATATQRLXNLFXXXXXXXXXNGPXPXVGS 34
|||||
DB 2 TATCETQCLANFLAPSSNKLGAIFSPTKMG 32
|||||

RESULT 20
CALCR_RANRI
ID CALCR_RANRI STANDARD; PRT; 37 AA.
AC P31888;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcitonin gene-related peptide (CGRP).
OS Rana ridibunda (Laughing frog) (Marsh frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Rana;
OC Pelophylax.
OX NCBI_TaxID=8406;
RN NUCLEOTIDE SEQUENCE.
[1]
RP TISSUE=Brain, and Intestine;
RC MEDLINE=93324452; PubMed=8332553; DOI=10.1016/0196-9781(93)90148-A;
RA Conlon J.M., Tonon M.-C., Vaudry H.;
RT "Isolation and structural characterization of calcitonin gene-related
RT peptide from the brain and intestine of the frog, Rana ridibunda.";
RL Peptides 14:581-586(1993).
CC -1- FUNCTION: CGRP induces vasodilatation. It dilates a variety of
CC vessels including the coronary, cerebral and systemic vasculature.
CC Its abundance in the CNS also points toward a neurotransmitter or
CC neuromodulator role.
CC -1- SIMILARITY: Belongs to the calcitonin family.
```

```
-----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc CGRP IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
KW Amidation; Direct protein sequencing; Hormone.
FT MOD_RES 37 37 Phenylalanine amide.
FT DISULFID 2 7 By similarity.
SQ SEQUENCE 37 AA; 3887 MW; 0EFE3AD2745EBDE CRC64;

Query Match 36.0%; Score 50; DB 1; Length 37;
Best Local Similarity 37.1%; Pred. No. 0.057;
Matches 13; Conservative 2; Mismatches 20; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFKLXXXXXNKGXPLPTXVGSNTY 37
||||| ||||| :||| :
DB 3 NTATCVTHRLADFLSRSGMGAKNFPVPTNVGSKAF 37
||||| ||||| :||| :

RESULT 21
P79814 ONCGO PRELIMINARY; PRT; 52 AA.
AC P79814;
DT 01-MAY-1997 (TrEMBLrel. 03, Created)
DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Calcitonin gene-related peptide 4 (Fragment).
OS Oncorhynchus gorbuscha (Pink salmon) (Humpback salmon).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8017;
[1]
NUCLEOTIDE SEQUENCE.
RP Cressent M.D.;
RX MEDLINE=97057244; PubMed=8901583; DOI=10.1073/pnas.93.22.12344;
RA Jansz H., Martial K., Zandberg J., Milhead G., Benson A.A.,
RA Julienne A., Mounkhar M.S., Cressent M.;
RT "Identification of a new calcitonin gene in the salmon Oncorhynchus
RT gorbuscha.";
RL Proc. Natl. Acad. Sci. U.S.A. 93:12344-12348(1996).
[2]
NUCLEOTIDE SEQUENCE.
RA Cressent M.D.;
RL Submitted (SEP-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U71287; AA38533.1; -, mRNA.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc CGRP IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
FT CHAIN <1 4 N-terminal peptide.
FT CHAIN 7 43 calcitonin gene-related peptide 4.
FT CHAIN 49 52 carboxy terminal peptide.
FT NON_TER 1 1
SQ SEQUENCE 52 AA; 5700 MW; 3F4C471D2A682321 CRC64;

Query Match 35.3%; Score 49; DB 2; Length 52;
Best Local Similarity 34.3%; Pred. No. 0.13;
Matches 12; Conservative 3; Mismatches 20; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFKLXXXXXNKGXPLPTXVGSNTY 37
||||| ||||| :||| :
-----
```

```
Db 9 NTATCVTHRLADFLSRSGMGNSNFPVPTNVGAKAF 43

RESULT 22
Q8QFT9_FUGRU PRELIMINARY; PRT; 126 AA.
AC Q8QFT9;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Calcitonin gene related peptide.
GN Name=cgrp;
OS Fugu rubripes (Japanese pufferfish) (Takifugu rubripes).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontoidea; Tetraodontidae; Takifugu.
OX NCBI_TaxID=31033;
[1]
NUCLEOTIDE SEQUENCE.
RP Clark M.S.;
RA "Structure and expression of Fugu calcitonin gene.";
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ309015; CAC81277.1; -, Genomic DNA.
DR Ensembl; SINFRUG0000125998; Fugu rubripes.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc CGRP IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
FT CHAIN 81 117 calcitonin gene related peptide.
SQ SEQUENCE 126 AA; 13863 MW; 31CB14A01BF2CD57 CRC64;

Query Match 35.3%; Score 49; DB 2; Length 126;
Best Local Similarity 34.3%; Pred. No. 0.36;
Matches 12; Conservative 3; Mismatches 20; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFKLXXXXXNKGXPLPTXVGSNTY 37
||||| ||||| :||| :
DB 83 NTATCVTHRLADFLSRSGMGNSNFPVPTNVGAKAF 117
||||| ||||| :||| :

RESULT 23
Q4S167_TETNG PRELIMINARY; PRT; 184 AA.
AC Q4S167;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Chromosome 13 SCAF14769, whole genome shotgun sequence.
DE (Fragment).
GN ORFNames=GSTENG0025692001;
OS Tetraodon nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontoidea; Tetraodontidae; Tetraodon.
OX NCBI_TaxID=99883;
[1]
NUCLEOTIDE SEQUENCE.
RP Jallion O., Aury J.M., Brunet F., Petit J.L., Stange-Thomann N.,
RA Mauceli E., Bouneau L., Fischer C., Ozouf-Costaz C., Bernot A.,
RA Nicaud S., Jaffe D., Fisher S., Lutfalla G., Dossat C., Segreus B.,
RA Dasilva C., Salanoubat M., Levy M., Boudet N., Castellano S.,
RA Anchaoud V., Jubin C., Castelli V., Katinka M., Vacherie B.,
RA Biemont C., Skalli Z., Cattolico L., Poulain J., De Berardinis V.,
RA Craud C., Duprat S., Bottier P., Coutanceau J.P., Gouzy J.,
RA Parra G., Lardier G., Chapple C., McKernan K.J., McEwan P., Bosak S.,
```

```
RA Kellis M., Volf JN., Guigo R., Zody M.C., Mesirov J.,
RA Lindblad-Toh K., Birren B., Nusbaum C., Kahn D., Robinson-Rechavi M.,
RA Laudet V., Schachter V., Quetier F., Saurin W., Scarpelli C.,
RA Wincker P., Lander E.S., Weissbach J., Roest Crollius H.,
RT "Genome duplication in the teleost fish Tetraodon nigroviridis reveals
RL the early vertebrate proto-karyotype.";
RN Nature 431:946-957(2004).
RN
RG NUCLEOTIDE SEQUENCE.
RG Genoscope; Whitehead Institute Centre for Genome Research;
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; CAAB01014769; CAG05615.1; -; Genomic_DNA.
FT NON TER 184
SQ SEQUENCE 184 AA; 20107 MW; 851FB9A69FD16F29 CRC64;

Query Match 35.3%; Score 49; DB 2; Length 184;
Best Local Similarity 34.3%; Pred. No. 0.55;
Matches 12; Conservative 3; Mismatches 20; Indels 0; Gaps 0;

Qy 3 NTATYATQRLXNLFXXXXXXXXXGXPLPTXVGSNTY 37
Db 141 NTATCVTHRLADFLNRSGMGNFVPTNVGAKAF 175

RESULT 24
Q92164.ONCSP
ID Q92164.ONCSP PRELIMINARY; PRT; 56 AA.
AC Q92164;
RA Janes H.S., Zandberg J.;
RT "Identification and partial characterization of the salmon
RL calcitonin/CGRP gene by polymerase chain reaction.";
RL Ann. N.Y. Acad. Sci. 657:63-69(1992).
DR EMBL; S40497; AAB22593.1; -; Genomic_DNA.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc-CGRP-IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
FT NON TER 1
SQ SEQUENCE 56 AA; 6019 MW; C7852837BAF74314 CRC64;

Query Match 34.5%; Score 48; DB 2; Length 56;
Best Local Similarity 34.3%; Pred. No. 0.22;
Matches 12; Conservative 3; Mismatches 20; Indels 0; Gaps 0;

Qy 3 NTATYATQRLXNLFXXXXXXXXXGXPLPTXVGSNTY 37
Db 9 NTATCVTHRLADFLNRSGMGNFVPTNVGAKAF 43

RESULT 25
CALCA_CHKCK
ID CALCA_CHKCK STANDARD; PRT; 125 AA.
AC P10286;
```

```
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcitonin gene-related peptide precursor (CGRP).
GN Name-CALCA; Synonyms=CALC;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
OC Gallus.
OX NCBI_TaxID=9031;
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=86030046; PubMed=3666142; DOI=10.1016/0014-5793(87)80510-0;
RA Minvielle S., Cressent M., Delehay M.C., Segond N., Milhaud G.,
RA Jullienne A., Moukhtar M.S., Lasmoles F.;
RT "Sequence and expression of the chicken calcitonin gene.";
RL FEBS Lett. 223:63-68(1987).
RN NUCLEOTIDE SEQUENCE OF 12-73.
RP MEDLINE=86030240; PubMed=4054101;
RA Lasmoles F., Jullienne A., Day F., Minvielle S., Milhaud G.,
RA Moukhtar M.S.;
RT "Elucidation of the nucleotide sequence of chicken calcitonin mRNA:
RT direct evidence for the expression of a lower vertebrate calcitonin-
RT like gene in man and rat.";
RL EMBO J. 4:2603-2607(1985).
RN NUCLEOTIDE SEQUENCE OF 74-125.
RP MEDLINE=86248126; PubMed=3487468; DOI=10.1016/0014-5793(86)81425-9;
RA Minvielle S., Cressent M., Lasmoles F., Jullienne A., Milhaud G.,
RA Moukhtar M.S.;
RT "Isolation and partial characterization of the calcitonin gene in a
RT lower vertebrate. Predicted structure of avian calcitonin gene-related
RT peptide.";
RL FEBS Lett. 203:7-10(1986).
CC -!- FUNCTION: CGRP induces vasodilatation. It dilates a variety of
CC vessels including the coronary, cerebral and systemic vasculature.
CC Its abundance in the CNS also points toward a neurotransmitter or
CC neuromodulator role.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=Calcitonin-gene related peptide;
CC IsoId=P10286-1; Sequence=Displayed;
CC Name=Calcitonin;
CC IsoId=P07660-1; Sequence=External;
CC -!- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
DR EMBL; X06311; CAA29630.1; -; Genomic_DNA.
DR EMBL; X06312; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; X06314; CAA29633.1; -; Genomic_DNA.
DR EMBL; X03012; CAA26796.1; ALT TERM; mRNA.
DR EMBL; D00007; BAA00006.1; -; Genomic_DNA.
DR PIR; S00154; TCCHRP.
DR Ensembl; ENSGALG0000006054; Gallus gallus.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc-CGRP-IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
DR Alternative splicing; Amidation; Cleavage on pair of basic residues;
KW Hormone; Signal.
FT SIGNAL 1 25 Potential.
FT PROPEP 26 77
```


Query Match 30.9%; Score 43; DB 1; Length 37;
Best Local Similarity 34.3%; Pred. No. 1.3;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFXLXXXXXNKGXPLPTXVGSNTY 37
|||||
Db 3 NTATCVTHRLAGLLSRSGGMVKSFPVPTDVGSEAF 37
|||||

RESULT 32

Q4THN9 TETNG
ID Q4THN9 TETNG PRELIMINARY; PRT; 44 AA.
AC Q4THN9;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Chromosome undetermined SCAF2800, whole genome shotgun sequence.
DE (Fragment).
GN ORFNames=GSTENG0000464001;
OS Tetraodon nigroviridis (Green puffer).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
OC Tetraodontidae; Tetraodontidae; Tetraodon.
OX NCBI_TaxID=99883;
RN [1]

NUCLEOTIDE SEQUENCE.

RA Jallou O., Aury J.M., Brunet F., Petit J.L., Stange-Thomann N.,
RA Mauceli E., Bouneau L., Fischer C., Ozouf-Costaz C., Bernot A.,
RA Nicaud S., Jaffe D., Fisher S., Lutfalla G., Doseat C., Segurens B.,
RA Dasilva C., Salanoubat M., Levy M., Boudet N., Castellano S.,
RA Anthouard V., Jubin C., Castelli V., Katinka M., Vacherie B.,
RA Biemont C., Skalli Z., Cattolico L., Poulain J., De Berardinis V.,
RA Cruaud C., Duprat S., Brottier P., Coutanceau J.P., Gouzy J.,
RA Parra G., Lardier G., Chapple C., McKernan K.J., McEwan P., Bosak S.,
RA Kellis M., Wolff J.N., Guigo R., Zody M.C., Mesirov J.,
RA Lindblad-Toh K., Birren B., Nusbaum C., Kahn D., Robinson-Rechavi M.,
RA Laudet V., Schachter V., Quetier F., Saurin W., Scarpelli C.,
RA Winkler P., Lander E.S., Weissbach J., Roest Crollius H.,
RA "Genome duplication in the teleost fish Tetraodon nigroviridis reveals
RT the early vertebrate proto-karyotype.";
RL Nature 431:946-957(2004).
RN [2]

NUCLEOTIDE SEQUENCE.

RG Genoscope; Whitehead Institute Centre for Genome Research;
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; CAAB01002800; CAP87593.1; -; Genomic_DNA.
FT NON TER 1
FT NON TER 44
SQ SEQUENCE 44 AA; 4556 MW; EE24C0ED223F4E96 CRC64;

Query Match 30.9%; Score 43; DB 2; Length 44;
Best Local Similarity 64.3%; Pred. No. 1.6;
Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFXL 16
|||||
Db 11 NTATCVTHRLADFL 24
|||||

RESULT 33

Q8WNX2 CALJA
ID Q8WNX2 CALJA PRELIMINARY; PRT; 53 AA.
AC Q8WNX2;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Beta-calcitonin-related protein (Fragment).
GN Name=Beta-CGRP;

OS Callithrix jacchus (Common marmoset).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Platyrrhini;
OC Callitrichidae; Callithrix.
OX NCBI_TaxID=9483;
RN [1]

NUCLEOTIDE SEQUENCE.

RA Schindler M., Fischer B.,
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF442154; AAL35593.1; -; Genomic_DNA.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR000443; Amylin.
DR InterPro; IPR001693; Calcitonin-like.
DR InterPro; IPR002163; Calcitonin B.
DR Pfam; PF00214; Calc CGRP_IAPP; I.
DR PRINTS; PR00817; CALCITONINB.
DR PRINTS; PR00818; ISLETAMYLOID.
DR SMART; SM00113; CALCITONIN; 1.
DR PROSITE; PS00258; CALCITONIN; 1.
FT NON TER 1
SQ SEQUENCE 53 AA; 5710 MW; A76A34E3D5E3E99C CRC64;

Query Match 30.9%; Score 43; DB 2; Length 53;

Best Local Similarity 34.3%; Pred. No. 2;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;

Oy 3 NTATXATQRLXNFXLXXXXXNKGXPLPTXVGSNTY 37
|||||
Db 10 NTATCVTHRLAGLLSRSGGMVKSFPVPTDVGSKAF 44
|||||

RESULT 34

ID CALCB HUMAN STANDARD; PRT; 127 AA.
AC P10092; Q9UCN9;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcitonin gene-related peptide II precursor (CGRP-II) (Beta-type CGRP).
DE Name=CALCB; Synonyms=CALC2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]

NUCLEOTIDE SEQUENCE.

RX MEDLINE=87105923; PubMed=3492393; DOI=10.1016/0014-5793(86)81091-2;
RA Steenbergh P.H., Hoepfner J.W.M., Zandberg J., Visser A.,
RA Lips C.J.M., Jansz H.S.;
RT "Structure and expression of the human calcitonin/CGRP genes.";
RL FEBS Lett. 209:97-103(1986).
RN [2]

NUCLEOTIDE SEQUENCE OF 56-127.

RX MEDLINE=85180007; PubMed=2985435; DOI=10.1016/0014-5793(85)80820-6;
RA Steenbergh P.H., Hoepfner J.W.M., Zandberg J., Lips C.J.M.,
RA Jansz H.S.;
RT "A second human calcitonin/CGRP gene.";
RL FEBS Lett. 183:403-407(1985).
RN [3]

PARTIAL PROTEIN SEQUENCE OF 82-108.

RX MEDLINE=87109142; PubMed=3492492;
RA Petermann J.B., Born W., Chang J.Y., Fischer J.A.;
RT "Identification in the human central nervous system, pituitary, and
RT thyroid of a novel calcitonin gene-related peptide, and partial amino
RT acid sequence in the spinal cord.";
RL J. Biol. Chem. 262:542-545(1987).
RN [4]

PROTEIN SEQUENCE OF 82-86 AND 104-117.

RN PROTEIN SEQUENCE OF 82-86 AND 104-117.
RC TISSUE=Spinal cord;
RX MEDLINE=90211348; PubMed=2322288;

RA Wimalawansa S.J., Morris H.R., Etienne A., Blench I., Panico M.,
 RA McIntyre I.,
 RT "Isolation, purification and characterization of beta-hCGRP from human
 RT spinal cord";
 RL Biochem. Biophys. Res. Commun. 167:993-1000(1990).
 RN [5]
 RP PROTEIN SEQUENCE OF 82-104.
 RC TISSUE=Pheochromocytoma;
 RX MEDLINE=92287083; PubMed=1318039;
 RA Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Matsuo H., Eto T.,
 RT "Isolation and characterization of peptides which act on rat
 RT platelets, from a pheochromocytoma";
 RL Biochem. Biophys. Res. Commun. 185:134-141(1992).
 CC -!- FUNCTION: CGRP induces vasodilatation. It dilates a variety of
 CC vessels including the coronary, cerebral and systemic vasculature.
 CC Its abundance in the CNS also points toward a neurotransmitter or
 CC neuromodulator role.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- SIMILARITY: Belongs to the calcitonin family.
 CC
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC
 CC EMBL; X04855; CAC05295.1; -; Genomic DNA.
 CC EMBL; X04857; CAC05295.1; JOINED; Genomic DNA.
 CC EMBL; X04861; CAC05295.1; JOINED; Genomic DNA.
 CC EMBL; X02404; CAA26249.1; -; mRNA.
 CC PIR; A25864; A25864.
 CC PIR; 137232; I37232.
 CC DR ENSEMBL; ENSG00000175868; Homo sapiens.
 CC DR HGNC; HGNC:1438; CALCB.
 CC DR H-InvDB; HIX0009469; -.
 CC DR MIM; 114160; -.
 CC DR GO; GO:0005625; C:soluble fraction; TAS.
 CC DR GO; GO:0005184; F:neuropeptide hormone activity; TAS.
 CC DR GO; GO:0006874; P:calcium ion homeostasis; TAS.
 CC DR GO; GO:0007165; P:signal transduction; TAS.
 CC DR InterPro; IPR001693; Calcitonin-like.
 CC DR InterPro; IPR002163; Calcitonin B.
 CC DR Pfam; PF00214; Calc CGRP IAPP; 1.
 CC DR PRINTS; PR00817; CALCITONINB.
 CC DR SMART; SM00113; CALCITONIN; 1.
 CC DR PROSITE; PS00258; CALCITONIN; 1.
 KW Amidation; Cleavage on pair of basic residues;
 KW Direct protein sequencing; Hormone; Signal.
 FT SIGNAL 1 25 Potential.
 FT PROPEP 26 79
 FT PEPTIDE 82 118
 FT PROPEP 124 127
 FT MOD_RES 118 118
 FT
 FT DISULFID 83 88
 FT CONFLICT 73 73 G -> S (in Ref. 2).
 SQ SEQUENCE 127 AA; 13706 MW; 13706 MW; BOA71A063CDSACE7 CRC64;
 Query Match 30.9%; Score 43; DB 1; Length 127;
 Best Local Similarity 34.3%; Pred. No. 5.4;
 Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;
 Qy 3 NTATXATQRLXNLFXXXXXGXPLPXTXVGSNTY 37
 |||||
 Db 84 NTATCVTHRLAGLLSRSGGMVKSFNFTVPTNVGSKAF 118
 |||||
 RESULT 35
 Q56910_HUMAN PRELIMINARY; PRT; 127 AA.
 AC Q56910;
 DT 10-MAY-2005 (TrEMBLrel. 30, Created)
 DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)

DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
 DE Calcitonin-related polypeptide, beta.
 GN Name=CALCB;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H.; Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bobak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Pahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Myers R.M.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Skalska U., Smalls D.E.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RG NIH MGC Project;
 RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
 DR EMBL; BC092468; AAH92468.1; -; mRNA.
 DR Ensembl; ENSG00000175868; Homo sapiens.
 DR GO; GO:0005576; C:extracellular region; IEA.
 DR GO; GO:0005179; F:hormone activity; IEA.
 DR InterPro; IPR000443; Amylin.
 DR InterPro; IPR001693; Calcitonin-like.
 DR InterPro; IPR002163; Calcitonin B.
 DR Pfam; PF00214; Calc CGRP IAPP; 1.
 DR PRINTS; PR00817; CALCITONINB.
 DR PRINTS; PR00818; ISLETAMYLID.
 DR SMART; SM00113; CALCITONIN; 1.
 DR PROSITE; PS00258; CALCITONIN; 1.
 SQ SEQUENCE 127 AA; 13706 MW; BOA71A063CDSACE7 CRC64;
 Query Match 30.9%; Score 43; DB 2; Length 127;
 Best Local Similarity 34.3%; Pred. No. 5.4;
 Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;
 Qy 3 NTATXATQRLXNLFXXXXXGXPLPXTXVGSNTY 37
 |||||
 Db 84 NTATCVTHRLAGLLSRSGGMVKSFNFTVPTNVGSKAF 118
 |||||
 RESULT 36
 CALCB_MOUSE
 ID CALCB_MOUSE STANDARD; PRT; 130 AA.
 AC Q99MP3;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Calcitonin gene-related peptide II precursor (CGRP-II) (Beta-type
 DE CGRP).
 GN Name=Calcb;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

```

OC Muroidea; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=129/SV;
RX MEDLINE=21604266; PubMed=11761712;
RA Thomas P.M., Nasonkin I., Zhang H., Gagel R.F., Core G.J.;
RT "Structure of the mouse calcitonin/calcitonin gene-related peptide
RL DNA Seq. 12:131-135(2001).
CC -!- FUNCTION: CGRP induces vasodilatation. It dilates a variety of
CC vessels including the coronary, cerebral and systemic vasculature.
CC Its abundance in the CNS also points toward a neurotransmitter or
CC neuromodulator role. (By similarity).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- SIMILARITY: Belongs to the calcitonin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; AF325526; AAK16431.1; -; Genomic DNA.
CC EMBL; AF325524; AAK16431.1; JOINED; Genomic DNA.
CC Ensembl; ENSMUSG00000030666; Mus musculus.
CC MGI; MGI:2151254; Calc.
CC GO; GO:0005615; C:extracellular space; TAS.
CC InterPro; IPR000443; Amylin.
CC InterPro; IPR001693; Calcitonin-like.
CC InterPro; IPR002163; Calcitonin.B.
CC Pfam; PF00214; Calc_CGRP_IAPP; I.
CC PRINTS; PR00817; CALCITONINB.
CC PRINTS; PR00818; ISLETAMYLID.
CC SMART; SM00113; CALCITONIN; 1.
CC PROSITE; PS00258; CALCITONIN; 1.
KW Amidation; Cleavage on pair of basic residues; Hormone; Signal.
FT SIGNAL 1 26 Potential.
FT PROPEP 27 82 By similarity.
FT PEPTIDE 84 120 Calcitonin gene-related peptide II.
FT PROPEP 127 130 By similarity.
FT MOD_RES 120 130 Phenylalanine amide (G-121 provides amide
FT group) (By similarity).
FT DISULFID 85 90 By similarity.
FT SEQUENCE 130 AA; 14623 MW; 972992448F6C536 CRC64;
Query Match 30.9%; Score 43; DB 1; Length 130;
Best Local Similarity 34.3%; Pred. No. 5.6;
Matches 12; Conservative 2; Mismatches 21; Indels 0; Gaps 0;
Oy 3 NTATXATQRLXNLFXXXXXXXXXGXPLPTXVGSNTY 37
Db 86 NTATCVTHRLADLLSRGSGVLKDNFVPTDVGSEAF 120
RESULT 37
IOBI_CABEL
ID YQBI_CABEL STANDARD; PRT; 469 AA.
AC Q09255;
DT 01-NOV-1997 (Rel. 35, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Hypothetical protein C30G12.1 in chromosome II.
GN ORFNames=C30G12.1;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN (1)
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG The C. elegans sequencing consortium;

```

```

RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology.";
RL Science 282:2012-2018(1998).
RN (2)
RP SEQUENCE REVISION.
RG WormBase consortium;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; U21319; AAL16307.1; -; Genomic DNA.
CC Ensembl; C30G12.1; Caenorhabditis elegans.
CC WormBase; WBGene00016273; C30G12.1.
CC WormPep; C30G12.1; CE29685.
CC InterPro; IPR010480; Prot inh_I33.
CC Pfam; PF06394; Pepsin-I3; 1.
KW Complete proteome; Hypothetical protein.
FT COMPIAS 90 93 Poly-Ser.
FT COMPIAS 294 304 Poly-Thr.
FT COMPIAS 310 314 Poly-Thr.
FT COMPIAS 345 353 Poly-Ser.
FT COMPIAS 392 395 Poly-Thr.
FT SEQUENCE 469 AA; 52847 MW; 845099206BB9885D CRC64;
Query Match 30.9%; Score 43; DB 1; Length 469;
Best Local Similarity 35.5%; Pred. No. 24;
Matches 11; Conservative 1; Mismatches 19; Indels 0; Gaps 0;
Oy 3 NTATXATQRLXNLFXXXXXXXXXGXPLPTXVG 33
Db 389 NVATTTPLPLRFLPTPAAPNPFPLSTRVG 419
RESULT 38
Q4WLC6_ASFPF
ID Q4WLC6_ASFPF PRELIMINARY; PRT; 482 AA.
AC Q4WLC6;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Hypothetical protein.
GN ORFNames=Afu6g14020;
OS Aspergillus fumigatus Af293.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
OX NCBI_TaxID=330879;
RN (1)
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Af293;
RA Nierman W., Pain A., Anderson M.J., Wortman J., Kim H.Stanley.,
RA Arroya J., Berriman M., Abe K., Archer B.B., Bermejo C., Bennett J.,
RA Bowyer P., Chen D., Collins M., Coulson R., Davies R., Dyer P.S.,
RA Farman M., Fedorova N., Fedorova N., Feldblyum T.V., Fischer R.,
RA Fosker N., Fraser A., Garcia J.L., Garcia M.J., Goble A.,
RA Goldman G.H., Gomi K., Griffith-Jones S., Gwilliam R., Haas B.,
RA Haas H., Harris D., Horiuchi H., Huang J., Humphrey S., Jimenez J.,
RA Keller N., Khouri H., Kitamoto K., Kobayashi T., Kulkarni R.,
RA Kumagai T., Lafton A., Latge J.-P., Li W., Lord A., Lu C.,
RA Majores W.H., May G.S., Miller B.L., Mohamoud Y., Molina M., Monod M.,
RA Mounya I., Mulligan S., Murphy L., O'Neil S., Paulsen I.,
RA Penalba M.A., Partea M., Price C., Pritchard B.L., Quail M.A.,
RA Rabinowitz E., Rawlins N., Rajandream M.-A., Reichard U.,
RA Renauld H., Robson G.D., Rodriguez de Cordoba S., Rodriguez-Pena J.M.,
RA Ronning C.M., Rutter S., Salzberg S.L., Sanchez M.,
RA Sanchez-Ferrero J.C., Saunders D., Seeger K., Squares R., Squares S.,
RA Takeuchi M., Tekala F., Turner G., Vazquez de Aldana C.R., Weidman J.,
RA White O., Woodward J., Yu J.-H., Fraser C., Galagan J.E., Asai K.,
RA Machida M., Hall N., Barrell B., Denning D.W.;
RG "Genomic sequence of the pathogenic and allergenic filamentous fungus

```



```

RT Aspergillus fumigatus.";
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
CC !- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAH01000006; EAL89238.1; -; Genomic_DNA.
KW Hypothetical protein.
SQ SEQUENCE 482 AA; 53183 MW; BE79BD9B597F8216 CRC64;

Query Match 30.9%; Score 43; DB 2; Length 482;
Best Local Similarity 50.0%; Pred. No. 25;
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 24 GPXLPXTXVGSNTY 37
Db 214 GPEIPYTIYGSNSF 227
|||:|||||:
214 GPEIPYTIYGSNSF 227

RESULT 39
Q55HY4 CRYNE PRELIMINARY; PRT; 1502 AA.
AC Q55HY4;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Hypothetical protein.
GN ORFNames=CNM2330;
OS Cryptococcus neoformans var. neoformans B-3501A.
OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Heterobasidiomycetes;
OC Tremellomycetidae; Tremellales; Tremellaceae; Filobasidiella.
OX NCBI_TaxID=283643;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=B-3501A;
RA Fung E., Hyman R.W., Rowley D., Bruno D., Miranda M., Fukushima M.,
RA Wickes B.L., Fu J., Davis R.W.;
RT "Cryptococcus neoformans serotype D sequencing.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
CC !- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AA01000064; EAL17429.1; -; Genomic_DNA.
KW Hypothetical protein.
SQ SEQUENCE 1502 AA; 164196 MW; AEF63A266216FF3C CRC64;

Query Match 30.9%; Score 43; DB 2; Length 1502;
Best Local Similarity 33.3%; Pred. No. 89;
Matches 11; Conservative 2; Mismatches 20; Indels 0; Gaps 0;

Qy 4 TATXATQRLNFXLXXXXXNGPXLPTXVGSNT 36
Db 956 TATDAVSHFLNCLLGSLNPAPVASVTPIGINS 988
|||||:|||||:
956 TATDAVSHFLNCLLGSLNPAPVASVTPIGINS 988

RESULT 40
Q5K7G8 CRYNE PRELIMINARY; PRT; 1502 AA.
AC Q5K7G8;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Translational initiation-related protein, putative.
GN ORFNames=CNM02490;
OS Cryptococcus neoformans var. neoformans JEC21.
OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Heterobasidiomycetes;
OC Tremellomycetidae; Tremellales; Tremellaceae; Filobasidiella.
OX NCBI_TaxID=214684;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=JEC21;
RA Loftus B., Amedeo P., Roncaglia P., Vamathevan J., Utterback T.,
RA Van Aken S., Fraser C.;
RL Submitted (MAY-2004) to the EMBL/GenBank/DBJ databases.

```

```

RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=JEC21;
RX PubMed=15653466; DOI=10.1126/science.1103773;
RA Loftus B.J., Fung E., Roncaglia P., Rowley D., Amedeo P., Bruno D.,
RA Vamathevan J., Miranda M., Anderson I.J., Fraser J.A., Allen J.E.,
RA Bodet I.E., Brent M.R., Chiu R., Doering T.L., Donlin M.J.,
RA D'Souza C.A., Fox D.S., Grinberg V., Fu J., Fukushima M., Haas B.J.,
RA Huang J.C., Janbon G., Jones S.J.M., Koo H.L., Krzywinski M.I.,
RA Kwon-Chung K.J., Lengeler K.B., Maiti R., Marra M.A., Marra R.E.,
RA Mathewson C.A., Mitchell T.G., Pertea M., Riggs F.R., Salzberg S.L.,
RA Schein J.E., Shvartsbeyn A., Shin H., Shumway M., Specht C.A.,
RA Suh B.B., Tenney A., Utterback T.R., Wickes B.L., Wortman J.R.,
RA Wye N.H., Kronstad J.W., Lodge J.K., Heitman J., Davis R.W.,
RA Fraser C.M., Hyman R.W.;
RT "The genome of the basidiomycetous yeast and human pathogen
RL Cryptococcus neoformans.";
RL Science 307:1321-1324(2005).
DR EMBL; AB017353; AAM46737.1; -; Genomic_DNA.
DR InterPro; IPR011990; TPR-like_helical.
KW Complete proteome.
SQ SEQUENCE 1502 AA; 164198 MW; AEF63A266216FF3C CRC64;

Query Match 30.9%; Score 43; DB 2; Length 1502;
Best Local Similarity 33.3%; Pred. No. 89;
Matches 11; Conservative 2; Mismatches 20; Indels 0; Gaps 0;

Qy 4 TATXATQRLNFXLXXXXXNGPXLPTXVGSNT 36
Db 956 TATDAVSHFLNCLLGSLNPAPVASVTPIGINS 988
|||||:|||||:
956 TATDAVSHFLNCLLGSLNPAPVASVTPIGINS 988

RESULT 41
CALCA SHEEP STANDARD; PRT; 37 AA.
AC P30881;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcitonin gene-related peptide (CGRP).
GN Name=CALCA; Synonyms=CALC;
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC Pecora; Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP PROTEIN SEQUENCE.
RC TISSUE=Hypothalamus;
RX MEDLINE=93038624; PubMed=1417824;
RA Miyata A., Jiang L., Minamino N., Arimura A.;
RT "Identification of calcitonin gene related peptide in ovine
RL hypothalamic extract.";
RL Biochem. Biophys. Res. Commun. 187:1474-1479(1992).
CC !- FUNCTION: CGRP induces vasodilation. It dilates a variety of
CC vessels including the coronary, cerebral and systemic vasculature.
CC Its abundance in the CNS also points toward a neurotransmitter or
CC neuromodulator role.
CC !- SUBCELLULAR LOCATION: Secreted.
CC !- SIMILARITY: Belongs to the calcitonin family.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC PIR; JH0709; JH0709.
CC InterPro; IPR001693; Calcitonin-like.
CC InterPro; IPR002163; Calcitonin.B.
CC Pfam; PF00214; Calc_CGRP_IAPP; 1.
CC PRINTS; PR00817; CALCITONINB.
CC SMART; SM00113; CALCITONIN; 1.

```

```
DR PROSITE: PS00258; CALCITONIN; 1.
KW Amidation; Direct protein sequencing; Hormone.
FT MOD_RES 37 37 Phenylalanine amide.
FT DISULFID 2 7 By similarity.
SQ SEQUENCE 37 AA; 3780 MW; F5DDF64D248B6A47 CRC64;

Query Match 30.2%; Score 42; DB 1; Length 37;
Best Local Similarity 34.3%; Pred. No. 2.1;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPTXVGSNTY 37
|||||
Db 3 NTATCVTHRLAGLLSRSGVGVKDFVPTNVGSQAF 37

RESULT 42
Q66VCL1 RAT PRELIMINARY; PRT; 50 AA.
AC Q66VCL1;
DT 25-OCT-2004 (TRENBLrel. 28, Created)
DT 25-OCT-2004 (TRENBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TRENBLrel. 28, Last annotation update)
DE Alpha-calcitonin gene-related peptide (Fragment).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=Wistar;
RA Gerritagoitia I.; Garcia del Cano G.; Canudas J.; Sarasa M.;
RT "Evidence for expression of calcitonin gene-related peptide in
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY702025; AAU07931.1; -; mRNA.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR001693; Calcitonin-like.
DR Pfam; PF00214; Calc CGRP IAPP; I.
DR PRINTS; PR00817; CALCITONIN.
DR SMART; SM00113; CALCITONIN.
DR PROSITE; PS00258; CALCITONIN; 1.
FT NON TER 1
SQ SEQUENCE 50 AA; 5402 MW; 295BEFF036BCF7FA CRC64;

Query Match 30.2%; Score 42; DB 2; Length 50;
Best Local Similarity 34.3%; Pred. No. 3;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPTXVGSNTY 37
|||||
Db 7 NTATCVTHRLAGLLSRSGVGVKDFVPTNVGSQAF 41

RESULT 43
CALCA MOUSE
ID CALCA MOUSE STANDARD; PRT; 128 AA.
AC Q99JA0;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Calcitonin gene-related peptide I precursor (CGRP-I) (Alpha-type
DE CGRP).
GN Name=Calca; Synonyms=Calc;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]

NUCLEOTIDE SEQUENCE.
Saras M., Catalan J., Aramayona J., Sotribas V.;
"Mouse CGRP precursor is highly homologous to that of the rat.";
Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
[2]
NUCLEOTIDE SEQUENCE.
STRAIN=129/SV;
MEDLINE=21604266; PubMed=11761712;
Thomas P.M., Nasonkin I., Zhang H., Gagel R.F., Core G.J.;
"Structure of the mouse calcitonin/calcitonin gene-related peptide
alpha and beta genes.";
DNA Seq. 12:131-135(2001).
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
STRAIN=C57BL/6J; TISSUE=Mammary gland;
MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.A., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Wozny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Faney J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
-!- FUNCTION: CGRP induces vasodilation. It dilates a variety of
vessels including the coronary, cerebral and systemic vasculature.
Its abundance in the CNS also points toward a neurotransmitter or
neuromodulator role. It also elevates platelet cAMP (By
similarity).
-!- SUBCELLULAR LOCATION: Secreted.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=Calcitonin-gene related peptide I;
IsoId=Q99JA0-1; Sequence=Displayed,
Name=Calcitonin;
IsoId=P70160-1; Sequence=External;
-!- SIMILARITY: Belongs to the calcitonin family.
-----
This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
-----
EMBL; AF330212; AAK06841.1; -; mRNA.
EMBL; AF325522; AAK18181.1; -; Genomic_DNA.
EMBL; AF325521; AAK18181.1; JOINED; Genomic_DNA.
EMBL; BC028771; AAH28771.1; -; mRNA.
Ensembl; ENSMUSG0000030669; Mus musculus.
MGI; MGI:2151253; Calca.
GO; GO:0005615; C:extracellular space; TAS.
GO; GO:0005622; C:intracellular; IDA.
GO; GO:0001635; F:calcitonin gene-related polypeptide recepto. . ; IDA.
GO; GO:0005102; F:receptor binding; IDA.
GO; GO:0007631; P:feeding behavior; IDA.
GO; GO:0006954; P:inflammatory response; IDA.
GO; GO:0045986; P:negative regulation of smooth muscle contra. . ; IDA.
GO; GO:0007218; P:neuropeptide signaling pathway; IDA.
InterPro; IPR000443; Amylin.
InterPro; IPR001693; Calcitonin-like.
InterPro; IPR002163; Calcitonin_B.
```

DR Pfam; PF00214; Calc_CGRP_IAPP; 1.
 DR PRINTS; PR00817; CALCITONINB.
 DR PRINTS; PR00818; ISLETAMYLID.
 DR SMART; SM00113; CALCITONIN; 1.
 DR PROSITE; PS00258; CALCITONIN; 1.
 KW Alternative splicing; Amidation; Cleavage on pair of basic residues;
 KW Hormone; Signal.
 FT SIGNAL 1 25 Potential.
 FT PROPEP 26 80 By similarity.
 FT PEPTIDE 83 119 Calcitonin gene-related peptide I.
 FT PROPEP 125 128 By similarity.
 FT MOD_RES 119 119 Phenylalanine amide (G-120 provides amide group).
 FT DISULFID 84 89 By similarity.
 SQ SEQUENCE 128 AA; 14065 MW; 83BB0E36C8B4239E CRC64;
 Query Match 30.2%; Score 42; DB 1; Length 128;
 Best Local Similarity 34.3%; Pred. No. 8.6;
 Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;
 Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNTY 37
 Db 85 NTATCVTHRLAGLLSRSGVVKDFVPTNVGSEAF 119
 RESULT 44
 CALCA RAT
 ID CALCA RAT STANDARD; PRT; 128 AA.
 AC P01256;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 01-APR-1998 (Rel. 07, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Calcitonin gene-related peptide I precursor (CGRP-I) (Alpha-type CGRP).
 GN Name=Calca; Synonyms=Calc;
 OS Rattus norvegicus (Rat);
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=85166259; PubMed=3872459;
 RA Jonas V., Lin C.R., Kawashima E., Semon D., Swanson L.W.,
 RA Mermod J.-J., Evans R.M., Rosenfeld M.G.;
 RT "Alternative RNA processing events in human calcitonin/calcitonin gene-related peptide gene expression."
 RL Proc. Natl. Acad. Sci. U.S.A. 82:1994-1998 (1985).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=8220111; PubMed=6283379;
 RA Amara S.G., Jonas V., Rosenfeld M.G., Ong E.S., Evans R.M.;
 RA "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products."
 RL Nature 298:240-244 (1982).
 RN [3]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=85300490; PubMed=2994212;
 RA Amara S.G., Arriza J.L., Leff S.E., Swanson L.W., Evans R.M.,
 RA Rosenfeld M.G.;
 RT "Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide."
 RL Science 229:1094-1097 (1985).
 CC -!- FUNCTION: CGRP induces vasodilatation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=Calcitonin-gene related peptide I;
 CC IsoId=P01256-1; Sequence=Displayed;
 CC Name=Calcitonin;

CC IsoId=P01257-1; Sequence=External;
 CC -!- SIMILARITY: Belongs to the calcitonin family.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
 CC -----
 CC EMBL; L29188; AAB59682.1; -; Genomic DNA.
 CC EMBL; L00109; AAB59682.1; JOINED; Genomic DNA.
 CC EMBL; L00110; AAB59682.1; JOINED; Genomic DNA.
 CC EMBL; V01231; CAA24541.1; -; mRNA.
 CC EMBL; M11597; AAA40847.1; -; mRNA.
 DR PIR; A01524; TCRT.
 DR PIR; B44173; B44173.
 DR InterPro; IPR000443; Amylin.
 DR InterPro; IPR001693; Calcitonin-like.
 DR InterPro; IPR002163; Calcitonin_B.
 DR Pfam; PF00214; Calc_CGRP_IAPP; 1.
 DR PRINTS; PR00817; CALCITONINB.
 DR PRINTS; PR00818; ISLETAMYLID.
 DR SMART; SM00113; CALCITONIN; 1.
 DR PROSITE; PS00258; CALCITONIN; 1.
 KW Alternative splicing; Amidation; Cleavage on pair of basic residues;
 KW Hormone; Signal.
 FT SIGNAL 1 25
 FT PROPEP 26 80
 FT PEPTIDE 83 119 Calcitonin gene-related peptide I.
 FT PROPEP 125 128
 FT MOD_RES 119 119 Phenylalanine amide (G-120 provides amide group).
 FT DISULFID 84 89 By similarity.
 FT CONFLICT 40 40 Missing (in Ref. 2 and 3).
 FT CONFLICT 51 51 Missing (in Ref. 2 and 3).
 FT CONFLICT 70 70 Q -> EQ (in Ref. 2 and 3).
 FT CONFLICT 99 99 S -> R (in Ref. 3).
 SQ SEQUENCE 128 AA; 13948 MW; 75D14869C17078D3 CRC64;
 Query Match 30.2%; Score 42; DB 1; Length 128;
 Best Local Similarity 34.3%; Pred. No. 8.6;
 Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;
 Qy 3 NTATXATQRLXNFXLXXXXXNXPXLPXTXVGSNTY 37
 Db 85 NTATCVTHRLAGLLSRSGVVKDFVPTNVGSEAF 119
 RESULT 45
 CALCB HORSE
 ID CALCB HORSE STANDARD; PRT; 129 AA.
 AC Q9NOT3;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 10-MAY-2005 (Rel. 47, Last annotation update)
 DE Calcitonin gene-related peptide II precursor (CGRP-II) (Beta-type CGRP).
 GN Name=CALCB;
 OS Equus caballus (Horse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Laurasiatheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9796;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX MEDLINE=22470155; PubMed=12581884; DOI=10.1016/S0303-7207(02)00289-7;
 RA Toribio R.E., Kohn C.W., Leone G.W., Capen C.C., Rosol T.J.;
 RT "Molecular cloning and expression of equine calcitonin, calcitonin gene-related peptide-I, and calcitonin gene-related peptide-II."
 RL Mol. Cell. Endocrinol. 199:119-128 (2003).
 CC -!- FUNCTION: CGRP induces vasodilatation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role (By similarity).
 CC

RA Mihova T., Mlenga V., Murphy T., Naylor J., Nguyen C., Nicol R.,
RA Nielsen C.B., Norbu C., O'Connor T., O'Donnell P., O'Neill D.,
RA Oliver J., Peterson K., Phunkhang P., Pierre N., Purcell S.,
RA Rachupka A., Ramasamy U., Raymond C., Retta R., Rise C., Rogov P.,
RA Roman J., Schauer S., Schupback R., Seaman S., Severy P., Smirnov S.,
RA Smith C., Spencer B., Stange-Thomann N., Stojanovic N., Stubbs M.,
RA Talamas J., Tesfaye S., Theodore J., Topham K., Travers M.,
RA Vassiliev H., Venkataraman V.S., Viel R., Vo A., Wang S., Wilson B.,
RA Wu X., Wyman D., Young G., Zainoun J., Zembek L., Zimmer A., Zody M.,
RA Lander E.;
RT "Fusarium graminearum genome sequence.";
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
CC EMBL; AACW01000367; EAA77358.1; -; Genomic_DNA.
DR HYPOTHETICAL protein.
KW EMBL; AACW01000367; EAA77358.1; -; Genomic_DNA.
SQ SEQUENCE 378 AA; 41574 MW; AIDF6C0C6E0650C CRC64;

Query Match 30.2%; Score 42; DB 2; Length 378;
Best Local Similarity 39.4%; Pred. No. 29;
Matches 13; Conservative 2; Mismatches 14; Indels 4; Gaps 2;

Qy 6 TXAT-QRLXNPLXXXXXGXPXLPXTXVGSNTY 37
Db 152 THATAQLQS---RTRSNFGSPRESTAMSYTY 181

RESULT 48
Q9Y0Z9 DROME PRELIMINARY; PRT; 465 AA.
AC Q9Y0Z9 DROME PRELIMINARY; PRT; 465 AA.
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Tailup (CG10619-PB, isoform B).
GN Name=tailup; ORFNames=CG10619;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
[1]
NUCLEOTIDE SEQUENCE.
RP Rubin G.M., Wan K.H., Harvey D., Lewis S.E., Brokstein P., Tsang G.,
RA Agbavani A., Arcaina T., Baxter E., Blazej R.G., Butenhoff C.,
RA Champe M., Chavez C., Chew M., Doyle C.M., Farfan D.E., Frise E.,
RA Galle R., George R.A., Harris N.L., Hoskins R.A., Evans-Holm M.,
RA Houston K.A., Hummasti S.R., Kim E., Li P., Moshrefi M., Pacleb J.M.,
RA Park S., Sequeira A., Sethi H., Snir E., Swirskas R.R., Weinburg T.,
RA Celniker S.E.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
[2]
NUCLEOTIDE SEQUENCE.
RP MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RX Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Anantides P.G., Scher S., Richards S., Ashburner M., Henderson S.N.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abil J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
RA Butis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablo B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Dou P.L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Fessler C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodok A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,

RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Laoko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Mishina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy D., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleb J.M.,
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Swirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wassarman D.A., Weinstein G.M., Weissbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
[3]
NUCLEOTIDE SEQUENCE.
RP MEDLINE=22426065; PubMed=12537568;
RX Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Lavery T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Swirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstein G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun: release 3 of the Drosophila
melanogaster euchromatic genome sequence.";
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
[4]
NUCLEOTIDE SEQUENCE.
RP MEDLINE=22426070; PubMed=12537573;
RX Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J.W., Swirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
a genomic perspective.";
RL Genome Biol. 3:RESEARCH0084.1-RESEARCH0084.20(2002).
[5]
NUCLEOTIDE SEQUENCE.
RP MEDLINE=22426069; PubMed=12537572;
RX Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
systematic review.";
RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
[6]
NUCLEOTIDE SEQUENCE.
RP Berkeley Drosophila Genome Project;
RX Celniker S., Carlson J., Wan K., Pfeiffer B., Frise E., George R.,
RA Hoskins R., Stapleton M., Pacleb J., Park S., Swirskas R., Smith E.,
RA Yu C., Rubin G.;
RT "Drosophila melanogaster release 4 sequence.";
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
[7]
NUCLEOTIDE SEQUENCE.
RP FlyBase;
RG Submitted (MAR-2005) to the EMBL/GenBank/DBJ databases.
CC -1- SUBCELLULAR LOCATION: Nuclear (by similarity).
CC -1- SIMILARITY: Contains 2 LIM zinc-binding domains.
DR EMBL; AF145674; AAD38649.1; -; mRNA.
DR EMBL; AE003660; AAN11018.1; -; Genomic_DNA.
DR HSP; P50480; 1BWS
DR SW; Q9Y0Z9; 240-304.
DR FlyBase; FBGN0003896; tup.

THIS PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:38:06 ; Search time 37 Seconds
(without alignments)
96.217 Million cell updates/sec

Title: US-09-445-517-14
Perfect score: 139
Sequence: 1 XXNTATYATQRLNLFXXXXXXNGPXLPTXVGSNTY 37

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database :

PIR_80.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	116	83.5	93	1	C3542
2	116	83.5	93	1	TCRTTA
3	109	78.4	91	2	A36118
4	107	77.0	37	2	S05037
5	107	77.0	92	2	S13116
6	102	73.4	89	1	TCCHUA
7	100	71.9	89	2	S22344
8	100	71.9	89	2	A33542
9	99	71.2	92	2	D33542
10	87	62.6	135	2	A56855
11	68	48.9	29	2	A61509
12	48	34.5	125	1	TCCHRP
13	43	30.9	23	2	I46933
14	43	30.9	23	2	I46934
15	43	30.9	72	2	I37232
16	43	30.9	127	2	A25864
17	43	30.9	451	2	T15718
18	42.5	30.6	634	2	A64521
19	42	30.2	37	2	JH0709
20	42	30.2	128	1	TCRTR
21	41.5	29.2	668	2	A71986
22	41	29.5	128	2	B44173
23	41	29.5	134	2	A44173
24	40	28.8	89	2	E75101
25	40	28.8	990	2	T14756
26	39	28.1	384	2	D87599
27	39	28.1	405	2	A64388
28	39	28.1	833	2	A80448
29	39	28.1	1376	1	JQ1534

30	39	28.1	1376	1	VGIHJ2
31	39	28.1	1662	2	T18540
32	38	27.3	925	2	T37475
33	37.5	27.0	379	2	S23443
34	37.5	27.0	474	2	T31064
35	37.5	27.0	9376	2	T14593
36	37	26.6	218	2	G87324
37	37	26.6	299	2	F90867
38	37	26.6	299	2	C85751
39	37	26.6	299	2	C64882
40	37	26.6	315	1	HNW24X
41	37	26.6	389	2	T23167
42	37	26.6	420	2	S53916
43	37	26.6	538	2	E96492
44	37	26.6	1162	2	JH0557
45	37	26.6	1309	2	H96850
46	36.5	26.3	175	2	S65828
47	36.5	26.3	1026	2	A48995
48	36.5	26.3	1073	2	C87374
49	36.5	26.3	3092	2	S46009
50	36	25.9	128	1	TCCHUR
51	36	25.9	218	2	F70524
52	36	25.9	258	2	H81321
53	36	25.9	265	2	I48679
54	36	25.9	319	2	C64852
55	36	25.9	319	2	D85671
56	36	25.9	319	2	H90811
57	36	25.9	406	2	T31786
58	36	25.9	451	2	F95869
59	36	25.9	475	2	S49886
60	36	25.9	535	2	T32139
61	36	25.9	611	2	S76211
62	36	25.9	749	2	A95068
63	36	25.9	797	2	B97936
64	36	25.9	805	2	T21957
65	36	25.9	848	2	I55498
66	36	25.9	1339	2	A55301
67	36	25.9	3643	2	T36410
68	35.5	25.5	509	2	S36572
69	35.5	25.5	549	1	A47468
70	35	25.2	182	2	F96951
71	35	25.2	200	2	C70308
72	35	25.2	241	2	T27917
73	35	25.2	354	2	H82557
74	35	25.2	431	2	E96671
75	35	25.2	461	2	A82220
76	35	25.2	467	2	F91328
77	35	25.2	468	2	A5476
78	35	25.2	469	2	E86075
79	35	25.2	487	2	S40820
80	35	25.2	499	2	B84776
81	35	25.2	556	2	A44441
82	35	25.2	616	2	A46230
83	35	25.2	688	2	D72418
84	35	25.2	713	2	B75489
85	35	25.2	716	1	JC5061
86	35	25.2	735	2	S54147
87	35	25.2	742	2	B98801
88	35	25.2	754	2	C81326
89	35	25.2	756	2	F83704
90	35	25.2	758	2	E84933
91	35	25.2	759	2	G86781
92	35	25.2	761	2	E82167
93	35	25.2	762	2	C69657
94	35	25.2	765	1	S57636
95	35	25.2	765	2	T12575
96	35	25.2	792	2	T50122
97	35	25.2	792	2	S03232
98	35	25.2	822	2	JC4076
99	35	25.2	915	2	S38090
100	35	25.2	1270	2	T26720
101	35	25.2	1337	2	T30291
102	35	25.2	1616	2	S62504

E2 glycoprotein pr
mofA protein precu
lipoprotein recept
hypothetical prote
hypothetical prote
syringomycin synth
probable secreted
probable transcrip
probable transcrip
probable transcrip
hemagglutinin prec
hypothetical prote
SUN4 protein precu
hypothetical prote
exo-alpha-stalidas
protein T3P18.3 [i
probable movement
paracrystalline su
S-layer protein R8
GIFase-activating
calcitonin gene-re
hypothetical prote
probable integral
neutrophil elastas
probable pseudouri
hypothetical prote
hypothetical prote
hypothetical prote
probable ABC trans
probable membrane
hypothetical prote
hypothetical prote
hypothetical prote
5-methyltetrahydro
hypothetical prote
testicular dynamin
1,3-beta-D-glucan-
Li protein - human
cytochrome-c oxida
uncharacterized me
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
probable permease
protein kinase (EC
probable permease
probable permease
hypothetical prote
B-cell antigen CD1
RNA-binding protei
DNA ligase - Therm
hypothetical prote
macrophage-scinula
alpha adducin - ra
hypothetical prote
5-methyltetrahydro
homosysteine methyl
5-methyltetrahydro
5-methyltetrahydro
5-methyltetrahydro
cobalamin-independ
5-methyltetrahydro
5-methyltetrahydro
vesicular transpor
hypothetical prote
dextranase (EC 3.2
hypothetical prote
dextranase - Strep
conserved hypothet

103 35 25.2 2697 2 T25444
104 35 25.2 2971 2 T08026
105 34.5 24.8 361 2 T30402
106 34.5 24.8 395 2 AB2229
107 34.5 24.8 478 2 T04519
108 34.5 24.8 495 2 B35721
109 34.5 24.8 517 2 A30992
110 34.5 24.8 574 2 T16868
111 34.5 24.8 716 2 AC2449
112 34.5 24.8 2090 2 S26058
113 34 24.5 169 2 B86522
114 34 24.5 169 2 G81570
115 34 24.5 249 2 T45217
116 34 24.5 251 2 B89402
117 34 24.5 263 2 G70583
118 34 24.5 264 2 S55367
119 34 24.5 264 2 A31818
120 34 24.5 317 2 D96569
121 34 24.5 332 2 A39185
122 34 24.5 339 2 T41126
123 34 24.5 345 2 H86814
124 34 24.5 365 2 AF1952
125 34 24.5 371 2 E72601
126 34 24.5 371 2 H81303
127 34 24.5 395 2 A46031
128 34 24.5 418 2 JC2352
129 34 24.5 418 2 B72565
130 34 24.5 424 2 S71837
131 34 24.5 429 2 AC1163
132 34 24.5 429 2 A31522
133 34 24.5 430 2 I48142
134 34 24.5 470 2 T22785
135 34 24.5 564 2 T40883
136 34 24.5 625 2 D64107
137 34 24.5 675 2 G46433
138 34 24.5 695 2 D86392
139 34 24.5 716 1 A40332
140 34 24.5 737 2 S18207
141 34 24.5 745 2 E64559
142 34 24.5 749 2 T38327
143 34 24.5 756 1 B64137
144 34 24.5 758 2 G81880
145 34 24.5 758 2 E81140
146 34 24.5 759 2 F70539
147 34 24.5 760 2 C87029
148 34 24.5 777 2 A87309
149 34 24.5 785 2 G96825
150 34 24.5 785 2 T52059

ALIGNMENTS

RESULT 1
C33542
islet amyloid polypeptide precursor - mouse
N;Alternate names: insulinoma amyloid protein
C;Species: Mus musculus (house mouse)
C;Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 09-Jul-2004
C;Accession: C33542; S05039
R;Nishi, M.; Chan, S.J.; Nagamatsu, S.; Bell, G.I.; Steiner, D.F.
Proc. Natl. Acad. Sci. U.S.A. 86, 5738-5742, 1989
A;Title: Conservation of the sequence of islet amyloid polypeptide in five mammals is conserved in five mammals is conserved
A;Reference number: A33542; MUID:89345542; PMID:2668946
A;Accession: C33542
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-93 <NIS>
A;Cross-references: UNIPROT:P12968; UNIPARC:UPI0000001443; GB:M25389; NID:g1940666; PIDN:R;Betsholtz, C.; Christmannson, L.; Engstrom, U.; Rorsman, F.; Svensson, V.; Johnson, K; FEBS Lett. 251, 261-264, 1989
A;Title: Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) ex

A;Reference number: S05037; MUID:89325677; PMID:2666169
A;Accession: S05039
A;Status: not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 38-74 <BET>
A;Cross-references: UNIPARC:UPI0000003519C
C;Superfamily: calcitonin
C;Keywords: amyloid

Query Match 83.5%; Score 116; DB 1; Length 93;
Best Local Similarity 68.6%; Pred. No. 7, 4e-16;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLNFXLXXXXXNGPXLPTXVCSNTY 37
||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 40 NTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY 74

RESULT 2
TCRTTA
islet amyloid polypeptide precursor - rat
N;Alternate names: amylin precursor; diabetes-associated peptide; insulinoma amyloid protein
C;Species: Rattus norvegicus (Norway rat)
C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
C;Accession: S13566; A30312; B33542; A35038; S05038; A35481; B35481
R;van Mansfeld, A.D.M.; Mosselman, S.; Hoepfner, J.W.M.; Zandberg, J.; van Teeffelen, H; Biochim. Biophys. Acta 1087, 235-240, 1990
A;Title: Islet amyloid polypeptide: structure and upstream sequences of the IAPP gene in man
A;Reference number: S13566; MUID:91027936; PMID:2223885
A;Accession: S13566
A;Molecule type: DNA
A;Residues: 1-93 <VAN>
A;Cross-references: UNIPROT:P12969; UNIPARC:UPI000012DOCA; EMBL:X52820; NID:g56394; PIDN:R;Leftert, J.D.; Newgard, C.B.; Okamoto, H.; Milburn, J.L.; Luskey, K.L.
Proc. Natl. Acad. Sci. U.S.A. 86, 3127-3130, 1989
A;Title: Rat amylin: cloning and tissue-specific expression in pancreatic islets.
A;Reference number: A30312; MUID:89240689; PMID:2654937
A;Accession: A30312
A;Molecule type: mRNA
A;Residues: 1-93 <LEF>
A;Cross-references: UNIPARC:UPI000012DOCA; GB:J04544; NID:g202887; PIDN:AAA40730.1; PID:R;Nishi, M.; Chan, S.J.; Nagamatsu, S.; Bell, G.I.; Steiner, D.F.
Proc. Natl. Acad. Sci. U.S.A. 86, 5738-5742, 1989
A;Title: Conservation of the sequence of islet amyloid polypeptide in five mammals is conserved in five mammals is conserved
A;Reference number: A33542; MUID:89345542; PMID:2668946
A;Accession: B33542
A;Molecule type: mRNA
A;Residues: 1-93 <NIS>
A;Cross-references: UNIPARC:UPI000012DOCA; GB:M25390; NID:g204676; PIDN:AAA41359.1; PID:R;Asai, J.; Nakazato, M.; Kangawa, K.; Matsukura, S.; Matsuo, H.
Biochem. Biophys. Res. Commun. 164, 400-405, 1989
A;Title: Isolation and sequence determination of rat islet amyloid polypeptide.
A;Reference number: A33426; MUID:90026410; PMID:2679555
A;Accession: A33426
A;Molecule type: protein
A;Residues: 38-74 <ASA>
A;Cross-references: UNIPARC:UPI0000003519C
R;Betsholtz, C.; Christmannson, L.; Engstrom, U.; Rorsman, F.; Svensson, V.; Johnson, K; FEBS Lett. 251, 261-264, 1989
A;Title: Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) expressed in five mammals is conserved in five mammals is conserved
A;Reference number: S05037; MUID:89325677; PMID:2666169
A;Accession: S05038
A;Status: not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 38-74 <BET>
A;Cross-references: UNIPARC:UPI0000003519C
R;Asai, J.; Nakazato, M.; Miyazato, M.; Miyazato, M.; Matsukura, K.; Matsuo, H.; Matsukura, S.
Biochem. Biophys. Res. Commun. 169, 788-795, 1990
A;Title: Regional distribution and molecular forms of rat islet amyloid polypeptide.
A;Reference number: A35481; MUID:90290528; PMID:2357234
A;Accession: A35481
A;Molecule type: protein
A;Residues: 38-74 <AS2>

Db 36 NTATCATQRLANFLVRSNNLGAILLPTNVGSNTY 70

RESULT 8

A33542
islet amyloid polypeptide precursor - cat
C:Species: Felis silvestris catus (domestic cat)
C>Date: 21-Feb-1990 #sequence_revision 21-Feb-1990 #text_change 09-Jul-2004
C:Accession: A33542; A60499; B26619
R:Nishi, M.; Chan, S.J.; Nagamatsu, S.; Bell, G.I.; Steinert, D.F.
Proc. Natl. Acad. Sci. U.S.A. 86, 5738-5742, 1989
A:Title: Conservation of the sequence of islet amyloid polypeptide in five mammals is conserved
A:Reference number: A33542; MUID:89345542; PMID:2668946
A:Accession: A33542
A:Molecule type: mRNA
A:Residues: 1-89 <NIS>
A:Cross-references: UNIPROT:P12967; UNIPARC:UPI000012DOC3; GB:M25388; NID:g163861; PIDN:
R:Bertholtz, C.; Christmannson, L.; Engstroem, U.; Rorsman, F.; Jordan, K.; O'Brien, T.D.
Diabetes 39, 118-122, 1990
A:Title: Structure of cat islet amyloid polypeptide and identification of amino acid residues
A:Reference number: A60499; MUID:91006862; PMID:2210054
A:Accession: A60499
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 34-70 <BET>
A:Cross-references: UNIPARC:UPI000003519A
R:Westermarck, P.; Westermarck, C.; Willander, E.; Hayden, D.W.; O'Brien, T.D.; Johnson, K.H.
Proc. Natl. Acad. Sci. U.S.A. 84, 3881-3885, 1987
A:Title: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat
A:Reference number: A26619; MUID:87231921; PMID:3035556
A:Accession: B26619
A:Status: preliminary
A:Molecule type: protein
A:Residues: 34, 'X', 36-39, 'X', 41-60 <WES>
A:Cross-references: UNIPARC:UPI0000029C0
C:Superfamily: calcitonin
C:Keywords: amidated carboxyl end; amyloid; pancreas
F:70/Modified site: amidated carboxyl end (tyr) (amide in mature form from following gly

Query Match 71.9%; Score 100; DB 2; Length 89;

Best Local Similarity 62.9%; Pred. No. 1.2e-12;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNKGXPLPTXVGSNTY 37

Db 36 NTATCATQRLANFLVRSNNLGAILLPTNVGSNTY 70

RESULT 9

D33542
islet amyloid polypeptide precursor - guinea pig
C:Species: Cavia porcellus (guinea pig)
C>Date: 21-Feb-1990 #sequence_revision 04-Sep-1992 #text_change 09-Jul-2004
C:Accession: D33542
R:Nishi, M.; Chan, S.J.; Nagamatsu, S.; Bell, G.I.; Steinert, D.F.
Proc. Natl. Acad. Sci. U.S.A. 86, 5738-5742, 1989
A:Title: Conservation of the sequence of islet amyloid polypeptide in five mammals is conserved
A:Reference number: A33542; MUID:89345542; PMID:2668946
A:Accession: D33542
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-92 <NIS>
A:Cross-references: UNIPROT:P12966; UNIPARC:UPI000012DOC2; GB:M25387; NID:g191271; PIDN:
A:Note: the authors translated the codon CTA for residue 87 as Cys
C:Superfamily: calcitonin

Query Match 71.2%; Score 99; DB 2; Length 92;

Best Local Similarity 62.9%; Pred. No. 1.9e-12;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNKGXPLPTXVGSNTY 37

Db 39 NTATCATQRLTNFLVRSNNLGAALLPTDVGNTY 73

RESULT 10

A56855
islet amyloid polypeptide precursor - chicken
N:Alternate names: IAPP
C:Species: Gallus gallus (chicken)
C>Date: 11-Aug-1995 #sequence_revision 11-Aug-1995 #text_change 09-Jul-2004
C:Accession: A56855
R:Fan, L.; Westermarck, G.; Chan, S.J.; Steimer, D.F.
Mol. Endocrinol. 8, 713-721, 1994
A:Title: Altered gene structure and tissue expression of islet amyloid polypeptide in the chicken
A:Reference number: A56855; MUID:95021303; PMID:7935487
A:Accession: A56855
A:Status: preliminary
A:Molecule type: mRNA; DNA
A:Residues: 1-135 <FAN>
A:Cross-references: UNIPROT:Q90743; UNIPARC:UPI00000FDOB7; GB:L16955; NID:g289789; PIDN:
C:Superfamily: calcitonin
C:Keywords: hormone

Query Match 62.6%; Score 87; DB 2; Length 135;

Best Local Similarity 54.3%; Pred. No. 7.8e-10;
Matches 19; Conservative 1; Mismatches 15; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNKGXPLPTXVGSNTY 37

Db 82 NTATCVTQRLADFLVRSNNIGATVPTNVGSNTY 116

RESULT 11

A61509
islet amyloid polypeptide - cougar (fragment)
C:Species: Felis concolor (cougar)
C>Date: 19-Mar-1997 #sequence_revision 26-Feb-1998 #text_change 11-May-2000
C:Accession: A61509
R:Johnson, K.H.; Westermarck, C.; O'Brien, T.D.; Westermarck, P.
Comp. Biochem. Physiol. B 98, 115-119, 1991
A:Title: Amyloid in the pancreatic islets of the cougar (Felis concolor) is derived from
A:Reference number: A61509; MUID:91284578; PMID:2060275
A:Accession: A61509
A:Molecule type: protein
A:Residues: 1-29 <JOH>
A:Cross-references: UNIPARC:UPI0000017660F
C:Superfamily: calcitonin

Query Match 48.9%; Score 68; DB 2; Length 29;

Best Local Similarity 68.0%; Pred. No. 9.2e-07;
Matches 17; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNKGXPL 27

Db 3 NTATXATQRLANFLVRSNNLGAILL 27

RESULT 12

TCCHRP
calcitonin gene-related peptide precursor - chicken
C:Species: Gallus gallus (chicken)
C>Date: 30-Jun-1991 #sequence_revision 30-Jun-1991 #text_change 09-Jul-2004
C:Accession: S00154; I50183; A24855
R:Minvielle, S.; Cressent, M.; Delehay, M.C.; Segond, N.; Milhaud, G.; Jullienne, A.; M.
FEBS Lett. 223, 63-68, 1987
A:Title: Sequence and expression of the chicken calcitonin gene.
A:Reference number: S00153; MUID:88030046; PMID:3666142
A:Accession: S00154
A:Molecule type: DNA
A:Residues: 1-125 <MIN>
A:Cross-references: UNIPROT:P10286; UNIPARC:UPI0000126E2F; EMBL:X06311
A:Note: the sequences of codons 31-33 and 34-38 are interchanged in this reference; the
R:Laamoies, F.; Jullienne, A.; Day, F.; Minvielle, S.; Milhaud, G.; Moukhtar, M.S.
EMBO J. 4, 2603-2607, 1985

Query Match 71.2%; Score 99; DB 2; Length 92;

Best Local Similarity 62.9%; Pred. No. 1.9e-12;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNKGXPLPTXVGSNTY 37

Db 39 NTATCATQRLTNFLVRSNNLGAALLPTDVGNTY 73

A;Title: Elucidation of the nucleotide sequence of chicken calcitonin mRNA: direct evidence
A;Reference number: A25725; MUID:86030240; PMID:4054101
A;Contents: annotation
R;Minvielle, S.; Cressent, M.; Lasmoles, F.; Jullienne, A.; Milhaud, G.; Moukhtar, M.S.
FEBS Lett. 203, 7-10, 1986
A;Title: Isolation and partial characterization of the calcitonin gene in a lower vertebrate
A;Reference number: 150183; MUID:86248126; PMID:3487468
A;Accession: 150183
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 74-125 <M12>
A;Cross-references: UNIPARC:UPI00001712BC; GB:D00007; NID:g222801; PIDN:BAA00006.1; PID:
C;Comment: The calcitonin gene codes for two mRNA species by tissue-specific alternative
ripheral nervous system codes for calcitonin gene-related peptide.
C;Genetics:
A;Introns: 29/2; 73/2
C;Superfamily: calcitonin
C;Keywords: alternative splicing; amidated carboxyl end; neuropeptide
F;80-116/Product: calcitonin gene-related peptide #status predicted <MAT>
F;81-86/Disulfide bonds: #status predicted
F;116/Modified site: amidated carboxyl end (Phe) (amide in mature form from following gl
Query Match 34.5%; Score 48; DB 1; Length 125;
Best Local Similarity 37.1%; Pred. No. 0.05;
Matches 13; Conservative 2; Mismatches 20; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
||||| :||| :
Db 82 NTATCVTHRLADFLSRGSGVGNFVPTNVGSKAF 116
||||| :||| :
RESULT 13
146933
islet amyloid polypeptide - European hare (fragment)
C;Species: Lepus capensis europaeus (European hare)
C;Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 09-Jul-2004
C;Accession: 146933
R;Christianson, L.; Betsholtz, C.; Leckstrom, A.; Engstrom, U.; Cortie, C.; Johnson, K.H.
Diabetologia 36, 183-188, 1993
A;Title: Islet amyloid polypeptide in the rabbit and European hare: studies on its relat
A;Reference number: 146933; MUID:93215963; PMID:8462765
A;Accession: 146933
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-23 <CHR>
A;Cross-references: UNIPROT:Q07333; UNIPARC:UPI000012D0C5; GB:S57802; NID:g299056; PIDN:
C;Superfamily: calcitonin
Query Match 30.9%; Score 43; DB 2; Length 23;
Best Local Similarity 56.2%; Pred. No. 0.076; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Indels 7; Indels 0; Gaps 0;
Qy 9 TORLXNFXLXXXXXNGK 24
||||| :||| :
Db 1 TORLANFLIHSSNFG 16
||||| :||| :
RESULT 14
146934
islet amyloid polypeptide - rabbit (fragment)
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 14-Feb-1997 #sequence_revision 14-Feb-1997 #text_change 09-Jul-2004
C;Accession: 146934
R;Christianson, L.; Betsholtz, C.; Leckstrom, A.; Engstrom, U.; Cortie, C.; Johnson, K.H.
Diabetologia 36, 183-188, 1993
A;Title: Islet amyloid polypeptide in the rabbit and European hare: studies on its relat
A;Reference number: 146933; MUID:93215963; PMID:8462765
A;Accession: 146934
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-23 <CHR>
A;Cross-references: UNIPROT:Q07334; UNIPARC:UPI000016C61B; GB:S57804; NID:g299058; PIDN:
C;Superfamily: calcitonin

Query Match 30.9%; Score 43; DB 2; Length 23;
Best Local Similarity 56.2%; Pred. No. 0.076; Mismatches 0; Gaps 0;
Matches 9; Conservative 0; Indels 7; Indels 0; Gaps 0;
Qy 9 TORLXNFXLXXXXXNGK 24
||||| :||| :
Db 1 TORLANFLIHSSNFG 16
||||| :||| :

RESULT 15

I37232
calcitonin gene-related peptide 2 - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 06-Sep-1996 #sequence_revision 06-Sep-1996 #text_change 09-Jul-2004
C;Accession: 137232
R;Steenbergh, P.H.; Hoppener, J.W.; Zandberg, J.; Lips, C.J.; Jansz, H.S.
FEBS Lett. 183, 403-407, 1985
A;Title: A second human calcitonin/CGRP gene.
A;Reference number: 137232; MUID:85180007; PMID:2985435
A;Accession: 137232
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-72 <RES>
A;Cross-references: UNIPROT:P10092; UNIPARC:UPI000016A6C1; EMBL:X02404; NID:g29933; PIDN:
C;Superfamily: calcitonin

Query Match 30.9%; Score 43; DB 2; Length 72;
Best Local Similarity 34.3%; Pred. No. 0.27;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
||||| :||| :
Db 29 NTATCVTHRLAGLLSRGSGVGNFVPTNVGSKAF 63
||||| :||| :

RESULT 16

A25864
calcitonin gene-related peptide beta precursor - human
N;Alternate names: calcitonin gene-related peptide II
C;Species: Homo sapiens (man)
C;Date: 30-Jun-1988 #sequence_revision 30-Jun-1988 #text_change 09-Jul-2004
C;Accession: A25864; JH0620; B26142; A34565
R;Steenbergh, P.H.; Hoppener, J.W.M.; Zandberg, J.; Visser, A.; Lips, C.J.M.; Jansz, H.
FEBS Lett. 209, 97-103, 1986
A;Title: Structure and expression of the human calcitonin/CGRP genes.
A;Reference number: A25864; MUID:87105923; PMID:3492393
A;Accession: A25864
A;Molecule type: DNA
A;Residues: 1-127 <STE>
A;Cross-references: UNIPROT:P10092; UNIPARC:UPI0000126E36
R;Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Matsuo, H.; Eto, T.
Biochem. Biophys. Res. Commun. 185, 134-141, 1992
A;Title: Isolation and characterization of peptides which act on rat platelets, from a p
A;Reference number: JH0618; MUID:92287083; PMID:1318039
A;Accession: JH0620
A;Molecule type: protein
A;Residues: 82,'X',84-87,'X',89-104 <KIT>
A;Cross-references: UNIPARC:UPI0000176610
A;Experimental source: pheochromocytoma
R;Petermann, J.B.; Born, W.; Chang, J.Y.; Fischer, J.A.
J. Biol. Chem. 262, 542-545, 1987
A;Title: Identification in the human central nervous system, pituitary, and thyroid of a
A;Reference number: A92637; MUID:87109142; PMID:3492492
A;Accession: B26142
A;Molecule type: protein
A;Residues: 82,'X',84-87,'X',89-91,'X',93-98,'X',100-105,'X',107-109 <PET>
A;Cross-references: UNIPARC:UPI0000176611
R;Wimalawansa, S.J.; Morris, H.R.; Etienne, A.; Blench, I.; Panico, M.; MacIntyre, I.
Biochem. Biophys. Res. Commun. 167, 993-1000, 1990
A;Title: Isolation, purification and characterization of beta-hCGRP from human spinal co
A;Reference number: A34565; MUID:90211348; PMID:2322288
A;Accession: A34565

A;Molecule type: protein
A;Residues: 82-86;104-117 <WIM>
A;Cross-references: UNIPARC:UPI0000176612; UNIPARC:UPI0000176613
C;Comment: Calcitonin gene-related peptide II peptide is a potent vasorelaxant.
C;Genetics:
A;Gene: GDB:CALCB; CALC2
A;Cross-references: GDB:1120572; OMIM:114160
A;Map position: lhp15.2-llp15.1
C;Superfamily: calcitonin
C;Keywords: amidated carboxyl end; neuropeptide
F;82-118/Product: calcitonin gene-related peptide beta #status experimental <MAT>
F;83-88/Disulfide bonds: #status experimental
F;118/Modified site: amidated carboxyl end (Phe) (amide in mature form from following 91)

Query Match 30.9%; Score 43; DB 2; Length 127;
Best Local Similarity 34.3%; Pred. No. 0.52;
Matches 12; Conservative 1; Mismatches 22; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNLFXXXXXKGPXLPXTXVGSNTY 37
||||| ||| | ||| |
DB 84 NTATCTHRLAGLLRSRGGVMKSNFVPTNVGSKAF 118

RESULT 17
T15718
hypothetical protein C30G12.1 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999
C;Accession: T15718
R;Latraille, P.
submitted to the EMBL Data Library, July 1995
A;Description: The sequence of C. elegans cosmid C30G12.
A;Reference number: Z18393
A;Accession: T15718
A;Status: preliminary; translated from GB/EMBL/DBD
A;Molecule type: DNA
A;Residues: 1-451 <IAT>
A;Cross-references: UNIPARC:UPI0000179C77; EMBL:U21319; NID:g687832; PID:g687833; PIDN:A
A;Experimental source: strain Bristol N2
C;Genetics:
A;Gene: CBSP:C30G12.1
A;Introns: 37/3; 71/2; 107/3; 153/2; 205/1; 289/1; 376/3

Query Match 30.9%; Score 43; DB 2; Length 451;
Best Local Similarity 35.5%; Pred. No. 2.2;
Matches 11; Conservative 1; Mismatches 19; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNLFXXXXXKGPXLPXTXVG 33
||||| : ||| |
DB 371 NVATTTPLPLRFLPTTAAFPPLPSTRVG 401

RESULT 18
A64521
outer membrane protein - Helicobacter pylori (strain 26695)
C;Species: Helicobacter pylori
C;Date: 09-Aug-1997 #sequence_revision 09-Aug-1997 #text_change 09-Jul-2004
C;Accession: A64521
R;Tombs, J.F.; White, O.; Karlavage, A.R.; Clayton, R.A.; Sutton, G.G.; Fleischmann, R.D.; Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khalak, H.G.; Glodek, A.; McKenna, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Wathey, L.; Nature 388, 539-547, 1997
A;Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.; Fraser, C.;
A;Title: The complete genome sequence of the gastric pathogen Helicobacter pylori.
A;Reference number: A64520; MUID:97394467; PMID:9252185
A;Accession: A64521
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-634 <TOM>
A;Cross-references: UNIPROT:Q9ZN51; UNIPARC:UPI0000165585; GB:AE000511; TIGR:HP0009

Query Match 30.6%; Score 42.5; DB 2; Length 634;
Best Local Similarity 37.5%; Pred. No. 4;


```

A:Gene: ML2522
C:Superfamily: Mycobacterium tuberculosis hypothetical protein Rv0309

Query Match          26.6%; Score 37; DB 2; Length 218;
Best Local Similarity 57.1%; Pred. No. 15;
Matches 8; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 22 NXGFXLPXTXVGSN 35
Db 109 NPGSQLFYTVQGFN 122
      |||||
      |||||

RESULT 37
F90867
probable transcription regulator LYSR-type [imported] - Escherichia coli (strain
C:Species: Escherichia coli
C:Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 09-Jul-2004
C:Accession: F90867
R:Hayaashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.;
gasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.
DNA Res. 8, 11-22, 2001
A:Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7
A:Reference number: A99629; MUID:21156231; PMID:11258796
A:Accession: F90867
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-299 <HAY>
A:Cross-references: UNIPROT:Q8X4T4; UNIPARC:UPI00000D0D7E; GB:BA000007; PIDN:BA
A:Experimental source: strain O157:H7, substrain RIMD 050952
C:Genetics:
C:Gene: Ec61910
C:Superfamily: hypothetical protein b1328

Query Match          26.6%; Score 37; DB 2; Length 299;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 24 GPXLPTXTVGSNTY 37
Db 161 GPDIPMAIVGSPDY 174
      |||
      |||

RESULT 38
C85751
probable transcription regulator LYSR-type ycjZ [imported] - Escherichia coli (
C:Species: Escherichia coli
C:Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 09-Jul-2004
C:Accession: C85751
R:R;Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.
iller, L.; Grotbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.;
Nature 409, 529-533, 2001
A:Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.
A:Reference number: A85480; MUID:21074935; PMID:11206551
A:Accession: C85751
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-299 <STO>
A:Cross-references: UNIPROT:Q8X4T4; UNIPARC:UPI00000D0D7E; GB:AE005174; NID:g12
A:Experimental source: strain O157:H7, substrain EDL933
C:Genetics:
C:Gene: ycjZ
C:Superfamily: hypothetical protein b1328

Query Match          26.6%; Score 37; DB 2; Length 299;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 24 GPXLPTXTVGSNTY 37
Db 161 GPDIPMAIVGSPDY 174
      |||
      |||

RESULT 39

```

C64882

Probable transcription regulator ycjZ - Escherichia coli (strain K-12)
C;Species: Escherichia coli
C;Date: 12-Sep-1997 #sequence_revision 17-Sep-1997 #text_change 09-Jul-2004
C;Accession: C64882
R;Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.; Riley, M.; Cohen, A.; Rose, D.J.; Mau, B.; Shaoy, Y.
Science 277, 1453-1462, 1997
A;Title: The complete genome sequence of Escherichia coli K-12.
A;Reference number: A64720; MUID:97426617; PMID:9278503
A;Accession: C64882
A;Status: preliminary; nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-299 <BLAT>
A;Cross-references: UNIPROT:P77333; UNIPARC:UPI000013A5EA; GB:AE000231; GB:U00096; NID:9278503
A;Experimental source: strain K-12, substrain MGI655
C;Genetics:
A;Gene: ycjZ
C;Superfamily: hypothetical protein b1328
C;Keywords: DNA binding; transcription regulation
F;20-50/Region: regulatory protein lyse motif

Query Match 26.6%; Score 37; DB 2; Length 299;
Best Local Similarity 50.0%; Pred. No. 22;
Matches 7; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 24 GPXLPXTXVGSNTY 37
Db 161 GPDIPMAIVGSPDY 174
|||:|:|:|:|

RESULT 40

HN24X
hemagglutinin precursor - vaccinia virus (strain Copenhagen)
N;Alternate names: A56R protein
C;Species: vaccinia virus
A;Note: host Homo sapiens (man)
C;Date: 31-Mar-1991 #sequence_revision 31-Mar-1991 #text_change 09-Jul-2004
C;Accession: D42523
R;Goebel, S.J.; Johnson, G.P.; Perkus, M.E.; Davis, S.W.; Winslow, J.P.; Paoletti, E.
Virology 179, 517-563, 1990
A;Title: Appendix to "The complete DNA sequence of vaccinia virus".
A;Reference number: A42501
A;Accession: D42523
A;Molecule type: DNA
A;Residues: 1-315 <GOS>
A;Cross-references: UNIPROT:P20978; UNIPARC:UPI000012C587; GB:M35027; NID:g335317; PIDN:Virology 179, 517-563, 1990
A;Experimental source: strain Copenhagen
R;Goebel, S.J.; Johnson, G.P.; Perkus, M.E.; Davis, S.W.; Winslow, J.P.; Paoletti, E.
Virology 179, 247-266, 1990
A;Title: The complete DNA sequence of vaccinia virus.
A;Reference number: A42531; MUID:91021027; PMID:2219722
A;Contents: annotation; possible protein-coding frames
A;Note: neither amino acid nor nucleotide sequence is given
C;Superfamily: vaccinia virus hemagglutinin; immunoglobulin homology
C;Keywords: glycoprotein; hemagglutinin; late protein; transmembrane protein
F;1-16/Domain: signal sequence #status predicted <SIG>
F;17-315/Product: hemagglutinin #status predicted <HEG>
F;27-105/Domain: immunoglobulin homology <IMM>
F;280-302/Domain: transmembrane #status predicted <TM>
F;303-315/Domain: intracellular #status predicted <INT>
F;37,69,112,161,254/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 26.6%; Score 37; DB 1; Length 315;
Best Local Similarity 46.7%; Pred. No. 23;
Matches 7; Conservative 2; Mismatches 6; Indels 0; Gaps 0;

Qy 22 NXGPXLPXTXVGSNT 36
Db 252 NDNDTVPSTTVGSST 266
|:|:|:|:|

RESULT 41

T23167

hypothetical protein K01C8.2 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C;Accession: T23167
R;Sims, M.
submitted to the EMBL Data Library, April 1995
A;Reference number: Z19702
A;Accession: T23167
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-389 <WIL>
A;Cross-references: UNIPROT:Q21081; UNIPARC:UPI0000080155; EMBL:Z49068; PIDN:CAA88855.1;
A;Experimental source: clone K01C8
C;Genetics:
A;Gene: CESP:K01C8.2
A;Map position: 2
A;Introns: 54/2; 146/3; 208/3; 283/1; 379/3

Query Match 26.6%; Score 37; DB 2; Length 389;
Best Local Similarity 60.0%; Pred. No. 30;
Matches 9; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 22 NXGPXLPXTXVGSNT 36
Db 35 NGGTNLFTSVGSNT 49
|:|:|:|:|

RESULT 42

S53916
SUN4 protein precursor - Yeast (Saccharomyces cerevisiae)
N;Alternate names: protein N2411; protein YNL066w; protein YNL1612
C;Species: Saccharomyces cerevisiae
C;Date: 08-Jul-1995 #sequence_revision 01-Sep-1995 #text_change 09-Jul-2004
C;Accession: S53916; S58712; S62994; S62998; S63945
R;Poehlmann, R.; Philippsen, P.
submitted to the EMBL Data Library, April 1995
A;Reference number: S53896
A;Accession: S53916
A;Molecule type: DNA
A;Residues: 1-420 <POE>
A;Cross-references: UNIPROT:P53616; UNIPARC:UPI000013621B; EMBL:X86470; NID:g791101; PIDN:R;Bergez, P.; Doignon, F.; Crouzet, M.
Yeast 11, 967-974, 1995
A;Title: The sequence of a 44 420 bp fragment located on the left arm of chromosome XIV
A;Reference number: S58711; MUID:96021608; PMID:8533472
A;Accession: S58712
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: DNA
A;Residues: 1-420 <BER>
A;Cross-references: UNIPARC:UPI000013621B; EMBL:U12141; NID:gl314216; PIDN:AAA99645.1; P;Bergez, P.; Doignon, F.; Crouzet, M.
submitted to the Protein Sequence Database, April 1996
A;Reference number: S62975
A;Accession: S62994
A;Molecule type: DNA
A;Residues: 1-420 <BEF>
A;Cross-references: UNIPARC:UPI000013621B; EMBL:Z71342; NID:gl301944; PID:gl301945; MIPS
A;Note: the nucleotide sequence was submitted to the EMBL Data Library, July 1994
R;Poehlmann, R.; Philippsen, P.
submitted to the Protein Sequence Database, April 1996
A;Reference number: S62997
A;Accession: S62998
A;Molecule type: DNA
A;Residues: 1-420 <POW>
A;Cross-references: UNIPARC:UPI000013621B; EMBL:Z71342; NID:gl301944; PID:gl301945; MIPS
R;Poehlmann, R.; Philippsen, P.
submitted to the Protein Sequence Database, April 1996
A;Reference number: S62997
A;Accession: S62998
A;Molecule type: DNA
A;Residues: 1-420 <POW>
A;Cross-references: UNIPARC:UPI000013621B; EMBL:Z71342; NID:gl301944; PID:gl301945; MIPS
R;Poehlmann, R.; Philippsen, P.
Yeast 12, 391-402, 1996
A;Title: Sequencing a cosmid clone of Saccharomyces cerevisiae chromosome XIV reveals 12
A;Reference number: S63925; MUID:96267764; PMID:8701611
A;Accession: S63945

Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNT 36
Db 140 NPAGHLQRLTS-----TGRGTMTLPTNPGSST 168

RESULT 47
A48995
paracrystalline surface layer protein RsaA - Caulobacter crescentus
C:Species: Caulobacter crescentus
C:Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C:Accession: A48995
R:Gilchrist, A.; Fisher, J.A.; Smit, J.
Can. J. Microbiol. 38, 193-202, 1992
A:Title: Nucleotide sequence analysis of the gene encoding the Caulobacter crescentus pa
A:Reference number: A48995; MUID:93007489; PMID:1393820
A:Accession: A48995
A:Status: preliminary
A:Molecule type: nucleic acid
A:Residues: 1-1026 <GIL>
A:Cross-references: UNIPROT:P35828; UNIPARC:UPI000005415D; GB:M22663; GB:M6
A:Experimental source: CB15A, ATCC 19089
A:Note: sequence inconsistent with the nucleotide translation
A:Note: sequence extracted from NCBI backbone (NCBIN:116173, NCBIP:116174)

Query Match 26.3%; Score 36.5; DB 2; Length 1026;
Best Local Similarity 31.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 2; Mismatches 19; Indels 5; Gaps 1;

Qy 4 TATXATQRLXNFXLXXXXXN-----XGPXLPTXVGSNT 36
Db 361 TATTAQAQANNVAVDGGANVTVASTGVTSGTTTVGANS 398

RESULT 48
C87374
S-layer protein RsaA [imported] - Caulobacter crescentus
C:Species: Caulobacter crescentus
C:Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 20-Apr-2001
C:Accession: C87374
R:Nierman, W.C.; Feldblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg, J.
B.; Laub, M.T.; DeBoy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwinn, M.L.; Haft, D.H.; Kolon
n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C.M.
Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001
A:Title: Complete Genome Sequence of Caulobacter crescentus.
A:Reference number: A87249; MUID:21173698; PMID:11259647
A:Accession: C87374
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-1073 <STO>
A:Cross-references: UNIPARC:UPI00000165C01; GB:A5005673; NID:gl3422297; PIDN:AAK22991.1;
C:Genetics:
A:Gene: CC1007

Query Match 26.3%; Score 36.5; DB 2; Length 1073;
Best Local Similarity 31.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 19; Indels 5; Gaps 1;

Qy 4 TATXATQRLXNFXLXXXXXN-----XGPXLPTXVGSNT 36
Db 408 TATTAQAQANNVAVDGGANVTVASTGVTSGTTTVGANS 445

RESULT 49
S46009
GTPase-activating protein IRA1 - yeast (Saccharomyces cerevisiae)
N:Alternate names: protein YBR1016; protein YBR140C
C:Species: Saccharomyces cerevisiae
C:Date: 26-Aug-1994 #sequence_revision 09-Sep-1994 #text_change 09-Jul-2004
C:Accession: S46009; S46582; S46619; A30135
R:Becam, A.M.; Herbert, C.J.; Nasr, F.; Slonimski, P.P.; Zagulski, M.
submitted to the Protein Sequence Database, August 1994
A:Reference number: S45995

A:Accession: S46009
A:Molecule type: DNA
A:Residues: 1-3092 <BEC>
A:Cross-references: UNIPROT:P18963; UNIPARC:UPI000012D874; EMBL:Z36009; NID:G536437; PID
A:Experimental source: strain S288C
R:Becam, A.M.; Cullin, C.; Grzybowska, E.; Lacroute, F.; Nasr, F.; Ozier-Kalogeropoulos,
Yeast 10(Suppl.A), S1-S11, 1994
A:Title: The sequence of 29.7kb from the right arm of chromosome II reveals 13 complete
A:Reference number: S46569; MUID:94378717; PMID:8091856
A:Accession: S46582
A:Molecule type: DNA
A:Residues: 2768-3092 <BE2>
A:Cross-references: UNIPARC:UPI0000168A27; EMBL:X75891; NID:G496856; PIDN:CAA53498.1; PI
A:Experimental source: strain S288C
R:Zagulski, M.; Becam, A.M.; Grzybowska, E.; Lacroute, F.; Migdalski, A.; Slonimski, P.P
Yeast 10, 1227-1234, 1994
A:Title: The sequence of 12.5 kb from the right arm of chromosome II predicts a new N-te
A:Reference number: S46619; MUID:95274325; PMID:7754712
A:Accession: S46619
A:Status: nucleic acid sequence not shown; not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-312 <ZAG>
A:Cross-references: UNIPARC:UPI00001764E1
A:Experimental source: strain S288C
R:Tanaka, K.; Matsumoto, K.; Toh-e, A.
Mol. Cell. Biol. 9, 757-768, 1989
A:Title: IRA1, an inhibitory regulator of the RAS-cyclic AMP pathway in Saccharomyces ce
A:Reference number: A30135; MUID:89219070; PMID:2540426
A:Accession: A30135
A:Molecule type: DNA
A:Residues: 155-360, 'G', 362-3092 <TAN>
A:Cross-references: UNIPARC:UPI0000168C89; EMBL:M24378; NID:G295615; PIDN:AAA34709.1; PI
C:Genetics:
A:Gene: SGD: IRA1; PPDI
A:Cross-references: SGD:S0000344; MIPS:YBR140c
A:Map position: 2R
C:Superfamily: regulatory protein IRA2; ras-specific GAP catalytic domain homology
C:Keywords: phosphoprotein; transmembrane protein
F:93-109/Domain: transmembrane #status predicted <TM1>
F:238-254/Domain: transmembrane #status predicted <TM2>
F:291-307/Domain: transmembrane #status predicted <TM3>
F:571-587/Domain: transmembrane #status predicted <TM4>
F:664-680/Domain: transmembrane #status predicted <TM5>
F:801-817/Domain: transmembrane #status predicted <TM6>
F:1125-1141/Domain: transmembrane #status predicted <TM7>
F:1183-1204/Domain: transmembrane #status predicted <TM8>
F:1425-1442/Domain: transmembrane #status predicted <TM9>
F:1449-1465/Domain: transmembrane #status predicted <TM10>
F:1696-1712/Domain: transmembrane #status predicted <TM11>
F:1709-1918/Domain: ras-specific GAP catalytic domain homology <GAP>
F:1850-1868/Domain: transmembrane #status predicted <TM12>
F:2326-2344/Domain: transmembrane #status predicted <TM13>
F:2557-2573/Domain: transmembrane #status predicted <TM14>
F:2577-2593/Domain: transmembrane #status predicted <TM15>
F:2751-2767/Domain: transmembrane #status predicted <TM16>
F:2855-2871/Domain: transmembrane #status predicted <TM17>
F:2901-2917/Domain: transmembrane #status predicted <TM18>
F:2950-2966/Domain: transmembrane #status predicted <TM19>
F:2974-2990/Domain: transmembrane #status predicted <TM20>
F:3009-3025/Domain: transmembrane #status predicted <TM21>

Query Match 26.3%; Score 36.5; DB 2; Length 3092;
Best Local Similarity 36.7%; Pred. No. 3.8e+02;
Matches 11; Conservative 2; Mismatches 16; Indels 1; Gaps 1;

Qy 5 ATXATQRLXNFXLXXXXXNGPXLPTXVGS 34
Db 2631 ATFAQKL-NFISGFSQEKGRVLPNFAASS 2659

RESULT 50
TCHUR
calcitonin gene-related peptide alpha precursor [validated] - human

N:Alternate names: calcitonin gene-related peptide I; CGRP-I
C:Species: Homo sapiens (man)
C>Date: 30-Sep-1987 #sequence revision 02-Jul-1996 #text change 09-Jul-2004
A:Accession: S07644; A22949; I55536; J00005; S10813; A26142; JH0619; I52204; I84
R:Broad, P.M.; Symes, A.J.; Thakker, R.V.; Craig, R.K.
Nucleic Acids Res. 17, 6999-7011, 1989
A:Title: Structure and methylation of the human calcitonin/alpha-CGRP gene.
A:Reference number: S07643; MUID:89386053; PMID:2571128
A:Accession: S07644
A:Molecule type: DNA
A:Residues: 1-128 <BRO>
A:Cross-references: UNIPARC:UPI0000126E30; EMBL:X15943; NID:g29613; PIDN
A:Note: the authors translated the codon CAG for residue 19 as Glu
R:Jonas, V.; Lin, C.R.; Kawashima, E.; Semon, D.; Swanson, L.W.; Mermod, J.J.; Evans, R.
Proc. Natl. Acad. Sci. U.S.A. 82, 1994-1998, 1985
A:Title: Alternative RNA processing events in human calcitonin/calcitonin gene-related p
A:Reference number: A94030; MUID:85166259; PMID:3872459
A:Accession: A22949
A:Molecule type: mRNA
A:Residues: 1-128 <JON>
A:Cross-references: UNIPARC:UPI0000126E30; GB:M12667; NID:g179825; PIDN:AAA51914.1; PID:
R:Edbrooke, M.R.; Parker, D.; McVey, J.H.; Riley, J.H.; Sorenson, G.D.; Pettengill, O.S.
EMBO J. 4, 715-724, 1985
A:Title: Expression of the human calcitonin/CGRP gene in lung and thyroid carcinoma.
A:Reference number: A91034; MUID:85230541; PMID:2408883
A:Accession: B22716
A:Molecule type: DNA
A:Residues: 'V', 50-75, 'S', 76-128 <EDB>
A:Cross-references: UNIPARC:UPI000017349A
R:Steenbergh, P.H.; Hoppener, J.W.; Zandberg, J.; Van de Ven, W.J.; Jansz, H.S.; Lips, C
J. Clin. Endocrinol. Metab. 59, 358-360, 1984
A:Title: Calcitonin gene related peptide coding sequence is conserved in the human genom
A:Reference number: I55536; MUID:84240176; PMID:6610687
A:Accession: I55536
A>Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 77-128 <RES>
A:Cross-references: UNIPARC:UPI000016A651; GB:M28637; NID:g180467; PIDN:AAA52012.1; PID:
R:Morris, H.R.; Panico, M.; Etienne, T.; Tipples, J.; Girgis, S.I.; MacIntyre, I.
Nature 308, 746-748, 1984
A:Title: Isolation and characterization of human calcitonin gene-related peptide.
A:Reference number: A93329; MUID:84191466; PMID:6609312
A:Accession: J00005
A:Molecule type: protein
A:Residues: 83-119 <MOR>
A:Cross-references: UNIPARC:UPI000002B78E
A:Note: this peptide was detected in medullary thyroid carcinoma tissue and in plasma
R:Zaidi, M.; Brain, S.D.; Tipples, J.R.; di Marzo, V.; Moonga, B.S.; Chambers, T.J.; Mor
Biochem. J. 269, 775-780, 1990
A:Title: Structure-activity relationship of human calcitonin-gene-related peptide.
A:Reference number: S10813; MUID:90358780; PMID:2390067
A:Accession: S10813
A:Molecule type: protein
A:Residues: 83-99, 'A', 101-119 <ZAI>
A:Cross-references: UNIPARC:UPI000017349B
R:Petermann, J.B.; Born, W.; Chang, J.Y.; Fischer, J.A.
J. Biol. Chem. 262, 542-545, 1987
A:Title: Identification in the human central nervous system, pituitary, and thyroid of a
A:Reference number: A92637; MUID:87109142; PMID:3492492
A:Accession: A26142
A:Molecule type: protein
A:Residues: 83-88, 'X', 90-101, 'X', 103-111, 'X', 113-115, 'X', 117 <PET>
A:Cross-references: UNIPARC:UPI000017349C
R:Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Matsuo, H.; Eto, T.
Biochem. Biophys. Res. Commun. 185, 134-141, 1992
A:Title: Isolation and characterization of peptides which act on rat platelets, from a p
A:Reference number: JH0618; MUID:92287083; PMID:1318039
A:Accession: JH0619
A:Molecule type: protein
A:Residues: 83, 'X', 85-88, 'X', 90-108 <KIT>
A:Cross-references: UNIPARC:UPI000017349D
A:Experimental source: pheochromocytoma
R:Neiklin, B.D.; Rosenfeld, K.I.; de Bustros, A.; Leong, S.S.; Roos, B.A.; Baylin, S.B.

Biochem. Biophys. Res. Commun. 123, 648-655, 1984
A:Title: Structure and expression of a gene encoding human calcitonin and calcitonin gen
A:Reference number: I52204; MUID:85022523; PMID:6148938
A:Accession: I52204
A>Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 48-119 <RE2>
A:Cross-references: UNIPARC:UPI000016A6C0; GB:K03512; NID:g180465; PIDN:AAA52011.1; PID:
R:Craig, R.K.; Riley, J.H.; Edbrooke, M.R.; Broad, P.M.; Foord, S.M.; Al-Kazwini, S.J.;
Biochem. Soc. Symp. 52, 91-105, 1986
A:Title: Expression and function of the human calcitonin/alpha-CGRP gene in health and d
A:Reference number: I39387; MUID:87213363; PMID:3034287
A:Accession: I84508
A>Status: translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 77-128 <RE3>
A:Cross-references: UNIPARC:UPI000016A651; GB:M26094; NID:g179798; PIDN:AAA51912.1; PID:
C:Comment: This peptide is a potent vasorelaxant.
C:Comment: This peptide increases the rate and force of contraction of rat auricles in v
C:Genetics:
A:Gene: GDB:CALCA; CALCI
A:Cross-references: GDB:I20571; OMIM:114130
A:Map position: 11p15.2-11p15.1
A:Introns: 29/2; 76/2
C:Superfamily: calcitonin
C:Keywords: alternative splicing; amidated carboxyl end; neuropeptide; vasodilator
F:83-119/Product: calcitonin gene-related peptide alpha #status experimental <CTN>
F:84-89/Disulfide bonds: #status experimental
F:119/Modified site: amidated carboxyl end (Phe) (amide in mature form from following gl
Query Match 25.9%; Score 36; DB 1; Length 128;
Best Local Similarity 31.4%; Pred. No.13;
Matches 11; Conservative 2; Mismatches 22; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFXLXXXXXNKGPLPXTXVGSNTY 37
Db 85 DTATCVTHRLAGLLSRSGGVVKNFVPTNVGSKAF 119
Search completed: January 4, 2006, 11:47:09
Job time : 42 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:32:26 ; Search time 46 Seconds
(without alignments)
66.500 Million cell updates/sec

Title: US-09-445-517-14
Perfect score: 139
Sequence: 1 XXNTATYATQRLXNLFXXXXXXGXPXLPXTXVGSNTY 37

Scoring table:
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database : Issued Patents AA.*

1: /cgn2_6/ptodata/1/iaa/5_COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/6_COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/H_COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	118	84.9	36	1	US-08-477-727A-83
2	118	84.9	36	1	US-08-477-727A-92
3	118	84.9	36	1	US-08-471-675A-7
4	118	84.9	36	1	US-08-471-675A-14
5	118	84.9	36	1	US-08-892-549-18
6	118	84.9	36	1	US-08-892-549-39
7	118	84.9	36	2	US-08-302-069A-6
8	118	84.9	36	2	US-08-302-069A-13
9	118	84.9	36	2	US-09-576-062A-6
10	118	84.9	36	2	US-09-576-062A-13
11	118	84.9	36	2	US-09-454-533-18
12	118	84.9	36	2	US-09-454-533-39
13	118	84.9	37	1	US-08-477-727A-82
14	118	84.9	37	1	US-08-477-727A-89
15	118	84.9	37	1	US-08-477-727A-91
16	118	84.9	37	1	US-08-477-727A-93
17	118	84.9	37	1	US-08-477-727A-95
18	118	84.9	37	1	US-08-471-675A-4
19	118	84.9	37	1	US-08-471-675A-13
20	118	84.9	37	1	US-08-471-675A-15
21	118	84.9	37	1	US-08-471-675A-17
22	118	84.9	37	1	US-08-892-549-10
23	118	84.9	37	1	US-08-892-549-17
24	118	84.9	37	1	US-08-892-549-19
25	118	84.9	37	1	US-08-892-549-21
26	118	84.9	37	1	US-08-892-549-38
27	118	84.9	37	2	US-08-302-069A-3

28	118	84.9	37	2	US-08-302-069A-12	Sequence 12, Appl
29	118	84.9	37	2	US-08-302-069A-14	Sequence 14, Appl
30	118	84.9	37	2	US-08-302-069A-16	Sequence 16, Appl
31	118	84.9	37	2	US-09-576-062A-3	Sequence 3, Appl
32	118	84.9	37	2	US-09-576-062A-12	Sequence 12, Appl
33	118	84.9	37	2	US-09-576-062A-14	Sequence 14, Appl
34	118	84.9	37	2	US-09-576-062A-16	Sequence 16, Appl
35	118	84.9	37	2	US-09-454-533-10	Sequence 10, Appl
36	118	84.9	37	2	US-09-454-533-17	Sequence 17, Appl
37	118	84.9	37	2	US-09-454-533-19	Sequence 19, Appl
38	118	84.9	37	2	US-09-454-533-21	Sequence 21, Appl
39	118	84.9	37	2	US-09-454-533-38	Sequence 38, Appl
40	117	84.2	36	1	US-08-892-549-11	Sequence 11, Appl
41	117	84.2	36	1	US-08-454-533-11	Sequence 11, Appl
42	117	84.2	37	1	US-08-477-727A-107	Sequence 107, App
43	117	84.2	37	1	US-08-471-675A-29	Sequence 29, Appl
44	117	84.2	37	1	US-08-892-549-33	Sequence 33, Appl
45	117	84.2	37	2	US-08-302-069A-28	Sequence 28, Appl
46	117	84.2	37	2	US-09-576-062A-28	Sequence 28, Appl
47	117	84.2	37	2	US-09-454-533-33	Sequence 33, Appl
48	116	83.5	36	1	US-08-477-727A-86	Sequence 86, Appl
49	116	83.5	36	1	US-08-477-727A-88	Sequence 88, Appl
50	116	83.5	36	1	US-08-477-727A-98	Sequence 98, Appl
51	116	83.5	36	1	US-08-471-675A-11	Sequence 11, Appl
52	116	83.5	36	1	US-08-471-675A-20	Sequence 20, Appl
53	116	83.5	36	1	US-08-892-549-24	Sequence 24, Appl
54	116	83.5	36	2	US-08-302-069A-9	Sequence 9, Appl
55	116	83.5	36	2	US-08-302-069A-10	Sequence 10, Appl
56	116	83.5	36	2	US-08-302-069A-19	Sequence 19, Appl
57	116	83.5	36	2	US-09-576-062A-9	Sequence 9, Appl
58	116	83.5	36	2	US-09-576-062A-10	Sequence 10, Appl
59	116	83.5	36	2	US-09-576-062A-19	Sequence 19, Appl
60	116	83.5	36	2	US-09-454-533-24	Sequence 24, Appl
61	116	83.5	37	1	US-07-794-288D-2	Sequence 2, Appl
62	116	83.5	37	1	US-08-477-727A-4	Sequence 4, Appl
63	116	83.5	37	1	US-08-477-727A-29	Sequence 29, Appl
64	116	83.5	37	1	US-08-477-727A-81	Sequence 81, Appl
65	116	83.5	37	1	US-08-477-727A-84	Sequence 84, Appl
66	116	83.5	37	1	US-08-477-727A-87	Sequence 87, Appl
67	116	83.5	37	1	US-08-477-727A-90	Sequence 90, Appl
68	116	83.5	37	1	US-08-477-727A-94	Sequence 94, Appl
69	116	83.5	37	1	US-08-477-727A-96	Sequence 96, Appl
70	116	83.5	37	1	US-08-477-727A-97	Sequence 97, Appl
71	116	83.5	37	1	US-08-477-727A-101	Sequence 101, App
72	116	83.5	37	1	US-08-471-675A-2	Sequence 2, Appl
73	116	83.5	37	1	US-08-471-675A-8	Sequence 8, Appl
74	116	83.5	37	1	US-08-471-675A-9	Sequence 9, Appl
75	116	83.5	37	1	US-08-471-675A-12	Sequence 12, Appl
76	116	83.5	37	1	US-08-471-675A-16	Sequence 16, Appl
77	116	83.5	37	1	US-08-471-675A-18	Sequence 18, Appl
78	116	83.5	37	1	US-08-471-675A-19	Sequence 19, Appl
79	116	83.5	37	1	US-08-471-675A-23	Sequence 23, Appl
80	116	83.5	37	1	US-08-259-762-9	Sequence 9, Appl
81	116	83.5	37	1	US-08-892-549-4	Sequence 4, Appl
82	116	83.5	37	1	US-08-892-549-9	Sequence 9, Appl
83	116	83.5	37	1	US-08-892-549-12	Sequence 12, Appl
84	116	83.5	37	1	US-08-892-549-13	Sequence 13, Appl
85	116	83.5	37	1	US-08-892-549-16	Sequence 16, Appl
86	116	83.5	37	1	US-08-892-549-20	Sequence 20, Appl
87	116	83.5	37	1	US-08-892-549-22	Sequence 22, Appl
88	116	83.5	37	1	US-08-892-549-23	Sequence 23, Appl
89	116	83.5	37	1	US-08-892-549-27	Sequence 27, Appl
90	116	83.5	37	2	US-08-784-582-51	Sequence 51, Appl
91	116	83.5	37	2	US-08-302-069A-1	Sequence 1, Appl
92	116	83.5	37	2	US-08-302-069A-7	Sequence 7, Appl
93	116	83.5	37	2	US-08-302-069A-8	Sequence 8, Appl
94	116	83.5	37	2	US-08-302-069A-11	Sequence 11, Appl
95	116	83.5	37	2	US-08-302-069A-15	Sequence 15, Appl
96	116	83.5	37	2	US-08-302-069A-17	Sequence 17, Appl
97	116	83.5	37	2	US-08-302-069A-18	Sequence 18, Appl
98	116	83.5	37	2	US-08-302-069A-22	Sequence 22, Appl
99	116	83.5	37	2	US-09-070-504-17	Sequence 17, Appl
100	116	83.5	37	2	US-09-576-062A-1	Sequence 1, Appl

101	116	83.5	37	2	US-09-576-062A-7	Sequence 7, Appl
102	116	83.5	37	2	US-09-576-062A-8	Sequence 8, Appl
103	116	83.5	37	2	US-09-576-062A-11	Sequence 11, Appl
104	116	83.5	37	2	US-09-576-062A-15	Sequence 15, Appl
105	116	83.5	37	2	US-09-576-062A-17	Sequence 17, Appl
106	116	83.5	37	2	US-09-576-062A-18	Sequence 18, Appl
107	116	83.5	37	2	US-09-576-062A-22	Sequence 22, Appl
108	116	83.5	37	2	US-09-454-533A-9	Sequence 4, Appl
109	116	83.5	37	2	US-09-454-533-3	Sequence 9, Appl
110	116	83.5	37	2	US-09-454-533-12	Sequence 12, Appl
111	116	83.5	37	2	US-09-454-533-13	Sequence 13, Appl
112	116	83.5	37	2	US-09-454-533-16	Sequence 16, Appl
113	116	83.5	37	2	US-09-454-533-20	Sequence 20, Appl
114	116	83.5	37	2	US-09-454-533-22	Sequence 22, Appl
115	116	83.5	37	2	US-09-454-533-23	Sequence 23, Appl
116	116	83.5	37	2	US-09-454-533-27	Sequence 27, Appl
117	116	83.5	37	2	US-09-813-345C-17	Sequence 17, Appl
118	116	83.5	37	2	US-09-623-548A-321	Sequence 321, App
119	116	83.5	37	2	US-09-623-548A-334	Sequence 334, App
120	116	83.5	37	2	US-09-657-276-321	Sequence 321, App
121	116	83.5	37	2	US-09-657-276-334	Sequence 334, App
122	116	83.5	93	2	US-08-589-028-8	Sequence 8, Appl
123	116	83.5	93	2	US-08-784-582-8	Sequence 8, Appl
124	116	83.5	93	2	US-08-785-271-8	Sequence 8, Appl
125	113	81.3	37	1	US-08-477-727A-5	Sequence 5, Appl
126	113	81.3	37	1	US-08-477-727A-30	Sequence 30, Appl
127	112	80.6	36	1	US-08-892-549-14	Sequence 14, Appl
128	112	80.6	36	1	US-08-892-549-15	Sequence 15, Appl
129	112	80.6	36	1	US-08-892-549-40	Sequence 40, Appl
130	112	80.6	36	2	US-09-454-533-14	Sequence 14, Appl
131	112	80.6	36	2	US-09-454-533-15	Sequence 15, Appl
132	112	80.6	36	2	US-09-454-533-40	Sequence 40, Appl
133	111	79.9	36	1	US-08-477-727A-104	Sequence 104, App
134	111	79.9	36	1	US-08-477-727A-26	Sequence 26, Appl
135	111	79.9	36	2	US-08-302-069A-25	Sequence 25, Appl
136	111	79.9	36	2	US-09-576-062A-25	Sequence 25, Appl
137	110	79.1	36	1	US-08-892-549-30	Sequence 30, Appl
138	110	79.1	36	2	US-09-454-533-30	Sequence 30, Appl
139	110	79.1	37	1	US-08-477-727A-77	Sequence 77, Appl
140	110	79.1	37	1	US-08-477-727A-80	Sequence 80, Appl
141	110	79.1	37	1	US-08-471-675A-6	Sequence 6, Appl
142	110	79.1	37	2	US-08-892-549-8	Sequence 8, Appl
143	110	79.1	37	2	US-08-302-069A-5	Sequence 5, Appl
144	110	79.1	37	2	US-09-576-062A-5	Sequence 5, Appl
145	110	79.1	37	2	US-09-454-533-8	Sequence 8, Appl
146	109	78.4	37	1	US-08-459-762-12	Sequence 12, Appl
147	109	78.4	37	1	US-08-459-762-13	Sequence 13, Appl
148	108	77.7	37	1	US-08-477-727A-85	Sequence 85, Appl
149	108	77.7	37	1	US-08-477-727A-106	Sequence 106, App
150	108	77.7	37	1	US-08-471-675A-28	Sequence 28, Appl

ALIGNMENTS

RESULT 1
US-08-477-727A-83
Sequence 83, Application US/08477727A
Patent No. 5739106
GENERAL INFORMATION:
APPLICANT: Rink, Timothy
APPLICANT: Young, Andrew
APPLICANT: Beeley, Nigel
APPLICANT: Prickett, Kathryn
TITLE OF INVENTION: APPETITE REGULATING
TITLE OF INVENTION: COMPOSITIONS
NUMBER OF SEQUENCES: 108
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET, SUITE 4700
CITY: LOS ANGELES
STATE: CA
COUNTRY: USA

```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 83:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; /
; US-08-477-727A-83
;
Query Match 84.9%; Score 118; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels

Qy 3 NTATCATQRLXNFXLXXXXXNXPXLPXTXVGSNTY 37
      ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQELANFLVRSSNNFGPILPSTNVGSNTY 36
      ||||| ||||| ||||| ||||| |||||

RESULT 2
US-08-477-727A-92
; Sequence 92, Application US/08477727A
; Patent No. 5739106
; GENERAL INFORMATION:
; APPLICANT: Rink, Timothy
; APPLICANT: Young, Andrew
; APPLICANT: Beeley, Nigel
; APPLICANT: Prickett, Kathryn
; TITLE OF INVENTION: APPETITE REGULATING
; TITLE OF INVENTION: COMPOSITIONS
; NUMBER OF SEQUENCES: 108
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

```

```
;
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-92

Query Match 84.9%; Score 118; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXNKGXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNGLGVLPTSTNVSNTY 36

RESULT 3
US-08-471-675A-7
; Sequence 7, Application US/08471675A
; Patent No. 5795861
; GENERAL INFORMATION:
; APPLICANT: Kolterman, Orville
; APPLICANT: Rink, Timothy
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,675A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 213/048
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: disulfide bridge between the Cys
; residues at positions 1 and 6;
; OTHER INFORMATION: amidated Tyr at position 36
; US-08-471-675A-14

Query Match 84.9%; Score 118; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
```

```
;
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: disulfide bridge between the Cys
; residues at positions 1 and 6;
; OTHER INFORMATION: amidated Tyr at position 36
; US-08-471-675A-7

Query Match 84.9%; Score 118; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNLFXXXXXNKGXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVHSSNGLGVLPTSTNVSNTY 36

RESULT 4
US-08-471-675A-14
; Sequence 14, Application US/08471675A
; Patent No. 5795861
; GENERAL INFORMATION:
; APPLICANT: Kolterman, Orville
; APPLICANT: Rink, Timothy
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,675A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 213/048
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: disulfide bridge between the Cys
; residues at positions 1 and 6;
; OTHER INFORMATION: amidated Tyr at position 36
; US-08-471-675A-14

Query Match 84.9%; Score 118; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
```


NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/302.069A
FILING DATE: 07-SEP-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 209/146
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
LOCATION: 1,6
OTHER INFORMATION: disulfide bridge between
the Cys residues
LOCATION: 36
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-302-069A-6

Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXKXGXPXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVRSSNNGPILPSTNVGSNTY 36

RESULT 8
US-08-302-069A-13
Sequence 13, Application US/08302069A
Patent No. 6114304
GENERAL INFORMATION:
APPLICANT: KOLTERMAN, Orville G.
APPLICANT: YOUNG, Andrew A.
APPLICANT: RINK, Timothy J.
APPLICANT: BROWN, Kathleen Ann Keiting
TITLE OF INVENTION: METHODS FOR REGULATING
GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/302.069A
FILING DATE: 07-SEP-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 209/146
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
LOCATION: 1,6
OTHER INFORMATION: disulfide bridge between
the Cys residues
LOCATION: 36
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-302-069A-13

Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 8.4e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXKXGXPXLPXTXVGSNTY 37
|||||
Db 2 NTATCATQRLANFLVRSSNNGPILPSTNVGSNTY 36

RESULT 9
US-09-576-062A-6
Sequence 6, Application US/09576062A
Patent No. 6608029
GENERAL INFORMATION:
APPLICANT: KOLTERMAN, Orville G.
APPLICANT: YOUNG, Andrew A.
APPLICANT: RINK, Timothy J.
APPLICANT: BROWN, Kathleen Ann Keiting
TITLE OF INVENTION: METHODS FOR REGULATING
GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/576.062A
FILING DATE: 22-May-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/302,069
FILING DATE: 07-SEP-1994


```
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-91

Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPKLPTXVGSNTY 37
||| ||||| ||| ||| ||| ||| ||| ||| |||
Db 3 NTATCATQRLANFLVHSSNFGPVLPTNVGSNTY 37

RESULT 15
US-08-477-727A-91
; Sequence 91, Application US/08477727A
; Patent No. 5739106
; GENERAL INFORMATION:
; APPLICANT: Rink, Timothy
; APPLICANT: Young, Andrew
; APPLICANT: Beeley, Nigel
; APPLICANT: Prickett, Kathryn
; TITLE OF INVENTION: APPETITE REGULATING
; TITLE OF INVENTION: COMPOSITIONS
; NUMBER OF SEQUENCES: 108
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-89

Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPKLPTXVGSNTY 37
||| ||||| ||| ||| ||| ||| ||| ||| |||
Db 3 NTATCATQRLANFLVHSSNFGPVLPTNVGSNTY 37

RESULT 16
US-08-477-727A-93
; Sequence 93, Application US/08477727A
; Patent No. 5739106
; GENERAL INFORMATION:
; APPLICANT: Rink, Timothy
; APPLICANT: Young, Andrew
; APPLICANT: Beeley, Nigel
; APPLICANT: Prickett, Kathryn
; TITLE OF INVENTION: APPETITE REGULATING
; TITLE OF INVENTION: COMPOSITIONS
; NUMBER OF SEQUENCES: 108
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-91

Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPKLPTXVGSNTY 37
||| ||||| ||| ||| ||| ||| ||| ||| |||
Db 3 NTATCATQRLANFLVHSSNFGPVLPTNVGSNTY 37
```



```
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
;
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-93

Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
   ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVRSSNNLGPVLPSTNVGSNTY 37

RESULT 17
US-08-477-727A-95
; Sequence 95, Application US/08477727A
; Patent No. 5739106
; GENERAL INFORMATION:
; APPLICANT: Rink, Timothy
; APPLICANT: Young, Andrew
; APPLICANT: Beeley, Nigel
; APPLICANT: Prickett, Kathryn
; TITLE OF INVENTION: APETITE REGULATING
; TITLE OF INVENTION: COMPOSITIONS
; NUMBER OF SEQUENCES: 108
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,727A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 214/005
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
```

```
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; US-08-477-727A-95

Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
   ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVRSSNNLGPVLPSTNVGSNTY 37

RESULT 18
US-08-471-675A-4
; Sequence 4, Application US/08471675A
; Patent No. 5795861
; GENERAL INFORMATION:
; APPLICANT: Kolterman, Orville
; APPLICANT: Rink, Timothy
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,675A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 213/048
; TELEPHONE: 619-552-8400
; TELEFAX: 619-552-0157
; TELEX:
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Peptide
; FEATURE:
; OTHER INFORMATION: disulfide bridge between the Cys
; OTHER INFORMATION: residues at positions 2 and 7;
; OTHER INFORMATION: amidated Tyr at position 37
; US-08-471-675A-4

Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
   ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVRSSNNLGPVLPSTNVGSNTY 37
```

```

ADDRESSER: LYON & LYON
STREET: 633 WEST FIFTH STREET, SUITE 4700
CITY: LOS ANGELES
STATE: CA
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471.675A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/302,069
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 213/048
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURES:
OTHER INFORMATION: disulfide bridge between the Cys
OTHER INFORMATION: residues at positions 2 and 7;
OTHER INFORMATION: amidated Tyr at position 37
US-08-471-675A-15

Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels

QY    3 NTATCATQRLXNFLXXXXXXXXXXGPKLPXTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| |||||
DB    3 NTATCATQRLANFLVRSSNNLGGVLPPSTNVGSNTY 37

RESULT 21
US-08-471-675A-17
; Sequence 17, Application US/08471675A
; Patent No. 5795861
; GENERAL INFORMATION:
; APPLICANT: Kolterman, Orville
; APPLICANT: Rink, Timothy
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET, SUITE 4700
; CITY: LOS ANGELES
; STATE: CA
; COUNTRY: USA
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/08/471.675A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/302,069
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 213/048
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
OTHER INFORMATION: disulfide bridge between the Cys
OTHER INFORMATION: residues at positions 2 and 7;
OTHER INFORMATION: amidated Tyr at position 37
US-08-471-675A-17

Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPXLPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 22

US-08-892-549-10
Sequence 10, Application US/08892549
Patent No. 5998367
GENERAL INFORMATION:
APPLICANT: GAETA, Laura S.L. Et Al.
TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
TITLE OF INVENTION: USES THEREFOR
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/892,549
FILING DATE: 14-JUL-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/447,849
FILING DATE: 23-MAY-1995
APPLICATION NUMBER: 07/794,266
FILING DATE: 19-NOV-1991
APPLICATION NUMBER: US 07/667,040
FILING DATE: 08-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219

REFERENCE/DOCKET NUMBER: 227/006
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
LOCATION: 2,7
OTHER INFORMATION: disulfide bridge between
OTHER INFORMATION: the Cys residues
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-892-549-10

Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPXLPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 37

RESULT 23

US-08-892-549-17
Sequence 17, Application US/08892549
Patent No. 5998367
GENERAL INFORMATION:
APPLICANT: GAETA, Laura S.L. Et Al.
TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
TITLE OF INVENTION: USES THEREFOR
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/892,549
FILING DATE: 14-JUL-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/447,849
FILING DATE: 23-MAY-1995
APPLICATION NUMBER: 07/794,266
FILING DATE: 19-NOV-1991
APPLICATION NUMBER: US 07/667,040
FILING DATE: 08-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 227/006
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;
US-08-892-549-17
Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGPKLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 24
US-08-892-549-19
; Sequence 19, Application US/08892549
; Patent No. 5998367
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; TITLE OF INVENTION: USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/892,549
; FILING DATE: 14-JUL-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/447,849
; FILING DATE: 23-MAY-1995
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)

```

```

US-08-892-549-19
Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGPKLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 25
US-08-892-549-21
; Sequence 21, Application US/08892549
; Patent No. 5998367
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; TITLE OF INVENTION: USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/892,549
; FILING DATE: 14-JUL-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/447,849
; FILING DATE: 23-MAY-1995
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;
US-08-892-549-21
Query Match      84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGPKLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

```

RESULT 26
US-08-892-549-38
; Sequence 38, Application US/08892549
; Patent No. 598367
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; TITLE OF INVENTION: USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/892,549
; FILING DATE: 14-JUL-1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/447,849
; FILING DATE: 23-MAY-1995
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-892-549-38
Query Match 84.9%; Score 118; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFKLXXXXXKNGKPLPTXVGSNTY 37
Db 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37
RESULT 27
US-08-302-069A-3
; Sequence 3, Application US/08302069A
; Patent No. 6114304
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: RINK, Timothy J.
; APPLICANT: BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA

; APPLICANT: RINK, Timothy J.
; APPLICANT: BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/302,069A
; FILING DATE: 07-SEP-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-302-069A-3
Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFKLXXXXXKNGKPLPTXVGSNTY 37
Db 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37
RESULT 28
US-08-302-069A-12
; Sequence 12, Application US/08302069A
; Patent No. 6114304
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; APPLICANT: YOUNG, Andrew A.
; APPLICANT: RINK, Timothy J.
; APPLICANT: BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA


```
;
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 2,7
; OTHER INFORMATION: disulfide bridge between
; OTHER INFORMATION: the Cys residues
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;
US-08-302-069A-16
Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy      3 NTATXATQRLXNLFXXXXXNKGXLPXTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| |||||
Db      3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 31
US-09-576-062A-3
; Sequence 3, Application US/09576062A
; Patent No. 6608029
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; YOUNG, Andrew A.
; RINK, Timothy J.
; BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; GASTROINTESTINAL MOTILITY
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 22-May-2000
; APPLICATION NUMBER: US/09/576,062A
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; NAME: DUFT, BRADFORD J.
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;
US-09-576-062A-12
Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
```

```
;
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-576-062A-3
Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy      3 NTATXATQRLXNLFXXXXXNKGXLPXTXVGSNTY 37
      ||||| ||||| ||||| ||||| ||||| |||||
Db      3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

RESULT 32
US-09-576-062A-12
; Sequence 12, Application US/09576062A
; Patent No. 6608029
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; YOUNG, Andrew A.
; RINK, Timothy J.
; BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; GASTROINTESTINAL MOTILITY
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/576,062A
; FILING DATE: 22-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; NAME: DUFT, BRADFORD J.
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;
US-09-576-062A-12
Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
```

```

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 33
US-09-576-062A-14
; Sequence 14, Application US/09576062A
; Patent No. 6608029
; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; RINK, Timothy J.
; BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/576,062A
; FILING DATE: 22-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
;
; Query Match 84.9%; Score 118; DB 2; Length 37;
; Best Local Similarity 68.6%; Pred. No. 8.7e-15;
; Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 34
US-09-576-062A-16
; Sequence 16, Application US/09576062A
; Patent No. 6608029

```

```

; GENERAL INFORMATION:
; APPLICANT: KOLTERMAN, Orville G.
; RINK, Timothy J.
; BROWN, Kathleen Ann Keiting
; TITLE OF INVENTION: METHODS FOR REGULATING
; GASTROINTESTINAL MOTILITY
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/576,062A
; FILING DATE: 22-May-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/302,069
; FILING DATE: 07-SEP-1994
; APPLICATION NUMBER: 08/118,381
; FILING DATE: 07-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 209/146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
;
; Query Match 84.9%; Score 118; DB 2; Length 37;
; Best Local Similarity 68.6%; Pred. No. 8.7e-15;
; Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 35
US-09-454-533-10
; Sequence 10, Application US/09454533
; Patent No. 6610824
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA

```


;; COUNTRY: USA
;; ZIP: 90017
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/454,533
;; FILING DATE: 06-Dec-1999
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/892,549
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 07/794,266
;; FILING DATE: 19-NOV-1991
;; APPLICATION NUMBER: US 07/667,040
;; FILING DATE: 08-MAR-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 227/006
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 619/552-2200
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 10:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 37 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; FEATURE:
;; LOCATION: 37
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-454-533-10

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVRSSNNGPILPSTNVGSNTY 37
|||||

RESULT 36
US-09-454-533-17
; Sequence 17, Application US/09454533
; Patent No. 6610824
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/892,549
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 07/794,266
;; FILING DATE: 19-NOV-1991
;; APPLICATION NUMBER: US 07/667,040
;; FILING DATE: 08-MAR-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: DUFT, BRADFORD J.
;; REGISTRATION NUMBER: 32,219
;; REFERENCE/DOCKET NUMBER: 227/006
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/552-2200
;; TELEFAX: 619/552-2200
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 37 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
;; FEATURE:
;; LOCATION: 37
;; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-454-533-17

Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVRSSNNGPILPSTNVGSNTY 37
|||||

RESULT 37
US-09-454-533-19
; Sequence 19, Application US/09454533
; Patent No. 6610824
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S.L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-454-533-19

Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
Db 3 NTATCATQRLANFLVRSSNNLGPVLPSTNVGSNTY 37

RESULT 38
US-09-454-533-21
; Sequence 21, Application US/09454533
; Patent No. 6610824
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S. L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein

```

```

; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-09-454-533-21

Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37
Db 3 NTATCATQRLANFLVRSSNNLGPVLPSTNVGSNTY 37

RESULT 39
US-09-454-533-38
; Sequence 38, Application US/09454533
; Patent No. 6610824
; GENERAL INFORMATION:
; APPLICANT: GAETA, Laura S. L. Et Al.
; TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
; USES THEREFOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 WEST FIFTH STREET
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/454,533
; FILING DATE: 06-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/892,549
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/794,266
; FILING DATE: 19-NOV-1991
; APPLICATION NUMBER: US 07/667,040
; FILING DATE: 08-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DUFT, BRADFORD J.
; REGISTRATION NUMBER: 32,219
; REFERENCE/DOCKET NUMBER: 227/006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/552-2200
; TELEFAX: 213/955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 38
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; LOCATION: 37
; OTHER INFORMATION: amidated Tyr (Tyrosinamide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 38:
US-09-454-533-38

Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 8.7e-15;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37

```

DB	QY	DB	QY
3	NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37	3	NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37
US-08-892-549-11		US-08-892-549-11	
Sequence 11, Application US/08892549		Sequence 11, Application US/08892549	
Patent No. 5998367		Patent No. 5998367	
GENERAL INFORMATION:		GENERAL INFORMATION:	
APPLICANT: GAETA, Laura S.L. Et Al.		APPLICANT: GAETA, Laura S.L. Et Al.	
TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND		TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND	
USSES THEREFOR		USSES THEREFOR	
NUMBER OF SEQUENCES: 41		NUMBER OF SEQUENCES: 41	
CORRESPONDENCE ADDRESS:		CORRESPONDENCE ADDRESS:	
ADDRESSEE: LYON & LYON		ADDRESSEE: LYON & LYON	
STREET: 633 WEST FIFTH STREET		STREET: 633 WEST FIFTH STREET	
CITY: LOS ANGELES		CITY: LOS ANGELES	
STATE: CALIFORNIA		STATE: CALIFORNIA	
COUNTRY: USA		COUNTRY: USA	
ZIP: 90017		ZIP: 90017	
COMPUTER READABLE FORM:		COMPUTER READABLE FORM:	
MEDIUM TYPE: Floppy disk		MEDIUM TYPE: Floppy disk	
COMPUTER: IBM PC compatible		COMPUTER: IBM PC compatible	
OPERATING SYSTEM: PC-DOS/MS-DOS		OPERATING SYSTEM: PC-DOS/MS-DOS	
SOFTWARE: Patent In Release #1.0, Version #1.25		SOFTWARE: Patent In Release #1.0, Version #1.25	
CURRENT APPLICATION DATA:		CURRENT APPLICATION DATA:	
APPLICATION NUMBER: US/08/892,549		APPLICATION NUMBER: US/08/892,549	
FILING DATE: 14-JUL-1997		FILING DATE: 14-JUL-1997	
CLASSIFICATION: 514		CLASSIFICATION: 514	
PRIOR APPLICATION DATA:		PRIOR APPLICATION DATA:	
APPLICATION NUMBER: 08/447,849		APPLICATION NUMBER: 08/447,849	
FILING DATE: 23-MAY-1995		FILING DATE: 23-MAY-1995	
APPLICATION NUMBER: 07/794,266		APPLICATION NUMBER: 07/794,266	
FILING DATE: 19-NOV-1991		FILING DATE: 19-NOV-1991	
APPLICATION NUMBER: US 07/667,040		APPLICATION NUMBER: US 07/667,040	
FILING DATE: 08-MAR-1991		FILING DATE: 08-MAR-1991	
ATTORNEY/AGENT INFORMATION:		ATTORNEY/AGENT INFORMATION:	
NAME: DUFT, BRADFORD J.		NAME: DUFT, BRADFORD J.	
REGISTRATION NUMBER: 32,219		REGISTRATION NUMBER: 32,219	
REFERENCE/DOCKET NUMBER: 227/006		REFERENCE/DOCKET NUMBER: 227/006	
TELEPHONE: 619/552-2200		TELEPHONE: 619/552-2200	
TELEFAX: 213/955-0440		TELEFAX: 213/955-0440	
TELEX: 67-3510		TELEX: 67-3510	
INFORMATION FOR SEQ ID NO: 11:		INFORMATION FOR SEQ ID NO: 11:	
SEQUENCE CHARACTERISTICS:		SEQUENCE CHARACTERISTICS:	
LENGTH: 36 amino acids		LENGTH: 36 amino acids	
TYPE: amino acid		TYPE: amino acid	
STRANDEDNESS: single		STRANDEDNESS: single	
TOPOLOGY: linear		TOPOLOGY: linear	
MOLECULE TYPE: peptide		MOLECULE TYPE: peptide	
FEATURE:		FEATURE:	
LOCATION: 1,6		LOCATION: 1,6	
OTHER INFORMATION: disulfide bridge between		OTHER INFORMATION: disulfide bridge between	
the Cys residues		the Cys residues	
OTHER INFORMATION:		OTHER INFORMATION:	
SEQUENCE DESCRIPTION: amidated Tyr (Tyrosinamide)		SEQUENCE DESCRIPTION: amidated Tyr (Tyrosinamide)	
US-08-892-549-11		US-08-892-549-11	
Query Match	84.2%;	Score 117;	DB 1;
Best Local Similarity	68.6%;	Pred. No. 1.3e-14;	
Mismatches	24;	Conservative	0;
Mismatches	11;	Indels	0;
Gaps	0;		
QY	3	NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37	
DB	2	NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36	
RESULT 41			
US-09-454-533-11		US-09-454-533-11	
Sequence 11, Application US/09454533		Sequence 11, Application US/09454533	
Patent No. 6610824		Patent No. 6610824	
GENERAL INFORMATION:		GENERAL INFORMATION:	
APPLICANT: RINK, Timothy		APPLICANT: RINK, Timothy	
ADDRESSEE: BEELEY, Nigel		ADDRESSEE: BEELEY, Nigel	
STREET: 633 WEST FIFTH STREET		STREET: 633 WEST FIFTH STREET	
CITY: LOS ANGELES		CITY: LOS ANGELES	
STATE: CALIFORNIA		STATE: CALIFORNIA	
COUNTRY: USA		COUNTRY: USA	
ZIP: 90017		ZIP: 90017	
COMPUTER READABLE FORM:		COMPUTER READABLE FORM:	
MEDIUM TYPE: Floppy disk		MEDIUM TYPE: Floppy disk	
COMPUTER: IBM PC compatible		COMPUTER: IBM PC compatible	
OPERATING SYSTEM: PC-DOS/MS-DOS		OPERATING SYSTEM: PC-DOS/MS-DOS	
SOFTWARE: Patent In Release #1.0, Version #1.25		SOFTWARE: Patent In Release #1.0, Version #1.25	
CURRENT APPLICATION DATA:		CURRENT APPLICATION DATA:	
APPLICATION NUMBER: US/09/454,533		APPLICATION NUMBER: US/09/454,533	
FILING DATE: 06-DEC-1999		FILING DATE: 06-DEC-1999	
CLASSIFICATION: <Unknown>		CLASSIFICATION: <Unknown>	
PRIOR APPLICATION DATA:		PRIOR APPLICATION DATA:	
APPLICATION NUMBER: 08/892,549		APPLICATION NUMBER: 08/892,549	
FILING DATE: <Unknown>		FILING DATE: <Unknown>	
APPLICATION NUMBER: 07/794,266		APPLICATION NUMBER: 07/794,266	
FILING DATE: 19-NOV-1991		FILING DATE: 19-NOV-1991	
APPLICATION NUMBER: US 07/667,040		APPLICATION NUMBER: US 07/667,040	
FILING DATE: 08-MAR-1991		FILING DATE: 08-MAR-1991	
ATTORNEY/AGENT INFORMATION:		ATTORNEY/AGENT INFORMATION:	
NAME: DUFT, BRADFORD J.		NAME: DUFT, BRADFORD J.	
REGISTRATION NUMBER: 32,219		REGISTRATION NUMBER: 32,219	
REFERENCE/DOCKET NUMBER: 227/006		REFERENCE/DOCKET NUMBER: 227/006	
TELEPHONE: 619/552-2200		TELEPHONE: 619/552-2200	
TELEFAX: 213/955-0440		TELEF	

STATE: CA
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,727A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 214/005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 107:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
US-08-477-727A-107

Query Match 84.2%; Score 117; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.3e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATYATQRLNFXLXXXXXNGPXLPTXYXVGSNTY 37
|||||
DB 3 NTATCATQRLTNFLVRRSHNLGPALPPTDVGSNY 37

RESULT 43
US-08-471-675A-29
Sequence 29, Application US/08471675A
Patent No. 5795861
GENERAL INFORMATION:
APPLICANT: Kolterman, Orville
TITLE OF INVENTION: METHODS FOR REGULATING
TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET, SUITE 4700
CITY: LOS ANGELES
STATE: CA
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,675A
FILING DATE: 05-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/302,069

FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 213/048
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
OTHER INFORMATION: disulfide bridge between the Cys
residues at positions 2 and 7;
OTHER INFORMATION: amidated Tyr at position 37
US-08-471-675A-29

Query Match 84.2%; Score 117; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.3e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATYATQRLNFXLXXXXXNGPXLPTXYXVGSNTY 37
|||||
DB 3 NTATCATQRLTNFLVRRSHNLGPALPPTDVGSNY 37

RESULT 44
US-08-892-549-33
Sequence 33, Application US/08892549
Patent No. 5998367
GENERAL INFORMATION:
APPLICANT: GAETA, Laura S. L. Et Al.
TITLE OF INVENTION: NOVEL AMYLIN AGONIST PEPTIDES AND
TITLE OF INVENTION: USES THEREFOR
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/892,549
FILING DATE: 14-JUL-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/447,849
FILING DATE: 23-MAY-1995
APPLICATION NUMBER: 07/794,266
FILING DATE: 19-NOV-1991
APPLICATION NUMBER: US 07/667,040
FILING DATE: 08-MAR-1991
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 227/006
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 2,7
OTHER INFORMATION: disulfide bridge between
OTHER INFORMATION: the Cys residues
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-892-549-33

Query Match 84.2%; Score 117; DB 1; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.3e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXKXGXPXLPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLTNFLVRSSHNGLPALPPTDVGNTY 37
|||||

RESULT 45
US-08-302-069A-28
Sequence 28, Application US/08302069A
Patent No. 6114304
GENERAL INFORMATION:
APPLICANT: KOLTERMAN, Orville G.
APPLICANT: YOUNG, Andrew A.
APPLICANT: RINK, Timothy J.
APPLICANT: BROWN, Kathleen Ann Keiting
TITLE OF INVENTION: METHODS FOR REGULATING
TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/302.069A
FILING DATE: 07-SEP-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 209/146
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 2,7
OTHER INFORMATION: disulfide bridge between

OTHER INFORMATION: the Cys residues
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
US-08-302-069A-28

Query Match 84.2%; Score 117; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.3e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXKXGXPXLPXTXVGSNTY 37
|||||
Db 3 NTATCATQRLTNFLVRSSHNGLPALPPTDVGNTY 37
|||||

RESULT 46
US-09-576-062A-28
Sequence 28, Application US/09576062A
Patent No. 6608029
GENERAL INFORMATION:
APPLICANT: KOLTERMAN, Orville G.
APPLICANT: YOUNG, Andrew A.
APPLICANT: RINK, Timothy J.
APPLICANT: BROWN, Kathleen Ann Keiting
TITLE OF INVENTION: METHODS FOR REGULATING
TITLE OF INVENTION: GASTROINTESTINAL MOTILITY
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/576.062A
FILING DATE: 22-May-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/302,069
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/118,381
FILING DATE: 07-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J.
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 209/146
TELEPHONE: 619/552-2200
TELEFAX: 213/955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
LOCATION: 37
OTHER INFORMATION: amidated Tyr (Tyrosinamide)
SEQUENCE DESCRIPTION: SEQ ID NO: 28:
US-09-576-062A-28

Query Match 84.2%; Score 117; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 1.3e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXKXGXPXLPXTXVGSNTY 37

[illegible]

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: Fast-SEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,727A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 214/005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
US-08-477-727A-88

Query Match 83.5%; Score 116; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 2e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFLXXXXXXNGPXLPTXXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY 36

RESULT 50
US-08-477-727A-98
Sequence 98, Application US/08477727A
Patent No. 5739106
GENERAL INFORMATION:
APPLICANT: Rink, Timothy
APPLICANT: Young, Andrew
APPLICANT: Beeley, Nigel
APPLICANT: Prickett, Kathryn
TITLE OF INVENTION: APPETITE REGULATING
COMPOSITIONS
NUMBER OF SEQUENCES: 108
CORRESPONDENCE ADDRESS:
ADDRESSEE: LYON & LYON
STREET: 633 WEST FIFTH STREET, SUITE 4700
CITY: LOS ANGELES
STATE: CA
COUNTRY: USA
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,727A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: DUFT, BRADFORD J
REGISTRATION NUMBER: 32,219
REFERENCE/DOCKET NUMBER: 214/005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-552-8400
TELEFAX: 619-552-0157
TELEX:
INFORMATION FOR SEQ ID NO: 98:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
US-08-477-727A-98

Query Match 83.5%; Score 116; DB 1; Length 36;
Best Local Similarity 68.6%; Pred. No. 2e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFLXXXXXXNGPXLPTXXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY 36

Search completed: January 4, 2006, 11:46:22
Job time : 48 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.6
Copyright (c) 1993 - 2006 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 4, 2006, 11:29:11 ; Search time 188 Seconds

(without alignments)

86.473 Million cell updates/sec

Title: US-09-445-517-14

Perfect score: 139

Sequence: 1 XXNTATATQRLXNLFXXXXXXGXPXLPXTXVGSNTY 37

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database : A_Geneseq_21.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

9: Geneseqp2005s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	118	84.9	36	2	AAR29207
2	118	84.9	36	2	AAR29201
3	118	84.9	36	2	AAR38811
4	118	84.9	36	2	AAR37789
5	118	84.9	36	2	AAR37787
6	118	84.9	36	2	AA22438
7	118	84.9	36	2	AA22444
8	118	84.9	36	2	AAW90149
9	118	84.9	36	2	AAW90141
10	118	84.9	36	3	AAAB18584
11	118	84.9	36	3	AAAB18577
12	118	84.9	36	5	ABBO5499
13	118	84.9	36	5	ABBO5491
14	118	84.9	36	8	AD136176
15	118	84.9	36	8	AD136183
16	118	84.9	36	8	ADOS1020
17	118	84.9	36	8	ADOS1027
18	118	84.9	36	9	ADV92867
19	118	84.9	36	9	ADV92846
20	118	84.9	36	9	ABEB17945
21	118	84.9	36	9	ABEB17966
22	118	84.9	37	2	AAR29208
23	118	84.9	37	2	AAR29206
24	118	84.9	37	2	AAR29203

25	118	84.9	37	2	AAR29210	Aar29210	Arg(18)Le
26	118	84.9	37	2	AAR29200	Aar29200	Arg(18)Pr
27	118	84.9	37	2	AAR37786	Aar37786	Pro25, Pr
28	118	84.9	37	2	AAR38812	Aar38812	Arg18, Le
29	118	84.9	37	2	AAR38814	Aar38814	Arg18, Le
30	118	84.9	37	2	AAR37788	Aar37788	Arg18, Pr
31	118	84.9	37	2	AAR38810	Aar38810	Leu23, Pr
32	118	84.9	37	2	AA22443	AA22443	Leu23, Pr
33	118	84.9	37	2	AA22445	AA22445	Arg18, Le
34	118	84.9	37	2	AA22435	AA22435	Arg18, Pr
35	118	84.9	37	2	AA22447	AA22447	Arg18, Le
36	118	84.9	37	2	AAW90140	AAW90140	Human amy
37	118	84.9	37	2	AAW90150	AAW90150	Human amy
38	118	84.9	37	2	AAW90152	AAW90152	Human amy
39	118	84.9	37	2	AAW90148	AAW90148	Human amy
40	118	84.9	37	3	AAAB18587	AAAB18587	Amino aci
41	118	84.9	37	3	AAAB18585	AAAB18585	Amino aci
42	118	84.9	37	3	AAAB18574	AAAB18574	Amino aci
43	118	84.9	37	3	AAAB18604	AAAB18604	Amino aci
44	118	84.9	37	3	AAAB18583	AAAB18583	Amino aci
45	118	84.9	37	5	ABBO5496	ABBO5496	Human amy
46	118	84.9	37	5	ABBO5490	ABBO5490	Human amy
47	118	84.9	37	5	ABBO5498	ABBO5498	Human amy
48	118	84.9	37	5	ABBO5500	ABBO5500	Human amy
49	118	84.9	37	5	ABBO5502	ABBO5502	Human amy
50	118	84.9	37	5	ABBO5487	ABBO5487	Human amy
51	118	84.9	37	8	AD136182	AD136182	Human amy
52	118	84.9	37	8	AD136173	AD136173	Human amy
53	118	84.9	37	8	AD136186	AD136186	Human amy
54	118	84.9	37	8	AD136184	AD136184	Human amy
55	118	84.9	37	8	ADOS1028	ADOS1028	Human amy
56	118	84.9	37	8	ADOS1030	ADOS1030	Human amy
57	118	84.9	37	8	ADOS1017	ADOS1017	Human amy
58	118	84.9	37	8	ADOS1026	ADOS1026	Human amy
59	118	84.9	37	9	ADV92838	ADV92838	Amylin pe
60	118	84.9	37	9	ADV92845	ADV92845	Amylin pe
61	118	84.9	37	9	ADV92866	ADV92866	Amylin pe
62	118	84.9	37	9	ADV92849	ADV92849	Amylin pe
63	118	84.9	37	9	ADV92847	ADV92847	Amylin pe
64	118	84.9	37	9	ABEB17944	ABEB17944	Human amy
65	118	84.9	37	9	ABEB17948	ABEB17948	Human amy
66	118	84.9	37	9	ABEB17965	ABEB17965	Human amy
67	118	84.9	37	9	ABEB17937	ABEB17937	Human amy
68	118	84.9	37	9	ABEB17946	ABEB17946	Human amy
69	117	84.2	36	9	ADV92839	ADV92839	Amylin pe
70	117	84.2	36	9	ABEB17938	ABEB17938	Human amy
71	117	84.2	37	2	AAR29222	Aar29222	Thr(13)Ar
72	117	84.2	37	2	AAR38826	Aar38826	Thr13,Arg
73	117	84.2	37	2	AA22459	AA22459	Thr13,Arg
74	117	84.2	37	2	AAW90164	AAW90164	Amylin ag
75	117	84.2	37	3	AAAB18603	AAAB18603	Amino aci
76	117	84.2	37	3	AAAB18599	AAAB18599	Amino aci
77	117	84.2	37	5	ABBO5514	ABBO5514	Amylin ag
78	117	84.2	37	8	AD136198	AD136198	Human amy
79	117	84.2	37	8	ADOS1042	ADOS1042	Human amy
80	117	84.2	37	9	ADV92861	ADV92861	Amylin pe
81	117	84.2	37	9	ABEB17960	ABEB17960	Human amy
82	116	83.5	36	2	AAR29204	Aar29204	Des-Lys(1
83	116	83.5	36	2	AAR29213	Aar29213	Des-Lys(1
84	116	83.5	36	2	AAR37791	Aar37791	Des-Lys(1
85	116	83.5	36	2	AAR37794	Aar37794	Des-Lys(1
86	116	83.5	36	2	AAR38817	Aar38817	Des-Lys(1
87	116	83.5	36	2	AAR37793	Aar37793	Des-Lys(1
88	116	83.5	36	2	AA22450	AA22450	Des-Lys(1
89	116	83.5	36	2	AA22442	AA22442	Des-Lys(1
90	116	83.5	36	2	AA22441	AA22441	Des-Lys(1
91	116	83.5	36	2	AAW90143	AAW90143	Human amy
92	116	83.5	36	2	AAW90145	AAW90145	Human amy
93	116	83.5	36	2	AAW90155	AAW90155	Human amy
94	116	83.5	36	3	AAAB18581	AAAB18581	Amino aci
95	116	83.5	36	3	AAAB18580	AAAB18580	Amino aci
96	116	83.5	36	3	AAAB18590	AAAB18590	Amino aci
97	116	83.5	36	5	ABBO5494	ABBO5494	Human amy

PT adipose tissue deficiency etc.
 XX Disclosure; Page 16; 19pp; English.
 CC Treatment of a patient with anorexia or related condition comprises
 CC admin. of amylin or an analogue in an amt. sufficient to increase the
 CC amylin level in the plasma of the patient. The pref. amylin analogues are
 CC given in AAR29197-222. Treating a patient deficient in adipose tissue
 CC comprises admin. of amylin or an analogue and/or insulin in an amt. and
 CC ratio sufficient to increase adipose tissue. Typical dosage units contain
 CC 0.1-10 mg of amylin analogue and 0.1-1 mg of insulin. (Updated on 25-MAR-
 CC 2003 to correct PN field.)
 XX Sequence 36 AA;
 SQ

Query Match 84.9%; Score 118; DB 2; Length 36;
 Best Local Similarity 68.6%; Pred. No. 3.6e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNFLXXXNXXGXPXLPXTXVGSNTY 37
 DB 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36

RESULT 3
 AAR38811
 ID AAR38811 standard; peptide; 36 AA.
 AC AAR38811;
 XX
 XX 25-MAR-2003 (revised)
 DT 07-SEP-1993 (first entry)
 XX
 XX (Des-Lys1), Leu23, Val26, Pro28 human amylin analogue.
 XX Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
 KW hyperglycaemic agent.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH Disulfide-bond 1..6
 FT Misc-difference 22 /note= "Leu replaces wild-type Phe"
 FT Misc-difference 24 /note= "Pro replaces wild-type Ala"
 FT Misc-difference 25 /note= "Val replaces wild-type Ile"
 FT Misc-difference 27 /note= "Pro replaces wild-type Ser"
 FT Modified-site 36 /note= "amidated"
 XX WO9310146-A1.
 XX 27-MAY-1993.
 PD
 XX 19-NOV-1992; 92WO-US009842.
 PR 19-NOV-1991; 91US-00794266.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Gaeta LSL, Jones H, Albrecht E;
 XX WPI; 1993-182488/22.
 XX New amylin agonist peptide(s) - used for treatment and prevention of
 PT hypoglycaemia and diabetes mellitus.
 XX Example 20; Fig 3 and Page 29; 43pp; English.
 XX This peptide is an example of amylin agonists of the invention which can

CC be used as hyperglycaemics. The peptide is an analogue of human amylin
 CC which mimics the effects of the wild-type hormone. Preferred peptides are
 CC used in admixture with insulin for the treatment of diabetes mellitus or
 CC with glucagon for the treatment of hypoglycaemic conditions. See AAR37779
 CC -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 36 AA;
 SQ

Query Match 84.9%; Score 118; DB 2; Length 36;
 Best Local Similarity 68.6%; Pred. No. 3.6e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNFLXXXNXXGXPXLPXTXVGSNTY 37
 DB 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36

RESULT 4
 AAR37789
 ID AAR37789 standard; peptide; 36 AA.
 AC AAR37789;
 XX
 XX 25-MAR-2003 (revised)
 DT 07-SEP-1993 (first entry)
 XX
 XX (Des-Lys1), Arg18, Pro25, Pro28 human amylin analogue.
 XX Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
 KW hyperglycaemic agent.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH Disulfide-bond 1..6
 FT Misc-difference 17
 FT Misc-difference 24 /note= "Arg replaces wild-type His"
 FT Misc-difference 27 /note= "Pro replaces wild-type Ala"
 FT Modified-site 36 /note= "Pro replaces wild-type Ser"
 FT /note= "amidated"
 XX WO9310146-A1.
 XX 27-MAY-1993.
 PD
 XX 19-NOV-1992; 92WO-US009842.
 PR 19-NOV-1991; 91US-00794266.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Gaeta LSL, Jones H, Albrecht E;
 XX WPI; 1993-182488/22.
 XX New amylin agonist peptide(s) - used for treatment and prevention of
 PT hypoglycaemia and diabetes mellitus.
 XX Claim 46; Fig 1 and Page 21; 43pp; English.
 XX This peptide is an example of amylin agonists of the invention which can
 CC be used as hyperglycaemics. The peptide is an analogue of human amylin
 CC which mimics the effects of the wild-type hormone. Preferred peptides are
 CC used in admixture with insulin for the treatment of diabetes mellitus or
 CC with glucagon for the treatment of hypoglycaemic conditions. See AAR37779
 CC -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 36 AA;
 SQ

```
Query Match      84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36

RESULT 5
AAR37787
ID AAR37787 standard; peptide; 36 AA.
XX
AC AAR37787;
XX
XX 25-MAR-2003 (revised)
DT 07-SEP-1993 (first entry)
XX
XX (des-Lys1), Pro25, Pro28-human amylin analogue.
DE
XX Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
KW hypoglycaemic agent.
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Disulfide-bond 1..6
FT Misc-difference 24 /note= "Pro replaces wild-type Ala"
FT Misc-difference 27 /note= "Pro replaces wild-type Ser"
FT Modified-site 36 /note= "amidated"
FT
XX WO9310146-A1.
XX
XX 27-MAY-1993.
XX
XX 19-NOV-1992; 92WO-US009842.
XX
XX 19-NOV-1991; 91US-00794266.
XX (AMYL-) AMYLIN PHARM INC.
XX Gaeta LSL, Jones H, Albrecht E;
XX WPI; 1993-182488/22.
XX New amylin agonist peptide(s) - used for treatment and prevention of
XX hypoglycaemia and diabetes mellitus.
XX Example 9; Fig 1 and Page 20; 43pp; English.
XX
XX This peptide is an example of amylin agonists of the invention which can
XX be used as hyperglycaemics. The peptide is an analogue of human amylin
XX which mimics the effects of the wild-type hormone. Preferred peptides are
XX used in admixture with insulin for the treatment of diabetes mellitus or
XX with glucagon for the treatment of hypoglycaemic conditions. See AAR37779
XX -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN
XX field.)
XX
XX Sequence 36 AA;
Query Match      84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 36
```

```
RESULT 6
AAY22438
ID AAY22438 standard; peptide; 36 AA.
XX
XX AAY22438;
AC
XX 28-SEP-1999 (first entry)
DT
XX
XX Des-Lys1, Arg18, Pro25, Pro28 amylin analogue.
DE
XX Amylin agonist; human; insulin; diabetes; post-prandial glucose level;
KW therapy; mutein.
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Disulfide-bond 1..6
FT Misc-difference 17 /label= H18R
FT Misc-difference 24 /label= A25P
FT Misc-difference 27 /label= S28P
FT
XX WO9344822-A1.
XX
XX 15-JUL-1999.
XX
XX 09-JAN-1998; 98WO-US000288.
XX
XX 09-JAN-1998; 98WO-US000288.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX L'italian J, Musunuri S, Ruby C;
XX WPI; 1999-458254/38.
XX Stabilized liquid formulation for treatment of insulin-dependent diabetes
XX mellitus.
XX Disclosure; Page; 71pp; English.
XX
XX This sequence represents a human amylin analogue, that acts as a amylin
XX agonist. The invention relates to a liquid pharmaceutical formulation
XX (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10%
XX carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or
XX glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with
XX insulin, for treatment of diabetes, specifically to reduce post-prandial
XX increases in glucose levels of the blood. In these formulations, (I) is
XX stabilised, especially against deamidation and peptide bond hydrolysis
XX for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without
XX addition of a separate stabiliser. They also retain short-term (up to 24
XX hr) stability when combined with insulin, allowing both agents to be
XX administered together, reducing the number of injections required. Note:
XX This sequence was created by the indexer from information given in the
XX specification
XX
XX Sequence 36 AA;
Query Match      84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNFXLXXXXXNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36

RESULT 7
AAY22444
ID AAY22444 standard; peptide; 36 AA.
```

XX AAY22444;
 AC 28-SEP-1999 (first entry)
 XX Des-Lys1, Leu23, Pro25, Val26, Pro28 amylin analogue.
 DT Amylin agonist; human; insulin; diabetes; post-prandial glucose level;
 DE therapy; mutein.
 XX Homo sapiens.
 KW Synthetic.
 XX Key Location/Qualifiers
 FH Disulfide-bond 1..6
 FT Misc-difference 22 /label= F23L
 FT Misc-difference 24 /label= A25P
 FT Misc-difference 25 /label= I26V
 FT Misc-difference 27 /label= S28P
 FT WO9934822-A1.
 FN 15-JUL-1999.
 XX 09-JAN-1998; 98WO-US000288.
 XX 09-JAN-1998; 98WO-US000288.
 XX (AMYL-) AMYLIN PHARM INC.
 XX L'italian J, Musunuri S, Ruby C;
 XX WPI; 1999-458254/38.
 XX Stabilized liquid formulation for treatment of insulin-dependent diabetes mellitus.
 XX Disclosure; Page; 71pp; English.
 XX This sequence represents a human amylin analogue, that acts as a amylin agonist. The invention relates to a liquid pharmaceutical formulation (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10% carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with insulin, for treatment of diabetes, specifically to reduce post-prandial increases in glucose levels of the blood. In these formulations, (I) is stabilised, especially against deamidation and peptide bond hydrolysis for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without addition of a separate stabiliser. They also retain short-term (up to 24 hr) stability when combined with insulin, allowing both agents to be administered together, reducing the number of injections required. Note: This sequence was created by the indexer from information given in the specification
 XX Sequence 36 AA;
 SQ
 Query Match 84.9%; Score 118; DB 2; Length 36;
 Best Local Similarity 68.6%; Pred. No. 3.6e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXXNGPXLPTXVGSNTY 37
 |||||
 DB 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36
 |||||
 RESULT 8
 AAW90149
 ID AAW90149 standard; peptide; 36 AA.
 XX

AC AAW90149;
 XX 15-MAR-1999 (first entry)
 DT Human amylin agonist peptide des-1-Lys23-Leu25-Pro26-Val28-Pro-amylin.
 DE Amylin; human; agonist; gastritis; gastric ulceration; treatment;
 KW non-steroidal anti-inflammatory agent; NSAID; intravenous; subcutaneous;
 KW pain; fever; inflammation; arthritis; hypercoagulation.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH Disulfide-bond 1..6
 FT WO9850059-A1.
 FN 12-NOV-1998.
 PD 06-MAY-1998; 98WO-US009089.
 PF 06-MAY-1997; 97US-00851965.
 PR (AMYL-) AMYLIN PHARM INC.
 PA Young A, Gedulin B, Beynon GW;
 XX WPI; 1999-059652/05.
 XX Method for treating or preventing gastritis - comprises administering
 PT amylin or amylin agonist, except calcitonin.
 XX Claim 6; Page 42; 48pp; English.
 XX This invention relates to a method for treating or preventing gastritis
 CC or gastric ulceration which comprises administering amylin or an amylin
 CC agonist. Amylin administration is not carried out intra-
 CC cerebroventricularly. The specification describes a method for treating
 CC or preventing a condition for which a non-steroidal anti-inflammatory
 CC agent (NSAID) is indicated, comprising administering amylin or amylin
 CC agonist, which is not calcitonin, together with NSAID and also a
 CC composition comprising an amylin or an amylin agonist or their salts,
 CC except calcitonin and a NSAID in a carrier. The amylin composition is
 CC used to treat humans by administering it subcutaneously, intravenously or
 CC by nasal, oral, pulmonary, transdermal and buccal routes. The method is
 CC also used to treat pain, fever, inflammation, arthritis, hypercoagulation
 CC and other condition where an NSAID would be indicated. The present
 CC sequence is an example of an agonist used in the method
 XX Sequence 36 AA;
 SQ
 Query Match 84.9%; Score 118; DB 2; Length 36;
 Best Local Similarity 68.6%; Pred. No. 3.6e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXXNGPXLPTXVGSNTY 37
 |||||
 DB 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36
 |||||
 RESULT 9
 AAW90141
 ID AAW90141 standard; peptide; 36 AA.
 XX
 AC AAW90141;
 XX 15-MAR-1999 (first entry)
 DT Human amylin agonist peptide des-1-Lys18-Arg25,28-Pro-amylin.
 DE Amylin; human; agonist; gastritis; gastric ulceration; treatment;
 KW non-steroidal anti-inflammatory agent; NSAID; intravenous; subcutaneous;

KW pain; fever; inflammation; arthritis; hypercoagulation.

XX Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers

FT Disulfide-bond 1..6

XX WO9850059-A1.

XX 12-NOV-1998.

XX 06-MAY-1998; 98WO-US009089.

XX 06-MAY-1997; 97US-00851965.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B, Beynon GW;

XX WPI; 1999-059652/05.

XX Method for treating or preventing gastritis - comprises administering amylin or amylin agonist, except calcitonin.

XX Claim 6; Page 42; 48pp; English.

XX This invention relates to a method for treating or preventing gastritis or gastric ulceration which comprises administering amylin or an amylin agonist. Amylin administration is not carried out intracerebroventricularly. The specification describes a method for treating or preventing a condition for which a non-steroidal anti-inflammatory agent (NSAID) is indicated, comprising administering amylin or amylin agonist, which is not calcitonin, together with NSAID and also a composition comprising an amylin or an amylin agonist or their salts, except calcitonin and a NSAID in a carrier. The amylin composition is used to treat humans by administering it subcutaneously, intravenously or by nasal, oral, pulmonary, transdermal and buccal routes. The method is also used to treat pain, fever, inflammation, arthritis, hypercoagulation and other condition where an NSAID would be indicated. The present sequence is an example of an agonist used in the method

XX Sequence 36 AA;

Query Match 84.9%; Score 118; DB 2; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFLXXXXXXNGPXLPTXVGSNTY 37

DB 2 NTATCATQRLANFLVRSSNNFGPLPSTNVGSNTY 36

RESULT 10

AAAB18584

ID AAB18584 standard; peptide; 36 AA.

XX AAB18584;

DT 15-JAN-2001 (first entry)

DE Amino acid sequence of an amylin agonist analogue compound.

XX Amylin agonist; amylin; gastric motility; gastric emptying;
KW postprandial dumping syndrome; postprandial hyperglycemia;
KW gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm;
KW acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.

XX Synthetic.

XX Key Location/Qualifiers

FT Disulfide-bond 1..6

XX Modified-site 36

/note= "amidated residue"

XX US6114304-A.

XX 05-SEP-2000.

XX 07-SEP-1994; 94US-00302069.

XX 07-SEP-1993; 93US-00118381.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Rink TJ, Brown KAK, Kolterman OG;

XX WPI; 2000-601336/57.

XX Treating gastrointestinal disorder e.g. spasm by reducing gastric motility or delaying gastric emptying, postprandial dumping syndrome or postprandial hyperglycemia, by administering amylin or amylin agonist.

XX Disclosure; Col 43-44; 50pp; English.

XX The present sequence represents an amylin agonist analogue compound. Amylin or amylin agonists are administered for reducing gastric motility or delaying gastric emptying, and for treating postprandial dumping syndrome or postprandial hyperglycemia, by inducing amylin activity, in a mammal. The peptides are used to reduce gastric motility or for delaying gastric emptying in a mammal undergoing gastrointestinal diagnostic procedures, such as radiological examination or magnetic resonance imaging. They are also used for reducing gastric motility in gastrointestinal disorder, especially spasm, which is associated with a disorder of acute diverticulitis or disorders of biliary tract or sphincter of oddi. They are also used to treat postprandial dumping syndrome or postprandial hyperglycemia

XX Sequence 36 AA;

Query Match 84.9%; Score 118; DB 3; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFLXXXXXXNGPXLPTXVGSNTY 37

DB 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 11

AAAB18577

ID AAB18577 standard; peptide; 36 AA.

XX AAB18577;

XX 15-JAN-2001 (first entry)

XX Amino acid sequence of an amylin agonist analogue compound.

XX Amylin agonist; amylin; gastric motility; gastric emptying;
KW postprandial dumping syndrome; postprandial hyperglycemia;
KW gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm;
KW acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.

XX Synthetic.

XX Key Location/Qualifiers

FT Disulfide-bond 1..6

XX Modified-site 36

XX /note= "amidated residue"

XX US6114304-A.

XX 05-SEP-2000.

XX 07-SEP-1994; 94US-00302069.

XX 07-SEP-1993; 93US-00118381.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Rink TJ, Brown KAK, Kolterman OG;
XX WPI; 2000-601336/57.
XX Treating gastrointestinal disorder e.g. spasm by reducing gastric
XX motility or delaying gastric emptying, postprandial dumping syndrome or
XX postprandial hyperglycemia, by administering amylin or amylin agonist.
XX Disclosure; Col 39-40; 50pp; English.
XX The present sequence represents an amylin agonist analogue compound.
XX Amylin or amylin agonists are administered for reducing gastric motility
XX or delaying gastric emptying, and for treating postprandial dumping
XX syndrome or postprandial hyperglycemia, by inducing amylin activity, in a
XX mammal. The peptides are used to reduce gastric motility or for delaying
XX gastric emptying in a mammal undergoing gastrointestinal diagnostic
XX procedures, such as radiological examination or magnetic resonance
XX imaging. They are also used for reducing gastric motility in
XX gastrointestinal disorder, especially spasm, which is associated with a
XX disorder of acute diverticulitis or disorders of biliary tract or
XX sphincter of oddi. They are also used to treat postprandial dumping
XX syndrome or postprandial hyperglycemia
XX Sequence 36 AA;
Query Match 84.9%; Score 118; DB 3; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATCATQRLXNFKLXXXXXKXGPKLPTXVGSNTY 37
Db 2 NTATCATQRLANFLVRSSNFGPILPSTNVGSNTY 36
RESULT 12
ABB05499
ID ABB05499 standard; peptide; 36 AA.
AC ABB05499;
XX 19-APR-2002 (first entry)
XX Human amylin agonist des-llys23Leu25Pro26Val28Pro-h-amylin.
XX Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
XX liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
XX citrate; glutamate; buffer; antidiabetic; type II diabetes.
XX Homo sapiens.
XX Synthetic.
XX US2001043934-A1.
XX 22-NOV-2001.
XX 09-JAN-1998; 98US-00005262.
XX 08-JAN-1997; 97US-0035140P.
XX (LITA/) L'ITALIEN J.
XX (MUSU/) MUSUNURI S.
XX (RUBY/) RUBY K.
XX L'italien J, Musunuri S, Ruby K;
XX WPI; 2002-163554/21.
XX New pharmaceutical formulation useful for treating patients with type II

PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
XX a buffer.
XX Disclosure; Page: 19pp; English.
XX The present invention describes a liquid pharmaceutical formulation (A)
XX comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
XX polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or a
XX glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
XX commercial package containing the liquid pharmaceutical formulation (A).
XX The package comprises a borosilicate glass vial having an open end, a
XX stopper for multise compatible with the amylin and/or amylin agonist,
XX fixed in the open end of the vial and an aluminum band to retain the
XX stopper in the far end of the vial. The package also comprises a
XX cartridge for use in a pen injector. (A) has antidiabetic activity and
XX can be used in the treatment of patients with type II diabetes. The
XX formulation comprises amylin agonist which is biologically active, has a
XX reduced tendency to form aggregates in water or at a pressure of greater
XX than 2 psi and has a reduced tendency to precipitate in the presence of
XX NaCl compared to human amylin. The formulation maintains stability upon
XX storage under refrigerated or room-temperature conditions. The
XX formulation retains short-term mixing compatibility with insulin and
XX results in improved stability of the hormone and the patients no longer
XX need to refrigerate the vial of insulin in use. The present sequence
XX represents a human amylin peptide analogue, which can be used as an
XX amylin agonist in the present invention, N.B. The present sequence is not
XX given in the present specification but is derived from the 37 amino acid
XX human amylin as stated in the invention
XX Sequence 36 AA;
Query Match 84.9%; Score 118; DB 5; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATCATQRLXNFKLXXXXXKXGPKLPTXVGSNTY 37
Db 2 NTATCATQRLANFLVHSSNNGPVLPTNVGSNTY 36
RESULT 13
ABB05491
ID ABB05491 standard; peptide; 36 AA.
XX ABB05491;
XX 19-APR-2002 (first entry)
XX Human amylin agonist des-llys18arg25,28Pro-h-amylin.
XX Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
XX liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
XX citrate; glutamate; buffer; antidiabetic; type II diabetes.
XX Homo sapiens.
XX Synthetic.
XX US2001043934-A1.
XX 22-NOV-2001.
XX 09-JAN-1998; 98US-00005262.
XX 08-JAN-1997; 97US-0035140P.
XX (LITA/) L'ITALIEN J.
XX (MUSU/) MUSUNURI S.
XX (RUBY/) RUBY K.
XX L'italien J, Musunuri S, Ruby K;
XX WPI; 2002-163554/21.
XX

PT New pharmaceutical formulation useful for treating patients with type II
PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
PT a buffer.
XX
XX Disclosure; Page; 19pp; English.
XX
XX The present invention describes a liquid pharmaceutical formulation (A)
CC comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
CC polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or
CC glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
CC commercial package containing the liquid pharmaceutical formulation (A).
CC The package comprises a borosilicate glass vial having an open end, a
CC stopper for multiuse compatible with the amylin and/or amylin agonist
CC fixed in the open end of the vial and an aluminum band to retain the
CC stopper in the far end of the vial. The package also comprises a
CC cartridge for use in a pen injector. (A) has antidiabetic activity and
CC can be used in the treatment of patients with type II diabetes. The
CC formulation comprises amylin agonist which is biologically active, has a
CC reduced tendency to form aggregates in water or at a pressure of greater
CC than 2 psi and has a reduced tendency to precipitate in the presence of
CC NaCl compared to human amylin. The formulation maintains stability upon
CC storage under refrigerated or room-temperature conditions. The
CC formulation retains short-term mixing compatibility with insulin and
CC results in improved stability of the hormone and the patients no longer
CC need to refrigerate the vial of insulin in use. The present sequence
CC represents a human amylin peptide analogue, which can be used as an
CC amylin agonist in the present invention. N.B. The present sequence is not
CC given in the present specification but is derived from the 37 amino acid
CC human amylin as stated in the invention
XX
XX Sequence 36 AA;
XX
XX Query Match 84.9%; Score 118; DB 5; Length 36;
XX Best Local Similarity 68.6%; Pred. No. 3.6e-14;
XX Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFLXXXXXKXGXPXLPXTXVGSNTY 37
Db 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36
RESULT 14
ADI36176
ID ADI36176 standard; peptide; 36 AA.
AC ADI36176;
XX
XX 15-APR-2004 (first entry)
XX Human amylin agonist analogue #5.
XX Gastric motility; gastric emptying; amylin agonist; therapy; diagnosis;
XX antidiabetic; hypoglycaemia; human.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 1..6
FT Modified-site 36
FT /note= "Amidated tyrosine"
XX
XX US6608029-B1.
XX
XX 19-AUG-2003.
XX
XX 22-MAY-2000; 2000US-00576062.
XX
XX 07-SEP-1993; 93US-00118381.
XX 07-SEP-1994; 94US-00302069.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA, Rink TJ, Keating Brown KA;
XX WPI; 2004-118064/12.
XX
XX Reducing gastric motility or delaying gastric emptying in a mammal,
XX useful for treating post-prandial hyperglycemia, comprises administering
XX an amylin or an amylin agonist.
XX Disclosure; SEQ ID NO 13; 5lpp; English.
XX
XX The present invention is directed to novel methods for reducing gastric
XX motility and delaying gastric emptying, comprising the administration of
XX an amylin or an amylin agonist. The invention is useful for reducing
XX gastric motility and delaying gastric emptying for therapeutic and
XX diagnostic purposes. The invention is also useful for treating conditions
XX associated with elevated, inappropriate or undesired post-prandial blood
XX glucose levels and treating ingestion of a toxin. The present sequence is
XX human amylin agonist analogue.
XX
XX Sequence 36 AA;
XX
XX Query Match 84.9%; Score 118; DB 8; Length 36;
XX Best Local Similarity 68.6%; Pred. No. 3.6e-14;
XX Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFLXXXXXKXGXPXLPXTXVGSNTY 37
Db 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36
RESULT 15
ADI36183
ID ADI36183 standard; peptide; 36 AA.
XX
XX ADI36183;
XX
XX 15-APR-2004 (first entry)
XX Human amylin agonist analogue #12.
XX Gastric motility; gastric emptying; amylin agonist; therapy; diagnosis;
XX antidiabetic; hypoglycaemia; human.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 1..6
FT Modified-site 36
FT /note= "Amidated tyrosine"
XX
XX US6608029-B1.
XX
XX 19-AUG-2003.
XX
XX 22-MAY-2000; 2000US-00576062.
XX
XX 07-SEP-1993; 93US-00118381.
XX 07-SEP-1994; 94US-00302069.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA, Rink TJ, Keating Brown KA;
XX WPI; 2004-118064/12.
XX
XX Reducing gastric motility or delaying gastric emptying in a mammal,
XX useful for treating post-prandial hyperglycemia, comprises administering
XX an amylin or an amylin agonist.
XX Disclosure; SEQ ID NO 13; 5lpp; English.
XX
XX The present invention is directed to novel methods for reducing gastric
XX motility and delaying gastric emptying, comprising the administration of
XX an amylin or an amylin agonist. The invention is useful for reducing

XX
XX WPI; 2004-118064/12.
XX
XX Reducing gastric motility or delaying gastric emptying in a mammal,
XX useful for treating post-prandial hyperglycemia, comprises administering
XX an amylin or an amylin agonist.
XX Disclosure; SEQ ID NO 6; 5lpp; English.
XX
XX The present invention is directed to novel methods for reducing gastric
XX motility and delaying gastric emptying, comprising the administration of
XX an amylin or an amylin agonist. The invention is useful for reducing
XX gastric motility and delaying gastric emptying for therapeutic and
XX diagnostic purposes. The invention is also useful for treating conditions
XX associated with elevated, inappropriate or undesired post-prandial blood
XX glucose levels and treating ingestion of a toxin. The present sequence is
XX human amylin agonist analogue.
XX
XX Sequence 36 AA;
XX
XX Query Match 84.9%; Score 118; DB 8; Length 36;
XX Best Local Similarity 68.6%; Pred. No. 3.6e-14;
XX Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Qy 3 NTATXATQRLXNFLXXXXXKXGXPXLPXTXVGSNTY 37
Db 2 NTATCATQRLANFLVRSSNNFGPILPSTNVGSNTY 36
RESULT 15
ADI36183
ID ADI36183 standard; peptide; 36 AA.
XX
XX ADI36183;
XX
XX 15-APR-2004 (first entry)
XX Human amylin agonist analogue #12.
XX Gastric motility; gastric emptying; amylin agonist; therapy; diagnosis;
XX antidiabetic; hypoglycaemia; human.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 1..6
FT Modified-site 36
FT /note= "Amidated tyrosine"
XX
XX US6608029-B1.
XX
XX 19-AUG-2003.
XX
XX 22-MAY-2000; 2000US-00576062.
XX
XX 07-SEP-1993; 93US-00118381.
XX 07-SEP-1994; 94US-00302069.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA, Rink TJ, Keating Brown KA;
XX WPI; 2004-118064/12.
XX
XX Reducing gastric motility or delaying gastric emptying in a mammal,
XX useful for treating post-prandial hyperglycemia, comprises administering
XX an amylin or an amylin agonist.
XX Disclosure; SEQ ID NO 13; 5lpp; English.
XX
XX The present invention is directed to novel methods for reducing gastric
XX motility and delaying gastric emptying, comprising the administration of
XX an amylin or an amylin agonist. The invention is useful for reducing


```
Query Match      84.9%; Score 118; DB 8; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFXLXXXXXNNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 18
ADV92867
ID ADV92867 standard; peptide; 36 AA.
XX
AC ADV92867;
XX
DT 24-MAR-2005 (first entry)
XX
DE Amylin peptide amino acid sequence - SEQ ID 287.
XX
KW delivery mechanism; viral infections; virucide; bacterial infection;
KW antibacterial; amylin.
XX
OS Unidentified.
XX
FN WO2005000222-A2.
XX
PD 06-JAN-2005.
XX
PF 28-MAY-2004; 2004WO-US017456.
XX
PR 30-MAY-2003; 2003US-0474233P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Ong JTH, Stetsko G, Jennings R;
XX
DR WPI; 2005-075434/08.
XX
CC The invention comprises a pharmaceutical composition for transmucosal
CC administration of a bioactive peptide/protein (e.g. exendin, PYY, GLP-1
CC or amylin peptide/protein) of interest. The composition of the invention
CC is useful for the transmucosal administration of a bioactive peptide or
CC protein and is useful for treating or preventing viral or bacterial
CC diseases in humans. The present amino acid sequence represents an amylin
CC peptide that is used in the exemplification of the invention.
XX
SQ Sequence 36 AA;

Query Match      84.9%; Score 118; DB 9; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFXLXXXXXNNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 20
AEBI7945
ID AEBI7945 standard; peptide; 36 AA.
XX
AC AEBI7945;
XX
DT 08-SEP-2005 (first entry)
XX
DE Human amylin agonist, pramlintide peptide SEQ ID NO: 23.
XX
KW Pharmaceutical; weight loss; obesity; anorectic; nutritional disorder;
KW hyperglycemia; antidiabetic; metabolic disorder; antilipemic;
KW diabetes mellitus; metabolic disorder; glucose regulating peptide;
KW amylin agonist; pramlintide.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Disulfide-bond 2..7
FT Modified-site 36
FT /note= "Amidated"
XX
FN US2005143303-A1.
XX
DT 30-JUN-2005.
XX
PF 18-NOV-2004; 2004US-00991597.

Query Match      84.9%; Score 118; DB 9; Length 36;
Best Local Similarity 68.6%; Pred. No. 3.6e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFXLXXXXXNNGPXLPTXVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
Db 2 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 36

RESULT 19
ADV92846
ID ADV92846 standard; peptide; 36 AA.
XX
AC ADV92846;
XX
DT 24-MAR-2005 (first entry)
XX
DE Amylin peptide amino acid sequence - SEQ ID 266.
```



```
CC 2003 to correct PN field.)
XX
SQ Sequence 37 AA;

Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFXLXXXXXNGPXLPTXTVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
DB 3 NTATCATQRLANFLVRSNNLGPVLPSTNVGSNTY 37

RESULT 23
AAR29206
ID AAR29206 standard; protein; 37 AA.
XX
AC AAR29206;
XX
XX 25-MAR-2003 (revised)
DT 20-APR-1993 (first entry)
XX
XX Leu(23)Pro(25)Val(26)Pro(28)-h-amylin for treating anorexia.
XX
XX Anorexia; cachexia; adipose; amylin.
XX
XX Homo sapiens.
XX
XX WO9220367-A1.
XX
XX 26-NOV-1992.
XX
XX 23-MAY-1992; 92WO-US004357.
XX
XX 24-MAY-1991; 91US-00704995.
XX
XX 03-APR-1992; 92US-00862500.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Rink TJ, Young AA;
XX
XX WPI; 1992-415470/50.
XX
XX Use of amylin and opt. insulin for treating anorexia - increases plasma
XX amylin and/or insulin levels, also for treating cachexia conditions,
XX adipose tissue deficiency etc.
XX
XX Disclosure; Page 16; 19pp; English.
XX
XX Treatment of a patient with anorexia or related condition comprises
XX admin. of amylin or an analogue in an amt. sufficient to increase the
XX amylin level in the plasma of the patient. The pref. amylin analogues are
XX given in AAR29197-222. Treating a patient deficient in adipose tissue
XX comprises admin. of amylin or an analogue and/or insulin in an amt. and
XX ratio sufficient to increase adipose tissue. Typical dosage units contain
XX 0.1-10 mg of amylin analogue and 0.1-1 mg of insulin. (Updated on 25-MAR-
XX 2003 to correct PN field.)
XX
XX Rink TJ, Young AA;
XX
XX WPI; 1992-415470/50.
XX
XX 23-MAY-1992; 92WO-US004357.
XX
XX 24-MAY-1991; 91US-00704995.
XX
XX 03-APR-1992; 92US-00862500.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Rink TJ, Young AA;
XX
XX WPI; 1992-415470/50.
XX
XX Use of amylin and opt. insulin for treating anorexia - increases plasma
XX amylin and/or insulin levels, also for treating cachexia conditions,
XX adipose tissue deficiency etc.
XX
XX Disclosure; Page 16; 19pp; English.
XX
XX Treatment of a patient with anorexia or related condition comprises
XX admin. of amylin or an analogue in an amt. sufficient to increase the
XX amylin level in the plasma of the patient. The pref. amylin analogues are
XX given in AAR29197-222. Treating a patient deficient in adipose tissue
XX comprises admin. of amylin or an analogue and/or insulin in an amt. and
XX ratio sufficient to increase adipose tissue. Typical dosage units contain
XX 0.1-10 mg of amylin analogue and 0.1-1 mg of insulin. (Updated on 25-MAR-
XX 2003 to correct PN field.)
XX
XX Sequence 37 AA;

Query Match      84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATXATQRLXNFXLXXXXXNGPXLPTXTVGSNTY 37
    ||||| ||||| ||||| ||||| ||||| |||||
DB 3 NTATCATQRLANFLVHSSNFGPVLPTNVGSNTY 37

RESULT 25
AAR29210
ID AAR29210 standard; protein; 37 AA.
XX
XX AAR29210;
XX
XX 25-MAR-2003 (revised)
DT 20-APR-1993 (first entry)
XX
XX Arg(18)Leu(23)Pro(25,28)-h-amylin for treating anorexia.
XX
XX Anorexia; cachexia; adipose; amylin.
XX
XX Homo sapiens.
XX
XX WO9220367-A1.
XX
XX 26-NOV-1992.
XX
XX 23-MAY-1992; 92WO-US004357.
XX
XX
```


Best Local Similarity 68.6%; Pred. No. 3.7e-14; Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNLFVHSSNNFGPILPSTNVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37
|||||

RESULT 28
AAR38812
ID AAR38812 standard; peptide; 37 AA.
XX
AC AAR38812;
XX
DT 25-MAR-2003 (revised)
DT 07-SEP-1993 (first entry)
XX
DE Arg18, Leu23, Pro25, Val26, Pro28 human amylin analogue.
XX
KW Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
KW hyperglycaemic agent.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Disulfide-bond 2. .7
FT Misc-difference 18 /note= "Arg replaces wild-type His"
FT Misc-difference 23 /note= "Leu replaces wild-type Phe"
FT Misc-difference 25 /note= "Pro replaces wild-type Ala"
FT Misc-difference 26 /note= "Pro replaces wild-type Ile"
FT Misc-difference 28 /note= "Val replaces wild-type Ser"
FT Modified-site 37 /note= "amidated"

WO9310146-A1.
27-MAY-1993.
19-NOV-1992; 92WO-US009842.
19-NOV-1991; 91US-00794266.
(AMYL-) AMYLIN PHARM INC.
Gaeta LSL, Jones H, Albrecht E;
WPI; 1993-182488/22.
New amylin agonist peptide(s) - used for treatment and prevention of hypoglycaemia and diabetes mellitus.
Example 21; Fig 3 and Page 29; 43pp; English.
This peptide is an example of amylin agonists of the invention which can be used as hyperglycaemics. The peptide is an analogue of human amylin which mimics the effects of the wild-type hormone. Preferred peptides are used in admixture with insulin for the treatment of diabetes mellitus or with glucagon for the treatment of hypoglycaemic conditions. See AAR37779 -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN field.)
Sequence 37 AA;
Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14; Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNLFVHSSNNFGPILPSTNVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVHSSNNFGPILPSTNVGSNTY 37
|||||

RESULT 30
AAR37788
ID AAR37788 standard; peptide; 37 AA.
XX
AC AAR37788;
XX
DT 25-MAR-2003 (revised)
DT 07-SEP-1993 (first entry)
XX
DE Arg18, Leu23, Pro25, Val26, Pro28 human amylin analogue.
XX
KW Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
KW hyperglycaemic agent.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Disulfide-bond 2. .7
FT Misc-difference 18 /note= "Arg replaces wild-type His"
FT Misc-difference 23 /note= "Leu replaces wild-type Phe"
FT Misc-difference 25 /note= "Pro replaces wild-type Ala"
FT Misc-difference 26 /note= "Pro replaces wild-type Ile"
FT Misc-difference 28 /note= "Val replaces wild-type Ser"
FT Modified-site 37 /note= "amidated"

Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37
|||||

RESULT 29
AAR38814
ID AAR38814 standard; peptide; 37 AA.
XX
AC AAR38814;
XX
DT 25-MAR-2003 (revised)
DT 07-SEP-1993 (first entry)
XX
DE Arg18, Leu23, Pro25, Pro28-human amylin analogue.

XX
KW Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon;
KW hyperglycaemic agent.
XX
OS Homo sapiens.

XX
FH Key Location/Qualifiers
FT Disulfide-bond 2. .7
FT Misc-difference 18 /note= "Arg replaces wild-type His"
FT Misc-difference 23 /note= "Leu replaces wild-type Phe"
FT Misc-difference 25 /note= "Pro replaces wild-type Ala"
FT Misc-difference 28 /note= "Pro replaces wild-type Ser"
FT Modified-site 37 /note= "amidated"

WO9310146-A1.
27-MAY-1993.
19-NOV-1992; 92WO-US009842.
19-NOV-1991; 91US-00794266.
(AMYL-) AMYLIN PHARM INC.
Gaeta LSL, Jones H, Albrecht E;
WPI; 1993-182488/22.
New amylin agonist peptide(s) - used for treatment and prevention of hypoglycaemia and diabetes mellitus.
Example 23; Fig 3 and Page 29; 43pp; English.

XX
CC This peptide is an example of amylin agonists of the invention which can be used as hyperglycaemics. The peptide is an analogue of human amylin which mimics the effects of the wild-type hormone. Preferred peptides are used in admixture with insulin for the treatment of diabetes mellitus or with glucagon for the treatment of hypoglycaemic conditions. See AAR37779 -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN field.)
Sequence 37 AA;
Query Match 84.9%; Score 118; DB 2; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14; Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 NTATCATQRLXNLFVHSSNNLGPILPSTNVGSNTY 37
|||||
Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37
|||||

RESULT 30
AAR37788

AAR37788 standard; peptide; 37 AA.
 AAR37788;
 25-MAR-2003 (revised)
 07-SEP-1993 (first entry)
 Arg18, Pro25, Pro28 human amylin analogue.
 Hypoglycaemia; insulin; pancreatic amyloid; diabetes mellitus; glucagon; hyperglycaemic agent.
 Homo sapiens.
 Key Location/Qualifiers
 Disulfide-bond 2..7
 Misc-difference 23 /note= "Leu replaces wild-type Phe"
 Misc-difference 25 /note= "Pro replaces wild-type Ala"
 Misc-difference 26 /note= "Val replaces wild-type Ile"
 Misc-difference 28 /note= "Pro replaces wild-type Ser"
 Modified-site 37 /note= "amidated"
 WO9310146-A1.
 27-MAY-1993.
 19-NOV-1992; 92WO-US009842.
 19-NOV-1991; 91US-00794266.
 (AMYL-) AMYLIN PHARM INC.
 Gaeta LSL, Jones H, Albrecht E;
 WPI; 1993-182488/22.
 New amylin agonist peptide(s) - used for treatment and prevention of hypoglycaemia and diabetes mellitus.
 Example 19; Fig 3 and Page 29; 43pp; English.
 This peptide is an example of amylin agonists of the invention which can be used as hyperglycaemics. The peptide is an analogue of human amylin which mimics the effects of the wild-type hormone. Preferred peptides are used in admixture with insulin for the treatment of diabetes mellitus or with glucagon for the treatment of hypoglycaemic conditions. See AAR37779 -R37795 and AAR38809-R38826. (Updated on 25-MAR-2003 to correct PN field.)
 Query Match 84.9%; Score 118; DB 2; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNPLXXXXXXNGPXLPTXVGSNTY 37
 DB 3 NTATCATQRLANFLVHSSNNLGFPLPSTVGSNTY 37
 RESULT 32
 AAY22443
 ID AAY22443 standard; peptide; 37 AA.
 XX AC AAY22443;
 XX AC
 XX 28-SEP-1999 (first entry)
 XX Leu23, Pro25, Val26, Pro28 amylin analogue.
 XX Amylin agonist; human; insulin; diabetes; post-prandial glucose level; therapy; mutein.
 XX Homo sapiens.
 XX Synthetic.

```

FH Key Location/Qualifiers
FT Disulfide-bond 2. .7
FT Misc-difference 18 /label= H18R
FT Misc-difference 23 /label= F23L
FT Misc-difference 25 /label= A25P
FT Misc-difference 26 /label= I26V
FT Misc-difference 28 /label= S28P
XX
XX WO9934822-A1.
XX
XX 15-JUL-1999.
XX
XX 09-JAN-1998; 98WO-US000288.
XX
XX 09-JAN-1998; 98WO-US000288.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX L'italian J, Musunuri S, Ruby C;
XX
XX WPI; 1999-458254/38.
XX
XX Stabilized liquid formulation for treatment of insulin-dependent diabetes
XX mellitus.
XX
XX Disclosure; Page; 71pp; English.
XX
XX This sequence represents a human amylin analogue, that acts as a amylin
XX agonist. The invention relates to a liquid pharmaceutical formulation
XX (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10%
XX carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or
XX glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with
XX insulin, for treatment of diabetes, specifically to reduce post-prandial
XX increases in glucose levels of the blood. In these formulations, (I) is
XX stabilised, especially against deamidation and peptide bond hydrolysis
XX for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without
XX addition of a separate stabiliser. They also retain short-term (up to 24
XX hr) stability when combined with insulin, allowing both agents to be
XX administered together, reducing the number of injections required. Note:
XX This sequence was created by the indexer from information given in the
XX specification
XX
XX Sequence 37 AA;
XX
XX Query Match 84.9%; Score 118; DB 2; Length 37;
XX Best Local Similarity 68.6%; Pred. No. 3.7e-14;
XX Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
XX
OY 3 NTATXATQRLXNFLXXXXXXNGPXLPTXVGSNTY 37
DB 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
XX
RESULT 33
AAAY22445
ID AAY22445 standard; peptide; 37 AA.
XX
XX AC AAY22445;
XX
XX 28-SEP-1999 (first entry)
XX
XX Arg18, Leu23, Pro25, Val26, Pro28 amylin analogue.
XX
XX Amylin agonist; human; insulin; diabetes; post-prandial glucose level;
XX therapy; mutein.
XX
XX Homo sapiens.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FH Key Location/Qualifiers
FT Disulfide-bond 2. .7
FT Misc-difference 18 /label= H18R
FT Misc-difference 23 /label= F23L
FT Misc-difference 25 /label= A25P
FT Misc-difference 26 /label= I26V
FT Misc-difference 28 /label= S28P
XX
XX WO9934822-A1.
XX
XX 15-JUL-1999.
XX
XX 09-JAN-1998; 98WO-US000288.
XX
XX 09-JAN-1998; 98WO-US000288.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX L'italian J, Musunuri S, Ruby C;
XX
XX WPI; 1999-458254/38.
XX
XX Stabilized liquid formulation for treatment of insulin-dependent diabetes
XX mellitus.
XX
XX Disclosure; Page; 71pp; English.
XX
XX This sequence represents a human amylin analogue, that acts as a amylin
XX agonist. The invention relates to a liquid pharmaceutical formulation
XX (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10%
XX carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or
XX glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with
XX insulin, for treatment of diabetes, specifically to reduce post-prandial
XX increases in glucose levels of the blood. In these formulations, (I) is
XX stabilised, especially against deamidation and peptide bond hydrolysis
XX for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without
XX addition of a separate stabiliser. They also retain short-term (up to 24
XX hr) stability when combined with insulin, allowing both agents to be
XX administered together, reducing the number of injections required. Note:
XX This sequence was created by the indexer from information given in the
XX specification
XX
XX Sequence 37 AA;
XX
XX Query Match 84.9%; Score 118; DB 2; Length 37;
XX Best Local Similarity 68.6%; Pred. No. 3.7e-14;
XX Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
XX
OY 3 NTATXATQRLXNFLXXXXXXNGPXLPTXVGSNTY 37
DB 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37
XX
RESULT 34
AAAY22435
ID AAY22435 standard; peptide; 37 AA.
XX
XX AC AAY22435;
XX
XX 28-SEP-1999 (first entry)
XX
XX Arg18, Pro25, Pro28 amylin analogue.
XX
XX Amylin agonist; human; insulin; diabetes; post-prandial glucose level;
XX therapy; mutein.
XX
XX Homo sapiens.
XX
XX OS Synthetic.
XX
XX Key

```


FH Key Location/Qualifiers
 FT Disulfide-bond 2. .7
 FT Misc-difference 18
 FT /label= H18R
 FT Misc-difference 25
 FT /label= A25P
 FT Misc-difference 28
 FT /label= S28P
 FT
 XX WO9934822-A1.
 PN
 XX
 XX 15-JUL-1999.
 PD
 XX
 XX 09-JAN-1998; 98WO-US000288.
 PF
 XX 09-JAN-1998; 98WO-US000288.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX L'italian J, Musunuri S, Ruby C;
 PI
 XX WPI; 1999-458254/38.
 XX
 XX Stabilized liquid formulation for treatment of insulin-dependent diabetes
 PT mellitus.
 PT
 XX Disclosure; Page; 71pp; English.
 PS
 XX This sequence represents a human amylin analogue, that acts as a amylin
 CC agonist. The invention relates to a liquid pharmaceutical formulation
 CC (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10%
 CC carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or
 CC glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with
 CC insulin, for treatment of diabetes, specifically to reduce post-prandial
 CC increases in glucose levels of the blood. In these formulations, (I) is
 CC stabilised, especially against deamidation and peptide bond hydrolysis
 CC for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without
 CC addition of a separate stabiliser. They also retain short-term (up to 24
 CC hr) stability when combined with insulin, allowing both agents to be
 CC administered together, reducing the number of injections required. Note:
 CC This sequence was created by the indexer from information given in the
 CC specification
 CC
 XX Sequence 37 AA;
 SQ
 Query Match 84.9%; Score 118; DB 2; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 Qy 3 NTATCATQRLANFLVRSNNFGPILPSTNVGSNTY 37
 Db 3 NTATCATQRLANFLVRSNNFGPILPSTNVGSNTY 37
 RESULT 35
 AAY22447
 ID AAY22447 standard; peptide; 37 AA.
 XX
 XX AAY22447;
 AC
 XX 28-SEP-1999 (first entry)
 DT
 XX Arg18, Leu23, Pro25, Pro28 amylin analogue.
 DE
 XX Amylin agonist; human; insulin; diabetes; post-prandial glucose level;
 KW therapy; mutain.
 KW
 XX Homo sapiens.
 OS
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH Disulfide-bond 2. .7
 FT Misc-difference 18

FT /label= H18R
 FT Misc-difference 23
 FT /label= F23L
 FT Misc-difference 25
 FT /label= A25P
 FT Misc-difference 28
 FT /label= S28P
 FT
 XX WO9934822-A1.
 PN
 XX
 XX 15-JUL-1999.
 PD
 XX
 XX 09-JAN-1998; 98WO-US000288.
 PF
 XX 09-JAN-1998; 98WO-US000288.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX L'italian J, Musunuri S, Ruby C;
 PI
 XX WPI; 1999-458254/38.
 XX
 XX Stabilized liquid formulation for treatment of insulin-dependent diabetes
 PT mellitus.
 PT
 XX Disclosure; Page; 71pp; English.
 PS
 XX This sequence represents a human amylin analogue, that acts as a amylin
 CC agonist. The invention relates to a liquid pharmaceutical formulation
 CC (A), that contains (wt./vol.): 0.01-0.5% amylin agonist (I); 1-10%
 CC carbohydrate or polyol (II); and 0.02-0.5% acetate, phosphate, citrate or
 CC glutamate buffer (III); and has pH 3-6. (A) are used, in conjunction with
 CC insulin, for treatment of diabetes, specifically to reduce post-prandial
 CC increases in glucose levels of the blood. In these formulations, (I) is
 CC stabilised, especially against deamidation and peptide bond hydrolysis
 CC for up to 4 years at 5 degrees C and 30 days at 30 degrees C, without
 CC addition of a separate stabiliser. They also retain short-term (up to 24
 CC hr) stability when combined with insulin, allowing both agents to be
 CC administered together, reducing the number of injections required. Note:
 CC This sequence was created by the indexer from information given in the
 CC specification
 CC
 XX Sequence 37 AA;
 SQ
 Query Match 84.9%; Score 118; DB 2; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 Qy 3 NTATCATQRLANFLVRSNNFGPILPSTNVGSNTY 37
 Db 3 NTATCATQRLANFLVRSNNFGPILPSTNVGSNTY 37
 RESULT 36
 AAW90140
 ID AAW90140 standard; peptide; 37 AA.
 XX
 XX AAW90140;
 AC
 XX 15-MAR-1999 (first entry)
 DT
 XX Human amylin agonist peptide 18-Arg25, 28-Pro-amylin.
 DE
 XX Amylin; human; agonist; gastritis; gastric ulceration; treatment;
 KW non-steroidal anti-inflammatory agent; NSAID; intravenous; subcutaneous;
 KW pain; fever; inflammation; arthritis; hypercoagulation.
 KW
 XX Homo sapiens.
 OS
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH Disulfide-bond 2. .7
 FT Misc-difference 18

XX Claim 6; Page 42; 48pp; English.

XX This invention relates to a method for treating or preventing gastritis

XX or gastric ulceration which comprises administering amylin or an amylin

XX agonist. Amylin administration is not carried out intra-

XX cerebroventricularly. The specification describes a method for treating

XX or preventing a condition for which a non-steroidal anti-inflammatory

XX agent (NSAID) is indicated, comprising administering amylin or amylin

XX agonist, which is not calcitonin, together with NSAID and also a

XX composition comprising an amylin or an amylin agonist or their salts,

XX except calcitonin and a NSAID in a carrier. The amylin composition is

XX used to treat humans by administering it subcutaneously, intravenously or

XX by nasal, oral, pulmonary, transdermal and buccal routes. The method is

XX also used to treat pain, fever, inflammation, arthritis, hypercoagulation

XX and other condition where an NSAID would be indicated. The present

XX sequence is an example of an agonist used in the method

XX

SQ Sequence 37 AA;

Query Match 84.9%; Score 118; DB 2; Length 37;

Best Local Similarity 68.6%; Pred. NO. 3.7e-14;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37

||||| ||||| ||||| ||||| ||||| |||||

Db 3 NTATCATQRLANFLVRSSNNLGPILPSTNVGSNTY 37

||||| ||||| ||||| ||||| ||||| |||||

RESULT 39

AAW90148

ID AAW90148 standard; peptide; 37 AA.

AC AAW90148;

XX

DT 15-MAR-1999 (first entry)

XX

DE Human amylin agonist peptide 18-Leu25-Pro26-Val28-Pro-amylin.

XX

XX Amylin; human; agonist; gastritis; gastric ulceration; treatment;

XX non-steroidal anti-inflammatory agent; NSAID; intravenous; subcutaneous;

XX pain; fever; inflammation; arthritis; hypercoagulation.

XX

OS Homo sapiens.

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 2..7

XX WO9850059-A1.

XX

PD 12-NOV-1998.

XX

PF 06-MAY-1998; 98WO-US009089.

XX

PR 06-MAY-1997; 97US-00851965.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young A, Gedulin B, Beynon GW;

XX

DR WPI; 1999-059652/05.

XX

XX Method for treating or preventing gastritis - comprises administering

XX amylin or amylin agonist, except calcitonin.

XX

PS Claim 6; Page 42; 48pp; English.

XX

XX This invention relates to a method for treating or preventing gastritis

XX or gastric ulceration which comprises administering amylin or an amylin

XX agonist. Amylin administration is not carried out intra-

XX cerebroventricularly. The specification describes a method for treating

XX or preventing a condition for which a non-steroidal anti-inflammatory

CC agent (NSAID) is indicated, comprising administering amylin or amylin

CC agonist, which is not calcitonin, together with NSAID and also a

CC composition comprising an amylin or an amylin agonist or their salts,

CC except calcitonin and a NSAID in a carrier. The amylin composition is

CC used to treat humans by administering it subcutaneously, intravenously or

CC by nasal, oral, pulmonary, transdermal and buccal routes. The method is

CC also used to treat pain, fever, inflammation, arthritis, hypercoagulation

CC and other condition where an NSAID would be indicated. The present

CC sequence is an example of an agonist used in the method

XX

SQ Sequence 37 AA;

Query Match 84.9%; Score 118; DB 2; Length 37;

Best Local Similarity 68.6%; Pred. NO. 3.7e-14;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLXNFXLXXXXXNKGXPLPXTXVGSNTY 37

||||| ||||| ||||| ||||| ||||| |||||

Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

||||| ||||| ||||| ||||| ||||| |||||

RESULT 40

AAAB18587

ID AAB18587 standard; peptide; 37 AA.

XX

AC AAB18587;

XX

DT 15-JAN-2001 (first entry)

XX

DE Amino acid sequence of an amylin agonist analogue compound.

XX

XX Amylin agonist; amylin; gastric motility; gastric emptying;

XX postprandial dumping syndrome; postprandial hyperglycemia;

XX gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm;

XX acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 2..7

FT Modified-site 37

FT /note= "amidated residue"

XX

PN US6114304-A.

XX

PD 05-SEP-2000.

XX

PF 07-SEP-1994; 94US-00302069.

XX

PR 07-SEP-1993; 93US-00118381.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young AA, Rink TJ, Brown KAK, Kolterman OG;

XX

DR WPI; 2000-601336/57.

XX

XX Treating gastrointestinal disorder e.g. spasm by reducing gastric

XX motility or delaying gastric emptying, postprandial dumping syndrome or

XX postprandial hyperglycemia, by administering amylin or amylin agonist.

XX

PS Disclosure; Col 45-46; 50pp; English.

XX

XX The present sequence represents an amylin agonist analogue compound.

XX Amylin or amylin agonists are administered for reducing gastric motility

XX or delaying gastric emptying, and for treating postprandial dumping

XX syndrome or postprandial hyperglycemia, by inducing amylin activity, in a

XX mammal. The peptides are used to reduce gastric motility or for delaying

XX gastric emptying in a mammal undergoing gastrointestinal diagnostic

XX procedures, such as radiological examination or magnetic resonance

XX imaging. They are also used for reducing gastric motility in

XX gastrointestinal disorder, especially spasm, which is associated with a

XX disorder of acute diverticulitis or disorders of biliary tract or

CC sphincter of oddi. They are also used to treat postprandial dumping
 CC syndrome or postprandial hyperglycemia
 XX
 SQ Sequence 37 AA;

Query Match 84.9%; Score 118; DB 3; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37

RESULT 41
 AAB18585
 ID AAB18585 standard; peptide; 37 AA.
 XX
 AC AAB18585;
 XX
 DT 15-JAN-2001 (first entry)
 XX
 DE Amino acid sequence of an amylin agonist analogue compound.
 XX
 KW Amylin agonist; amylin; gastric motility; gastric emptying;
 KW postprandial dumping syndrome; postprandial hyperglycemia;
 KW gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm;
 KW acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Disulfide-bond 2..7
 FT Modified-site 37
 FT /note= "amidated residue"
 XX
 XX US6114304-A.
 XX
 XX 05-SEP-2000.
 XX
 XX 07-SEP-1994; 94US-00302069.
 XX
 XX 07-SEP-1993; 93US-00118381.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Rink TJ, Brown KAK, Kolterman OG;
 XX WPI; 2000-601336/57.
 XX
 XX Treating gastrointestinal disorder e.g. spasm by reducing gastric
 XX motility or delaying gastric emptying, postprandial dumping syndrome or
 XX postprandial hyperglycemia, by administering amylin or amylin agonist.
 XX
 XX Disclosure; Col 45-46; 50pp; English.
 XX
 XX The present sequence represents an amylin agonist analogue compound.
 XX Amylin or amylin agonists are administered for reducing gastric motility
 XX or delaying gastric emptying, and for treating postprandial dumping
 XX syndrome or postprandial hyperglycemia, by inducing amylin activity, in a
 XX mammal. The peptides are used to reduce gastric motility or for delaying
 XX gastric emptying in a mammal undergoing gastrointestinal diagnostic
 XX procedures, such as radiological examination or magnetic resonance
 XX imaging. They are also used for reducing gastric motility in
 XX gastrointestinal disorder, especially spasm, which is associated with a
 XX disorder of acute diverticulitis or disorders of biliary tract or
 XX sphincter of oddi. They are also used to treat postprandial dumping
 XX syndrome or postprandial hyperglycemia
 XX
 SQ Sequence 37 AA;

Query Match 84.9%; Score 118; DB 3; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37

RESULT 42
 AAB18574
 ID AAB18574 standard; peptide; 37 AA.
 XX
 AC AAB18574;
 XX
 DT 15-JAN-2001 (first entry)
 XX
 DE Amino acid sequence of an amylin agonist analogue compound.
 XX
 KW Amylin agonist; amylin; gastric motility; gastric emptying;
 KW postprandial dumping syndrome; postprandial hyperglycemia;
 KW gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm;
 KW acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Disulfide-bond 2..7
 FT Modified-site 37
 FT /note= "amidated residue"
 XX
 XX US6114304-A.
 XX
 XX 05-SEP-2000.
 XX
 XX 07-SEP-1994; 94US-00302069.
 XX
 XX 07-SEP-1993; 93US-00118381.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Rink TJ, Brown KAK, Kolterman OG;
 XX WPI; 2000-601336/57.
 XX
 XX Treating gastrointestinal disorder e.g. spasm by reducing gastric
 XX motility or delaying gastric emptying, postprandial dumping syndrome or
 XX postprandial hyperglycemia, by administering amylin or amylin agonist.
 XX
 XX Disclosure; Col 37-38; 50pp; English.
 XX
 XX The present sequence represents an amylin agonist analogue compound.
 XX Amylin or amylin agonists are administered for reducing gastric motility
 XX or delaying gastric emptying, and for treating postprandial dumping
 XX syndrome or postprandial hyperglycemia, by inducing amylin activity, in a
 XX mammal. The peptides are used to reduce gastric motility or for delaying
 XX gastric emptying in a mammal undergoing gastrointestinal diagnostic
 XX procedures, such as radiological examination or magnetic resonance
 XX imaging. They are also used for reducing gastric motility in
 XX gastrointestinal disorder, especially spasm, which is associated with a
 XX disorder of acute diverticulitis or disorders of biliary tract or
 XX sphincter of oddi. They are also used to treat postprandial dumping
 XX syndrome or postprandial hyperglycemia
 XX
 SQ Sequence 37 AA;

Query Match 84.9%; Score 118; DB 3; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3.7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 3 NTATCATQRLANFLVRSNNLGPILPSTNVGSNTY 37

Best Local Similarity	71.4%;	Pred. No. 3.7e-14;	Matches 25;	Conservative 0;	Mismatches 10;	Indels 0;	Gaps
Qy	3	NTATXATQRLXNLFXXXXXXXXXGFLPXTXVGSNTY	37				
Db	3	NTATXATQRLANFLVHSSNNLGPVLPSTNVGSNTY	37				
RESULT 44							
AAB18583							
ID	AAB18583	standard; peptide; 37 AA.					
XX	XX						
AC	AAB18583;						
XX	XX						
DT	15-JAN-2001	(first entry)					
XX	XX						
DE	DE	Amino acid sequence of an amylin agonist analogue compound.					
XX	XX						
XX	XX						
KW	KW	Amylin agonist; amylin; gastric motility; gastric emptying; postprandial dumping syndrome; postprandial hyperglycemia; gastrointestinal diagnostic procedure; gastrointestinal disorder; spasm; acute diverticulitis; biliary tract disorder; sphincter of oddi disorder.					
XX	XX						
OS	OS	Synthetic.					
XX	XX						
PH	PH	Key	Location/Qualifiers				
FT	FT	Disulfide-bond 2. 7					
FT	FT	Modified-site 37					
FT	FT	/note= "amidated residue"					
XX	XX						
PN	PN	US6114304-A.					
XX	XX						
PD	PD	05-SEP-2000.					
XX	XX						
PF	PF	07-SEP-1994; 94US-00302069.					
XX	XX						
PR	PR	07-SEP-1993; 93US-00118381.					
XX	XX						
PA	PA	(AMYL-) AMYLIN PHARM INC.					
XX	XX						
PI	PI	Young AA, Rink TJ, Brown KAK, Kolterman OG;					
XX	XX						
DR	DR	WPI; 2000-601336/57.					
XX	XX						
PT	PT	Treating gastrointestinal disorder e.g. spasm by reducing gastric motility or delaying gastric emptying, postprandial dumping syndrome or postprandial hyperglycemia, by administering amylin or amylin agonist.					
XX	XX						
PS	PS	Claim 4; Col; 50pp; English.					
XX	XX						
CC	CC	The present sequence represents an amylin agonist analogue compound.					
CC	CC	Amylin or amylin agonists are administered for reducing gastric motility or delaying gastric emptying, and for treating postprandial dumping syndrome or postprandial hyperglycemia, by inducing amylin activity, in a mammal. The peptides are used to reduce gastric motility or for delaying gastric emptying in a mammal undergoing gastrointestinal diagnostic procedures, such as radiological examination or magnetic resonance imaging. They are also used for reducing gastric motility in gastrointestinal disorder, especially spasm, which is associated with a disorder of acute diverticulitis or disorders of biliary tract or sphincter of oddi. They are also used to treat postprandial dumping syndrome or postprandial hyperglycemia. note: the present sequence does not appear in the specification; it was created using information provided					
XX	XX						
Qy	3	NTATXATQRLXNLFXXXXXXXXXGFLPXTXVGSNTY	37				
Db	3	NTATXATQRLANFLVHSSNNLGPVLPSTNVGSNTY	37				
Query Match	84.9%;	Score 118;	DB 3;	Length 37;			
Best Local Similarity	68.8%;	Pred. No. 3.7e-14;	Matches 24;	Conservative 0;	Mismatches 11;	Indels 0;	Gaps

RESULT 45
 ABB05496
 ID ABB05496 standard; peptide; 37 AA.
 XX AC ABB05496;
 XX DT 19-APR-2002 (first entry)
 XX DE Human amylin agonist 25Pro26Val28Pro-h-amylin.
 XX KW Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
 KW liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
 KW citrate; glutamate; buffer; antidiabetic; type II diabetes.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN US2001043934-A1.
 XX PD 22-NOV-2001.
 XX PF 09-JAN-1998; 98US-00005262.
 XX PR 08-JAN-1997; 97US-0035140P.
 XX PA (LITA/) L'ITALIEN J.
 XX PA (MUSU/) MUSUNURI S.
 XX PA (RUBY/) RUBY K.
 XX PI L'italien J, Musunuri S, Ruby K;
 XX WPI; 2002-163554/21.
 XX DR
 XX PT New pharmaceutical formulation useful for treating patients with type II
 PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
 PT a buffer.
 XX PS Disclosure; Page; 19pp; English.
 XX CC The present invention describes a liquid pharmaceutical formulation (A)
 CC comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
 CC polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or
 CC glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
 CC commercial package containing the liquid pharmaceutical formulation (A).
 CC The package comprises a borosilicate glass vial having an open end, a
 CC stopper for multiuse compatible with the amylin and/or amylin agonist
 CC fixed in the open end of the vial and an aluminium band to retain the
 CC stopper in the far end of the vial. The package also comprises a
 CC cartridge for use in a pen injector. (A) has antidiabetic activity and
 CC can be used in the treatment of patients with type II diabetes. The
 CC formulation comprises amylin agonist which is biologically active, has a
 CC reduced tendency to form aggregates in water or at a pressure of greater
 CC than 2 psi and has a reduced tendency to precipitate in the presence of
 CC NaCl compared to human amylin. The formulation maintains stability upon
 CC storage under refrigerated or room-temperature conditions. The
 CC formulation retains short-term mixing compatibility with insulin and
 CC results in improved stability of the hormone and the patients no longer
 CC need to refrigerate the vial of insulin in use. The present sequence
 CC represents a human amylin peptide analogue, which can be used as an
 CC amylin agonist in the present invention. N.B. The present sequence is not
 CC given in the present specification but is derived from the 37 amino acid
 CC human amylin as stated in the invention
 XX SQ Sequence 37 AA;
 Query Match 84.9%; Score 118; DB 5; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3 7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXXNGPXLPTXVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 3 NTATCATQRLANFLVHSSNNFGVLPSTNVGSNTY 37

RESULT 46
 ABB05490
 ID ABB05490 standard; peptide; 37 AA.
 XX AC ABB05490;
 XX DT 19-APR-2002 (first entry)
 XX DE Human amylin agonist 18Arg25,28Pro-h-amylin.
 XX KW Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
 KW liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
 KW citrate; glutamate; buffer; antidiabetic; type II diabetes.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN US2001043934-A1.
 XX PD 22-NOV-2001.
 XX PF 09-JAN-1998; 98US-00005262.
 XX PR 08-JAN-1997; 97US-0035140P.
 XX PA (LITA/) L'ITALIEN J.
 XX PA (MUSU/) MUSUNURI S.
 XX PA (RUBY/) RUBY K.
 XX PI L'italien J, Musunuri S, Ruby K;
 XX WPI; 2002-163554/21.
 XX DR
 XX PT New pharmaceutical formulation useful for treating patients with type II
 PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
 PT a buffer.
 XX PS Disclosure; Page; 19pp; English.
 XX CC The present invention describes a liquid pharmaceutical formulation (A)
 CC comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
 CC polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or
 CC glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
 CC commercial package containing the liquid pharmaceutical formulation (A).
 CC The package comprises a borosilicate glass vial having an open end, a
 CC stopper for multiuse compatible with the amylin and/or amylin agonist
 CC fixed in the open end of the vial and an aluminium band to retain the
 CC stopper in the far end of the vial. The package also comprises a
 CC cartridge for use in a pen injector. (A) has antidiabetic activity and
 CC can be used in the treatment of patients with type II diabetes. The
 CC formulation comprises amylin agonist which is biologically active, has a
 CC reduced tendency to form aggregates in water or at a pressure of greater
 CC than 2 psi and has a reduced tendency to precipitate in the presence of
 CC NaCl compared to human amylin. The formulation maintains stability upon
 CC storage under refrigerated or room-temperature conditions. The
 CC formulation retains short-term mixing compatibility with insulin and
 CC results in improved stability of the hormone and the patients no longer
 CC need to refrigerate the vial of insulin in use. The present sequence
 CC represents a human amylin peptide analogue, which can be used as an
 CC amylin agonist in the present invention. N.B. The present sequence is not
 CC given in the present specification but is derived from the 37 amino acid
 CC human amylin as stated in the invention
 XX SQ Sequence 37 AA;
 Query Match 84.9%; Score 118; DB 5; Length 37;
 Best Local Similarity 68.6%; Pred. No. 3 7e-14;
 Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
 QY 3 NTATXATQRLXNFXLXXXXXXNGPXLPTXVGSNTY 37
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Db 3 NTATCATQRLANFLVRSSNFGPILPSTNVGSNTY 37

RESULT 47
ABB05498
ID ABB05498 standard; peptide; 37 AA.
XX
AC ABB05498;
XX
DT 19-APR-2002 (first entry)
XX
DE Human amylin agonist 23Leu25Pro26Val28Pro-h-amylin.
XX
KW Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
KW liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
KW citrate; glutamate; buffer; antidiabetic; type II diabetes.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US2001043934-A1.
XX
PD 22-NOV-2001.
XX
PF 09-JAN-1998; 98US-00005262.
XX
PR 08-JAN-1997; 97US-0035140P.
XX
PA (LITA/) L'ITALIEN J.
PA (MUSU/) MUSUNURI S.
PA (RUBY/) RUBY K.
XX
PI L'italien J, Musunuri S, Ruby K;
XX
WPI; 2002-163554/21.
XX
PT New pharmaceutical formulation useful for treating patients with type II
PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
PT a buffer.
XX
PS Disclosure; Page; 19pp; English.
XX
CC The present invention describes a liquid pharmaceutical formulation (A)
CC comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
CC polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or
CC glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
CC commercial package containing the liquid pharmaceutical formulation (A).
CC The package comprises a borosilicate glass vial having an open end, a
CC stopper for multiuse compatible with the amylin and/or amylin agonist
CC fixed in the open end of the vial and an aluminum band to retain the
CC stopper in the far end of the vial. The package also comprises a
CC cartridge for use in a pen injector. (A) has antidiabetic activity and
CC can be used in the treatment of patients with type II diabetes. The
CC formulation comprises amylin agonist which is biologically active, has a
CC reduced tendency to form aggregates in water or at a pressure of greater
CC than 2 psi and has a reduced tendency to precipitate in the presence of
CC NaCl compared to human amylin. The formulation maintains stability upon
CC storage under refrigerated or room-temperature conditions. The
CC formulation retains short-term mixing compatibility with insulin and
CC results in improved stability of the hormone and the patients no longer
CC need to refrigerate the vial of insulin in use. The present sequence
CC represents a human amylin peptide analogue, which can be used as an
CC amylin agonist in the present invention. N.B. The present sequence is not
CC given in the present specification but is derived from the 37 amino acid
CC human amylin as stated in the invention
XX
SQ Sequence 37 AA;
Query Match 84.9%; Score 118; DB 5; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Db 3 NTATCATQRLANFLVHSSNNLGPVLPSTNVGSNTY 37

RESULT 48
ABB05500
ID ABB05500 standard; peptide; 37 AA.
XX
AC ABB05500;
XX
DT 19-APR-2002 (first entry)
XX
DE Human amylin agonist 18Arg23Leu25Pro26Val28Pro-h-amylin.
XX
KW Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;
KW liquid pharmaceutical formulation; polyhydric alcohol; phosphate;
KW citrate; glutamate; buffer; antidiabetic; type II diabetes.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US2001043934-A1.
XX
PD 22-NOV-2001.
XX
PF 09-JAN-1998; 98US-00005262.
XX
PR 08-JAN-1997; 97US-0035140P.
XX
PA (LITA/) L'ITALIEN J.
PA (MUSU/) MUSUNURI S.
PA (RUBY/) RUBY K.
XX
PI L'italien J, Musunuri S, Ruby K;
XX
WPI; 2002-163554/21.
XX
PT New pharmaceutical formulation useful for treating patients with type II
PT diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and
PT a buffer.
XX
PS Disclosure; Page; 19pp; English.
XX
CC The present invention describes a liquid pharmaceutical formulation (A)
CC comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a
CC polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or
CC glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a
CC commercial package containing the liquid pharmaceutical formulation (A).
CC The package comprises a borosilicate glass vial having an open end, a
CC stopper for multiuse compatible with the amylin and/or amylin agonist
CC fixed in the open end of the vial and an aluminum band to retain the
CC stopper in the far end of the vial. The package also comprises a
CC cartridge for use in a pen injector. (A) has antidiabetic activity and
CC can be used in the treatment of patients with type II diabetes. The
CC formulation comprises amylin agonist which is biologically active, has a
CC reduced tendency to form aggregates in water or at a pressure of greater
CC than 2 psi and has a reduced tendency to precipitate in the presence of
CC NaCl compared to human amylin. The formulation maintains stability upon
CC storage under refrigerated or room-temperature conditions. The
CC formulation retains short-term mixing compatibility with insulin and
CC results in improved stability of the hormone and the patients no longer
CC need to refrigerate the vial of insulin in use. The present sequence
CC represents a human amylin peptide analogue, which can be used as an
CC amylin agonist in the present invention. N.B. The present sequence is not
CC given in the present specification but is derived from the 37 amino acid
CC human amylin as stated in the invention
XX
SQ Sequence 37 AA;
Query Match 84.9%; Score 118; DB 5; Length 37;
Best Local Similarity 68.6%; Pred. No. 3.7e-14;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 3 NTATXATQRLANFLXXXXXNNGPXLPTXVGSNTY 37

QY	3	NTATXATQRLXNFKLXXXXXNKGXPLPXTXVGSNTY	37
Db	3	NTATCAIQRLANFLVRSSNNLGPVLPSTNVGSNTY	37
RESULT 49			
ABB05502			
ID	ABB05502	standard; peptide; 37 AA.	
XX			
AC	ABB05502;		
XX			
DT	19-APR-2002	(first entry)	
XX			
DE	Human amylin agonist 18Arg23Leu25,28Pro-h-amylin.		
XX			
KW	Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;		
KW	liquid pharmaceutical formulation; polyhydric alcohol; phosphate;		
KW	citrate; glutamate; buffer; antidiabetic; type II diabetes.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FN	US2001043934-A1.		
XX			
PD	22-NOV-2001.		
XX			
PF	09-JAN-1998;	98US-00005262.	
XX			
PR	08-JAN-1997;	97US-0035140P.	
XX			
PA	(LITA/) L'ITALIEN J.		
PA	(MUSU/) MUSUNURI S.		
PA	(RUBY/) RUBY K.		
XX			
PI	L'italien J, Musunuri S, Ruby K;		
XX			
DR	WPI; 2002-163554/21.		
XX			
PT	New pharmaceutical formulation useful for treating patients with type II		
PT	diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and		
PT	a buffer.		
XX			
PS	Disclosure; Page; 19pp; English.		
XX			
CC	The present invention describes a liquid pharmaceutical formulation (A)		
CC	comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a		
CC	polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or		
CC	glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a		
CC	commercial package containing the liquid pharmaceutical formulation (A).		
CC	The package comprises a borosilicate glass vial having an open end, a		
CC	stopper for multiuse compatible with the amylin and/or amylin agonist		
CC	fixed in the open end of the vial and an aluminium band to retain the		
CC	stopper in the far end of the vial. The package also comprises a		
CC	cartridge for use in a pen injector. (A) has antidiabetic activity and		
CC	can be used in the treatment of patients with type II diabetes. The		
CC	formulation comprises amylin agonist which is biologically active, has a		
CC	reduced tendency to form aggregates in water or at a pressure of greater		
CC	than 2 psi and has a reduced tendency to precipitate in the presence of		
CC	NaCl compared to human amylin. The formulation maintains stability upon		
CC	storage under refrigerated or room-temperature conditions. The		
CC	formulation retains short-term mixing compatibility with insulin and		
CC	results in improved stability of the hormone and the patients no longer		
CC	need to refrigerate the vial of insulin in use. The present sequence		
CC	represents a human amylin peptide analogue, which can be used as an		
CC	amylin agonist in the present invention. N.B. The present sequence is not		
CC	given in the present specification but is derived from the 37 amino acid		
CC	human amylin as stated in the invention		
XX			
SQ	Sequence 37 AA;		
Query Match	84.9%;	Score 118;	DB 5; Length 37;
Best Local Similarity	68.6%;	Pred. No. 3.7e-14;	
Matches	24; Conservative	0; Mismatches	11; Indels 0; Gaps 0;

QY	3	NTATXATQRLXNFKLXXXXXNKGXPLPXTXVGSNTY	37
Db	3	NTATCAIQRLANFLVRSSNNLGPVLPSTNVGSNTY	37
RESULT 50			
ABB05487			
ID	ABB05487	standard; peptide; 37 AA.	
XX			
AC	ABB05487;		
XX			
DT	19-APR-2002	(first entry)	
XX			
DE	Human amylin agonist 18Arg25,28Pro-h-amylin.		
XX			
KW	Human; amylin agonist; amylin peptide analogue; acetate; carbohydrate;		
KW	liquid pharmaceutical formulation; polyhydric alcohol; phosphate;		
KW	citrate; glutamate; buffer; antidiabetic; type II diabetes.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FN	US2001043934-A1.		
XX			
PD	22-NOV-2001.		
XX			
PF	09-JAN-1998;	98US-00005262.	
XX			
PR	08-JAN-1997;	97US-0035140P.	
XX			
PA	(LITA/) L'ITALIEN J.		
PA	(MUSU/) MUSUNURI S.		
PA	(RUBY/) RUBY K.		
XX			
PI	L'italien J, Musunuri S, Ruby K;		
XX			
DR	WPI; 2002-163554/21.		
XX			
PT	New pharmaceutical formulation useful for treating patients with type II		
PT	diabetes comprises amylin agonist, carbohydrate or polyhydric alcohol and		
PT	a buffer.		
XX			
PS	Disclosure; Page; 19pp; English.		
XX			
CC	The present invention describes a liquid pharmaceutical formulation (A)		
CC	comprising (wt/vol%) an amylin agonist (0.01 - 0.5), a carbohydrate or a		
CC	polyhydric alcohol (1 - 10) and an acetate, phosphate, citrate or		
CC	glutamate buffer (0.02 - 0.5) having a pH of 3 - 6. Also described is a		
CC	commercial package containing the liquid pharmaceutical formulation (A).		
CC	The package comprises a borosilicate glass vial having an open end, a		
CC	stopper for multiuse compatible with the amylin and/or amylin agonist		
CC	fixed in the open end of the vial and an aluminium band to retain the		
CC	stopper in the far end of the vial. The package also comprises a		
CC	cartridge for use in a pen injector. (A) has antidiabetic activity and		
CC	can be used in the treatment of patients with type II diabetes. The		
CC	formulation comprises amylin agonist which is biologically active, has a		
CC	reduced tendency to form aggregates in water or at a pressure of greater		
CC	than 2 psi and has a reduced tendency to precipitate in the presence of		
CC	NaCl compared to human amylin. The formulation maintains stability upon		
CC	storage under refrigerated or room-temperature conditions. The		
CC	formulation retains short-term mixing compatibility with insulin and		
CC	results in improved stability of the hormone and the patients no longer		
CC	need to refrigerate the vial of insulin in use. The present sequence		
CC	represents a human amylin peptide analogue, which can be used as an		
CC	amylin agonist in the present invention. N.B. The present sequence is not		
CC	given in the present specification but is derived from the 37 amino acid		
CC	human amylin as stated in the invention		
XX			
SQ	Sequence 37 AA;		
Query Match	84.9%;	Score 118;	DB 5; Length 37;
Best Local Similarity	68.6%;	Pred. No. 3.7e-14;	

Matches	24;	Conservative	0;	Mismatches	11;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	-----	--------	----	------	----

Qy 3 NTATXATQRLXNFLXXXXXXXXXGXPXPXTXVGSNTY 37

NTATXATQRLXNLFXXXXXXXXXGXPXPXTXVGSNTY

Db 3 NTATCATQRLANFLVRSSNFGPILPSTNVGSNTY 37

NTATCATQRLANFLVRSSNFGPILPSTNVGSNTY

Search completed: January 4, 2006, 11:41:37
Job time : 190 secs

```

search completed: 14
Job time : 190 secs

```

THIS PAGE LEFT BLANK